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Cardiovascular disease (CVD) is the number one cause of death in the US. 
Atherosclerosis, an inflammatory disease characterized by plaque accumulation on the 
arterial walls, is the major cause of CVD1,2. Atherosclerotic plaque rupture (thrombosis 
and embolism) blocks blood flow and oxygen delivery to tissues thereby causing a heart 
attack or stroke3. While there are several known risk factors and behaviors that increase 
the likelihood of developing atherosclerosis, the underlying cause of the disease remains 
unknown4.  
Atherosclerosis typically occurs in curves or branches in the vasculature where 
disturbed blood flow alters gene expression and induces endothelial cell (EC) 
dysfunction. Blood flow generates shear stress on vascular ECs. Unidirectional, laminar 
shear stress (LS, or s-flow) is crucial for normal vascular function, whereas low, 
disturbed flow (d-flow), and oscillatory shear stress (OS) causes vascular dysfunction and 
disease 5-9. ECs have dramatically altered gene expression patterns when exposed to d-
flow versus s-flow 10-15. 
Epigenetics controls aberrant gene expression in many diseases, but the 
mechanism of flow-induced epigenetic gene regulation in ECs via DNA methylation has 
not been well studied until very recently. The goal of this project was to determine how 
the DNA methylome responds to flow, causes altered gene expression, and regulates 
atherosclerosis development. The majority of our findings were published in the Journal 
of Clinical Investigation in May 2014 our research article titled Flow-dependent 
epigenetic DNA methylation regulates endothelial gene expression and atherosclerosis16. 
We found that d-flow increases DNA Methyltransferase 1 (DNMT1) expression in ECs, 
and we hypothesized that this causes a shift in the EC methylome and transcriptome 
 xxi 
towards a pro-inflammatory, pro-atherosclerotic gene expression program, and further 
that this leads to atherosclerosis development.  
To test this hypothesis, we employed both in vitro and in vivo experimental 
approaches combined with genome-wide studies of the transcriptome and DNA 
methylome and computational systems biology analyses according to the following three 
specific aims: 1) to elucidate the role of DNA Methyltransferase 1 in EC function, 2) to 
uncover the DNA methylation-dependent EC gene expression response to flow, and 3) to 
discover and examine master regulators of EC function that are controlled by DNA 
methylation. 
Our in vivo technique, mouse partial carotid ligation, induces d-flow in the left 
carotid artery (LCA) while the s-flow right carotid artery (RCA) serves as an internal 
control. Data from our lab’s previous in vivo mouse carotid artery mRNA microarrays 
implicated DNMT1 as a potentially functionally important mechanosensitive gene in EC 
biology that is upregulated by d-flow17. In Aim 1, we found that DNMT1 is upregulated 
by d-flow at the transcript and protein level in vivo and in vitro. DNMT1 inhibition using 
the chemical inhibitor 5-Aza-2’deoxycytdine (5Aza) or DNMT1 siRNA was done in 
vitro prior to shear in HUVECs, and 5Aza was used in mouse models of atherosclerosis 
to determine the functional outcome of blocking DNMT1 overexpression in d-flow. We 
show that DNMT1 inhibition by 5Aza inhibits inflammation and global methylation in 
ECs in vitro and plaque development in both acute and chronic murine models of d-flow-
induced atherosclerosis in vivo. Preliminary studies exploring the mechanism of upstream 
DNMT1 regulation point to the mir29 family as potential mechanosensitive regulators of 
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this pathway. This work establishes the importance of DNMT1 in EC biology and 
atherosclerosis. 
In the second aim we sought to determine the functional importance of DNMT1 
overexpression by d-flow and also the mechanism of action of DNMT inhibition by 5Aza 
in d-flow-exposed endothelium. Since DNMT1 is known to methylate genomic DNA and 
DNA methylation is a regulator of gene expression, we designed two parallel “omics” 
studies to examine the effects of both d-flow and DNMT inhibition on the EC DNA 
methylome and transcriptome in vivo. We carried out reduced representation bisulfite 
sequencing (RRBS) using EC-enriched genomic DNA (gDNA) obtained from the RCA 
and LCA of partially ligated mice at two different time points of two days and one week 
post-ligation. To further determine whether the flow-dependent DNA methylation 
changes were regulated in a DNMT-dependent manner, mice treated with 5Aza were 
compared to a saline vehicle control. Moreover, to determine which mechanosensitive 
genes have transcriptional dysregulation, potentially by DNA hypermethylation, we 
carried out a concomitant gene transcript microarray study using EC-enriched RNA 
obtained from the LCA and RCA of partially-ligated mice treated with either saline 
(RCA vs. LCA) or 5Aza (Aza-RCA vs. Aza-LCA). From these studies we found that 
DNMT inhibition by 5Aza rescues global gene expression in the d-flow-exposed LCA to 
a healthy state. While genome-wide DNA methylation and specific functional genomic 
elements did not have dramatically changed methylation under these conditions, we 
followed a specific hypothesis and discovered a subset of genes that have d-flow-induced 
promoter hypermethylation correlating with gene suppression, both of which were 5Aza-
reversible. Based on systems biology and further bioinformatics analysis, we found that 
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gene promoters containing cyclic AMP Response Elements (CRE) are preferentially 
demethylated at their CG sites as compared to other promoter CG sites in the RCA. 
Additionally, these promoter CRE CG sites are specifically hypermethylated by d-flow. 
We further discovered that, on the genome scale, CRE CG hypermethylation corresponds 
to decreased gene expression. These studies, described in detail in Aim 2, used “omics” 
datasets to uncover a key regulatory network regulated by DNA methylation that had 
never before been studied in the context of atherosclerosis. 
To discover genes that are important in EC biology and regulated by DNA 
methylation, we performed detailed examination of the methylome and transcriptome 
data described in Aim 2. To determine the mechanisms by which 5Aza inhibited 
atherosclerosis in vivo and EC inflammation in vitro (as described in Aim 1), we tested 
the specific hypothesis that d-flow induces hypermethylation of anti-atherogenic EC 
genes at their promoter thereby silencing their expression, and that 5Aza treatment 
prevents this hypermethylation, leading to prevention of atherosclerosis. We found 11 
genes that were strongly hypermethylated and had suppressed expression in d-flow, and 
these were reversed by treatment with 5Aza. These included HoxA5, Tmem184b, 
Adamtsl5, Klf3, Cmkrl1, Pkp4, Acvrl1, Dok4, Spry2, Zfp46, and F2rl1. We also found 
that genes containing promoter cyclic AMP response elements (CRE) are enriched in this 
subset of promoter hypermethylated, d-flow suppressed genes. In addition to HoxA5, we 
found that the entire family of Hox genes, including the co-localized mir10 family, had 
strong flow-dependent methylation changes in the same manner as described for the 11 
genes. We further examined the role of several novel genes, including HoxA5 and Klf3, 
in EC biology using knockdown combined with EC inflammation assays. The findings 
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described in Aim 3 uncover the importance of DNMT-dependent mechanosensitive gene 
regulation by promoter methylation in EC function and highlight novel EC genes as that 
may provide useful targets for future atherosclerosis therapies.  
The work presented here has resulted in new knowledge about the epigenetic EC 
shear response, details the previously unstudied EC methylome, and implicates specific 
loci within the genome for additional studies on their role in EC biology and 
atherosclerosis. This work provides a foundation for future studies to develop more 
targeted therapeutic strategies for CVD. 
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CHAPTER 1 INTRODUCTION 
Clinical Significance of Atherosclerosis  
Atherosclerosis is the major cause of cardiovascular disease, including coronary 
artery disease, coronary microvascular disease, carotid artery disease, peripheral arterial 
disease, and chronic kidney disease1. Coronary artery disease is the number one cause of 
death in the US1,2. In addition to acute symptoms caused by atherosclerosis, a number of 
associated chronic pathologies also burden the healthcare system, including angina (chest 
pain), heart failure (reduced blood flow from the heart due to a weakening of the muscle), 
and arrhythmias (loss of rhythm of the heartbeat). While there are several known risk 
factors and behaviors that increase the likelihood of developing atherosclerosis, the 
underlying cause of the disease remains unknown 4. 
Atherosclerosis, Hemodynamics, and Endothelial Gene Expression 
Atherosclerosis is an inflammatory disease characterized by plaque accumulation 
on the arterial walls18. Endothelial cells (ECs) lining the inner wall of the blood vessels 
become a dysfunctional, permeable barrier to low density lipoprotein and immune cell 
infiltration and lose proper nitric oxide regulation to control vessel dilation.19 
Atherosclerotic plaque rupture (thrombosis and embolism) blocks blood flow and oxygen 
delivery to tissues thereby causing a heart attack or stroke.3 
Blood flow generates shear stress on the vascular walls. Unidirectional, laminar 
shear stress (LS) is crucial for normal vascular function, whereas low, disturbed flow (d-
flow), and oscillatory shear stress (OS) causes vascular dysfunction and disease.5-9 ECs 
have dramatically altered gene expression patterns when exposed to disturbed versus 
unidirectional flow.10-15 Atherosclerosis preferentially develops in areas of d-flow, where 
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the dysfunctional EC phenotype initiates and perpetuates plaque accumulation.20 D-flow-
induced genes are mainly involved in apoptosis, inflammation, angiogenesis, and smooth 
muscle cell proliferation. 
High throughput genome-wide microarray studies have generated clear evidence 
of the endothelial cells’ keen ability to sense and convert mechanical stimuli into 
biochemical signaling responses.6,8,21-23 Endothelial cells have mechanoreceptors that 
sense regions of d-flow and initiate a complex cascade of inflammatory events that 
results in global gene expression changes, endothelial dysfunction, and plaque buildup on 
the vessel wall.24 Numerous key regulatory pathways as well as novel mechanosensitive 
genes and functional gene clusters have been illuminated from these high throughput 
studies.25,26 The data continues to support the working hypothesis that laminar, 
unidirectional flow upregulates “atheroprotective” genes and downregulates “pro-
atherogenic” genes while disturbed, reversing, or stagnant flow results in the opposite 
phenomenon of enhancing pro-atherogenic genes and suppressing atheroprotective genes. 
However, the mechanism by which disturbed flow causes changes in EC gene expression 
is unknown.  
The discovery of master regulators that control a large network of genes is of high 
interest to vascular biologists because such biomolecules would serve as excellent 
therapeutic targets for disease treatment and prevention. Potentially important master 
regulators include epigenetic modifiers and transcription factors that participate in pre-
transcriptional regulation, microRNAs involved in pre-translational regulation of protein 
expression, and post-translational modifiers. Epigenetic modifications such as DNA 
methylation, histone modifications, and chromatin remodeling complexes, alter the 
 3 
genomic DNA structure and accessibility.27 Transcription factors are recruited to specific 
regions of a gene promoter to form a transcriptional complex that assists RNA 
polymerase to bind and transcribe the gene to messenger RNA (mRNA). MicroRNAs 
have a complementary sequence to specific mRNAs and can block their translation or 
cause their degradation. Once mRNA has been successfully translated into protein, post-
translational modifications control their activity and stability. Putative key microRNAs 
(miR21, miR712, miR10a) and epigenetic chromosome structural organizers (HDACs, 
DNA-binding proteins) are currently the subject of extensive research to determine their 
role in large-scale gene network regulation.   
Epigenetics and DNA Methylation 
Epigenetics refers to the modification of genetic information in a sequence-
independent manner. Genomic DNA in an open, relaxed conformation is referred to as 
euchromatin and is associated with acetylated histones and unmethylated DNA. Genes in 
euchromatin are usually transcriptionally active. On the other hand, heterochromatin is 
condensed and is associated with repressive marks such as trimethylated-histone 3 lysine 
9 (H3K9), trimethylated-histone 3 lysine 27 (H3K27), and DNA methylation. 
Heterochromatin generally contains repeat elements and transcriptionally silent genes, 
and its compaction predominantly occurs during development and differentiation.28-32 
Shear stress has been found to mediate chromatin remodeling and histone modifications 
and this is thought to play a role in shear-induced gene expression changes.33,34 
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Figure 1.1: DNA methylation is placed by DNA methyltransferases at the fifth 
carbon of the cytosine ring. 
DNA methylation is the most stable epigenetic modification and involves the 
addition of a methyl group to the 5’ carbon of a cytosine base pair, which is then known 
as 5-methylcytosine (5mC) (Figure 1.1). This modification occurs most frequently in the 
context of a CpG (or CG) dinucleotide.35,36 CpG islands are dense regions of CG sites 
with a higher than expected CG content (generally defined as > 50% with an observed vs. 
expected ratio of >0.6, over a distance of at least 200 base pairs) and are normally 
unmethylated.37 Approximately 40% of human genes are associated with CpG islands.38-
41 Repetitive elements such as Alu, Line1, and B1 elements, and imprinted loci, are 
generally highly methylated.39 CG sites are otherwise sparse throughout the genome due 
to a high rate of C to T mutation caused by spontaneous deamination of methylated 
cytosine, and only functionally important CG sites are thought to be evolutionarily 
protected from this mutation.42-45 
DNA Methylation in disease  
DNA methylation is a regulatory mechanism of gene expression known to play a 
key role in cancer development, particularly in the silencing of tumor suppressor genes 
via aberrant hypermethylation, but its role in many other diseases remains poorly 
understood. Atherosclerosis is characterized by endothelial dysfunction, including 
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hyperproliferation, migration, and inflammation, which are phenotypes also shared by 
cancer cells.  
Recently, DNA methylation has been implicated as a novel risk factor for 
atherosclerosis in smooth muscle cells (SMCs).46-50 Three genes are known to be 
methylated at the promoter in atherosclerotic SMCs: estrogen receptors ER-α, ER-β, and 
fibroblast growth factor 2 (FGF2).51,52,53 Loss of estrogen receptor expression in SMCs 
causes a switch from the quiescent to the proliferative state. Hypermethylation of the ER-
α promoter as well as high plasma homocysteine levels were found in atherosclerosis 
patients.51,54 Age-related promoter hypermethylation of genes such as c-fos, c-myc, 
DBCCR1, E-cadherin, HIC1, IGF2, MYOD1, N33, PAX6, P15, and versican have been 
reported.55 5-methylcytosine (5mC) has been shown to be elevated in the intima of ApoE-
/- mice fed western diet, and high 5mC levels are linked LDLR and p53 mutation in 
vascular cells.45,50 15-lipoxygenase, a gene implicated in oxidative modification of LDL, 
is regulated by DNA methylation.56  
Aberrant DNA methylation is a well-known phenomenon in many cancers, and 
hypomethylating drugs that inhibit DNA methyltransferases have proven to be promising 
treatment options. 5Aza-2’-deoxycytidine (5Aza) is a well-studied DNMT1 preferential 
inhibitor.57-62 5Aza is a nucleoside analog that works by trapping DNMT1 in a covalent 
complex with DNA, resulting in DNMT1 degradation. 5Aza is commercially known as 
Decitabine and is used as a chemotherapeutic agent for cancers, more specifically, acute 
myeloid leukemia and myelodysplastic syndromes. Decitabine is thought to work by 
causing demethylation of oncogenes.58-62 However, it is somewhat cytotoxic to bone 
marrow cells and this limits its therapeutic capacity. Current research explores the use of 
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CHAPTER 2 SPECIFIC AIMS 
 
Significance and Impact 
Prior to the conception of this project there were no studies on the regulation of 
epigenetics in endothelial cells (ECs) by mechanical forces generated by blood flow, and 
further no studies on the role of DNA methyltransferases (DNMTs) in ECs. Early reports 
of shear stress effects on epigenetics described novel pathways by which shear stress 
mediates chromatin remodeling and histone modifications in cultured endothelial cells 
63,64. However, until very recently, detailed endothelial cell epigenetic responses to shear 
stress were unknown. During the culmination of this thesis project, several research 
groups in vascular mechanobiology independently converged on the seminal finding that 
DNA methyltransferases are shear responsive proteins that regulate flow-mediated 
endothelial gene expression programs via DNA methylation 16,65,66. These studies point to 
the opportune timing of our studies, and highlight the pertinence and novelty of this work 
to the field of vascular mechanobiology and disease. 
This study was the first to examine the global effects of blocking DNA 
methylation pathways using DNMT inhibition in ECs. 5Aza-2’deoxycytidine (5Aza) and 
short interfering RNA (siRNA) treatments allowed us to directly observe the functional 
consequence of DNMT1 inhibition on global EC DNA methylation patterns and EC 
biology. Results from our in vitro studies predicated the question of whether there would 
be a functional effect of DNMT1 inhibition on disease outcome. We used two in vivo 
models of acute d-flow-induced and chronic diet-induced atherosclerosis as a robust 
system to analyze DNMT inhibition effects on disease development. The question of 
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whether DNMT1 inhibition affects EC inflammation in vitro and atherosclerotic plaque 
development in vivo has never been addressed before this point. 
Many of the discoveries that are detailed in this dissertation were also published 
in the Journal of Clinical Investigation, and our work garnered international recognition 
through presentations at international conferences and coverage by various media outlets 
including the American Heart Association Science News 16. This work provides a 
foundation for future studies to develop more targeted therapeutic strategies for CVD. 
Rationale 
Data from our lab’s previous high throughput gene expression studies of 
endothelial cells in the in vivo mouse carotid artery using mRNA microarrays implicated 
DNA methyltransferase 1 as a potentially functionally important mechanosensitive gene 
17. DNA Methyltransferase 1 (DNMT1) was highlighted in the pool of ~600 shear-
sensitive endothelial cell (EC) genes discovered by microarray in the mouse partial 
carotid ligation model due to its flow-sensitivity (~2.4 fold expression increase in the 48 
hour disturbed flow LCA as compared with the control RCA) and its functional 
importance in development and disease. The other catalytically active DNA 
methyltransferases, DNMT3a, DNMT3b, and DNMT3L, were not found to be strongly 
flow-responsive in this model.  
Preliminary results established significant DNMT1 upregulation in ECs under 
oscillatory shear (OS) in vitro and in disturbed flow (d-flow) in vivo. Therefore it was 
hypothesized that DNMT1 may have an important role in the EC shear response, which is 
the gateway to d-flow-induced atherosclerosis development. The effect of DNMT1 
inhibition by 5Aza was tested on OS-induced EC inflammation, which is a major 
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hallmark of atherosclerosis, and on in vivo plaque development in atheroprone mice. 
Based on results demonstrating that DNMT1 inhibition reduces inflammatory signaling 
in ECs in vitro and plaque development in vivo, combined with the fact that the 
functional role of DNMT1 is to methylate DNA, the most probable and relevant 
downstream effect of DNMT1 upregulation is an alteration of DNA methylation. 
Resolving the EC methylome and transcriptome under disturbed versus unidirectional 
flow conditions enabled us to discover methylation and gene expression changes due to 
d-flow exposure. To implicate DNMT1 specifically in d-flow-induced methylation 
changes, the effect of DNMT1 inhibition on ECs under flow was also tested. We 
expected that DNMT1 inhibition would prevent the d-flow-induced methylation changes 
if DNMT1 is indeed the key player in establishing those methylation changes. Based on 
our discovery that DNMT1 is increased in d-flow, we hypothesized that d-flow leads to 
site-specific methylation changes that cause loss of anti-atherosclerotic gene expression 
by DNA methylation at the promoter. We further expected that DNMT1 inhibition by 
5Aza would rescue these genes and prevent the pro-atherosclerotic phenotype. 
Using a systems biology approach, the functional consequences of d-flow-induced 
DNA methylation and gene expression changes were explored to implicate novel genes 
that were previously unstudied in the context of the endothelial flow response and 
atherosclerosis. Discovery and validation of gene-specific methylation changes that cause 
gene expression changes produced a set of genes for further analysis. A subset of these 
genes were discovered by gene ontology analysis as transcription factors, and they were 
studied based their potential functional role as key network regulators. The effect of 
blocking d-flow-induced methylation changes in these genes on EC inflammation, which 
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is a hallmark of atherosclerosis, was explored. The work presented here has resulted in 
new knowledge about the epigenetic EC shear response, details the previously unstudied 
endothelial cell methylome, and implicates specific loci within the genome for additional 
studies on their role in EC biology and atherosclerosis.  
Innovation 
The finding that atherosclerosis is induced by disturbed blood flow (d-flow) is 
relatively recent, and is supported by the fact that global gene expression changes occur 
in ECs exposed to d-flow that cause a dysfunctional, pro-inflammatory EC phenotype. 
However, the mechanism by which these global gene expression changes take place is 
unknown, and the possibility of epigenetic gene regulation remained unexplored prior to 
this study. 
Major advancements in methylomics were established with the advent of new 
technologies to resolve genome-level methylation at the nucleotide scale. The Human 
Epigenome Project and the NIH Roadmap Epigenomics Mapping Consortium are part of 
a major undertaking across multiple research facilities to create high-resolution DNA 
methylation and other epigenomic maps in various cell types.67 While progress has been 
made, there is a clear lack of methylome data for ECs. One dataset using the Illumina 
450k methylation array in static cultured HUVECs is publicly available, but there are no 
in vivo EC datasets, and furthermore none under varying flow and treatment conditions. 
The study described herein was the first to tackle this missing puzzle piece, with six new 
methylome datasets (ECs exposed to d-flow for either 2 or 7 days in vivo, and also with 
DNMT1 inhibition by 5Aza) that are critical for both cardiovascular and epigenomic 
research advancements. 
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A major challenge in the “omics” field is data mining to produce intelligible 
results from vast arrays of uninterpretable raw data. Data analysis can often act as a 
bottleneck in the pipeline from benchtop experiments to elucidation of therapeutic 
candidates. The data analysis performed for this project produced specific candidate 
genes as targets of d-flow-induced methylation. The systematic a posteriori search for 
global trends combined with the a priori pattern filtering creates a robust methodology to 
analyze methylomics on the genome and single gene, and even single nucleotide, scale. 
Project Objective  
While we know that laminar, unidirectional flow upregulates “atheroprotective” 
genes and downregulates “pro-atherogenic” genes while disturbed, reversing, or stagnant 
flow results in the opposite phenomenon, the mechanism by which flow controls EC gene 
expression is unknown. The goal of this project was to determine how the DNA 
methylome responds to flow, causes altered gene expression, and regulates 
atherosclerosis development. 
Overall Hypothesis 
Disturbed flow increases DNA Methyltransferase 1 (DNMT1) expression in 
endothelial cells. This in turn causes a shift in the EC methylome and transcriptome 
towards a pro-inflammatory, pro-atherosclerotic gene expression program which leads to 
atherosclerosis development. More specifically, we hypothesize that DNMT1 
overexpression induces site-specific DNA hypermethylation in the promoter of key gene 
network regulators, which suppresses their expression and changes the endothelial 
transcriptome to a pro-atherosclerotic state. 
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Specific Aim 1: Elucidate the role of DNA Methyltransferase 1 in endothelial cell 
function  
Data from our lab’s previous in vivo mouse carotid artery mRNA microarrays 
implicated DNMT1 as a potentially functionally important mechanosensitive gene in EC 
biology. The mRNA array showed that DNMT1 expression was ~2.4-fold higher in the 
LCA exposed to d-flow for 48h following the partial ligation than in the contralateral 
RCA exposed to s-flow 17. In Chapter 3, we show that DNMT1 is upregulated by d-flow 
at the transcript and protein level in vivo and in vitro. DNMT1 inhibition using the 
chemical inhibitor 5-Aza-2’deoxycytdine (5Aza) or DNMT1 siRNA was done in vitro 
prior to shear in HUVECs, and 5Aza was used in mouse models of atherosclerosis to 
determine the functional outcome of blocking DNMT1 overexpression in d-flow. We 
show that DNMT1 inhibition by 5Aza inhibits inflammation and global methylation in 
ECs in vitro and plaque development in both acute and chronic murine models of 
disturbed flow-induced atherosclerosis in vivo. Preliminary studies exploring the 
mechanism of upstream DNMT1 regulation point to the mir29 family as potential 
mechanosensitive regulators of this pathway. This work establishes the importance of 
DNMT1 in EC biology and atherosclerosis. 
Specific Aim 2: Examine the DNA methylation-dependent endothelial gene 
expression response to flow 
Specific aim 2 was designed to determine the mechanistic importance of DNMT1 
overexpression by d-flow and also the mechanism of action of DNMT inhibition by 5Aza 
in disturbed-flow-exposed endothelium. Since DNMT1 is known to methylate genomic 
DNA and DNA methylation is a regulator of gene expression, we designed two parallel 
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“omics” studies to examine the effects of both disturbed flow and DNMT inhibition on 
the endothelial cell DNA methylome and transcriptome in vivo. We carried out the 
reduced representation bisulfite sequencing (RRBS) study using endothelial-enriched 
genomic DNA (gDNA) obtained from the RCA and LCA of partially ligated mice at two 
different time points of two days and one week post-ligation. To further determine 
whether the flow-dependent DNA methylation changes were regulated in a DNMT-
dependent manner, mice treated with 5Aza were compared to a saline vehicle control. 
Moreover, to determine which mechanosensitive genes have transcriptional 
dysregulation, potentially by DNA hypermethylation, we carried out a concomitant gene 
transcript microarray study using endothelial-enriched RNA obtained from the LCA and 
RCA of partially-ligated mice treated with either saline (RCA vs. LCA) or 5Aza (Aza-
RCA vs. Aza-LCA). From these studies we found that DNMT inhibition by 5Aza rescues 
global gene expression in the d-flow-exposed LCA to a healthy state. While genome-
wide DNA methylation and specific functional genomic elements did not have 
dramatically changed methylation under these conditions, we followed a specific 
hypothesis and discovered a subset of genes that have d-flow-induced promoter 
hypermethylation correlating with gene suppression, both of which were 5Aza-reversible. 
Based on systems biology and further bioinformatics analysis, we found that gene 
promoters containing cyclic AMP Response Elements (CRE) are preferentially 
demethylated at their CG sites as compared to other promoter CG sites in the RCA. 
Additionally, these promoter CRE CG sites are specifically hypermethylated by d-flow. 
We further discovered that, on the genome scale, CRE CG hypermethylation corresponds 
to decreased gene expression. These studies, described in detail in Chapter 4, used 
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“omics” datasets to uncover a key regulatory network regulated by DNA methylation that 
can provide a basis for future studies on novel therapeutic targets for atherosclerosis. 
Specific Aim 3: Discover and examine master regulators of endothelial function that 
are controlled by DNA methylation 
To discover genes that are important in endothelial biology and regulated by DNA 
methylation, we performed detailed examination of the methylome and transcriptome 
data described in Chapter 4. To determine the mechanisms by which 5Aza inhibited 
atherosclerosis in vivo and endothelial cell inflammation in vitro (as described in Chapter 
3), we tested the specific hypothesis that d-flow induces hypermethylation of anti-
atherogenic endothelial genes at their promoter thereby silencing their expression, and 
that 5Aza treatment prevents this hypermethylation, leading to prevention of 
atherosclerosis. We found 11 genes that were strongly hypermethylated and had 
suppressed expression in d-flow, and these were reversed by treatment with 5Aza. These 
included HoxA5, Tmem184b, Adamtsl5, Klf3, Cmkrl1, Pkp4, Acvrl1, Dok4, Spry2, Zfp46, 
and F2rl1. We also found that genes containing promoter cyclic AMP response elements 
(CRE) are enriched in this subset of promoter hypermethylated, d-flow suppressed genes. 
In addition to HoxA5, we found that the entire family of Hox genes, including the co-
localized mir10 family, had strong flow-dependent methylation changes in the same 
manner as described for the 11 genes. We further examined the role of several novel 
genes, including HoxA5 and Klf3, in endothelial biology using knockdown combined 
with endothelial inflammation assays. The findings described in Chapter 5 uncover the 
importance of DNMT-dependent mechanosensitive gene regulation by promoter 
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methylation in endothelial cell function and highlight novel endothelial genes as potential 
therapeutic targets for atherosclerosis.  
Study Approval 
All animal procedures were approved by the Institutional Animal Care and Use 




CHAPTER 3 THE ROLE OF DNA METHYLTRANSFERASE 1 
IN ENDOTHELIAL CELL FUNCTION  
Summary  
Data from our lab’s previous in vivo mouse carotid artery mRNA microarrays 
implicated the DNA methyltransferases as potentially functionally important 
mechanosensitive genes. The mRNA array showed that DNMT1 expression was ~2.4-
fold higher in the LCA exposed to d-flow for 48h following the partial ligation than in the 
contralateral RCA exposed to s-flow17. D-flow-induced DNMT1 upregulation was 
validated at the transcript and protein level in vivo and in vitro. DNMT1 inhibition using 
the chemical inhibitor 5-Aza-2’deoxycytdine or DNMT1 siRNA was done in vitro prior 
to shear in HUVECs, and 5Aza was used in chronic and acute models of atherosclerosis 
to determine the functional outcome of blocking DNMT1 overexpression in d-flow. A 
major portion of Chapter 3 was published as follows: Dunn, J., Qiu, H., Kim, S., Jjingo, 
D., Hoffman, R., Kim, C. W., Jang, I., Son, D. J., Kim, D., Pan, C., Fan, Y., Jordan, I. K. 
Jo, H. Flow-dependent epigenetic DNA methylation regulates endothelial gene 
expression and atherosclerosis. J Clin Invest 124, 3187-319916. Here, we demonstrated 
that disturbed, oscillatory shear stress induces DNMT1 overexpression at the transcript 
and protein level in vivo and in vitro and that DNMT1 inhibition by 5Aza inhibits 
inflammation and global methylation in ECs in vitro, and plaque development in both 
acute and chronic murine models of disturbed flow-induced atherosclerosis in vivo. 
Preliminary studies exploring the mechanism of upstream DNMT1 regulation point to the 
mir29 family as a potential mechanosensitive regulator of this pathway. This work 
establishes the importance of DNMT1 in EC biology and atherosclerosis. 
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Introduction 
The Role of Fluid Mechanics in Endothelial Cell Gene Expression, the Endothelial 
Response to Blood Flow, and Atherosclerosis Development 
Endothelial cells that line the blood vessel intima contain mechanoreceptors that 
sense regions of disturbed flow and initiate a complex cascade of inflammatory events 
that results in endothelial dysfunction and plaque buildup on the vessel wall.24 Global 
gene expression in endothelial cells is altered, and newly expressed genes are involved in 
apoptosis, inflammation, angiogenesis, and smooth muscle cell proliferation.  
Mechanosensitive Endothelial Cell Genes 
Traditionally, gene expression studies conducted in vascular tissue were limited to 
single gene analyses of mechanical responsiveness and functional role in regulating cell 
shape and behavior with regard to vascular homeostasis and disease development.68,69 
Model systems engineered to study the effect of fluid shear stress on endothelial cells 
included shear-exerting bioreactors (e.g. cone and plate viscometer, parallel plate 
perfusion flow chamber)22,70,71 for in vitro studies and porcine, murine, and canine 
models for in vivo studies. While bioreactor systems offered the advantage of precise 
control over flow conditions by bioreactor construction specifications, fluid composition, 
and environmental conditions, and allowed freedom to study human cells, they lacked 
several important factors that exist in the in vivo setting such as mechanical cell-substrate 
interactions, crosstalk with local and circulating cells and molecules, and variable 
rheologic properties.  
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In the early 1990s the idea of single gene analysis was advanced by the discovery 
of shear stress response elements (SSREs), or common cis-acting elements of gene 
promoters that are regulated by a single shear-controlled transcription factor. SSREs 
enable co-regulation of a host of genes under specific environmental conditions that 
activate their common transcription factor. Resnick et al. discovered the first SSRE 
common to the key signaling molecules platelet-derived growth factor beta (PDGF-B), 
tissue plasminogen activator, intercellular adhesion molecule 1 (ICAM1), and 
transforming growth factor beta 1 (TGFB1) that are all induced by laminar shear 
conditions.72 SSREs have also been identified in other key genes such as Vascular 
Endothelial Growth Factor (VEGFR) and endothelial nitric oxide synthase (eNOS) and 
there are likely many SSREs that remain to be discovered.14,73 
Genome-Wide Analysis and Discovery of Mechanosensitive Signaling Pathways  
Because in vitro environments cannot fully recapitulate the effects of shear stress 
on the vascular endothelium in vivo, microarray studies evolved to in vivo settings to 
reveal the pathophysiological relevance of gene expression profiles in vascular 
endothelium exposed to specific flow conditions. Though there has been progress in the 
characterization of endogenous flow profiles in vivo,9 the necessity for more detailed 
studies of gene function in vivo begot the development of the mouse partial carotid 
ligation model by our lab.74 In this model, disturbed flow is induced in the left common 
carotid artery by ligation while the right common carotid artery remains untouched as an 
internal control. Our lab also developed a novel endothelial mRNA and microRNA 
collection technique that enabled the use of microarray technology to study global gene 
expression changes in mouse endothelium exposed to disturbed flow in an in vivo setting. 
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The dataset generated findings of 523 mechanosensitive genes changed within two days 
of disturbed flow exposure, including numerous genes previously undescribed in the 
context of the cardiovascular system.17  
High throughput genome-wide microarray studies have demonstrated that 
endothelial cells respond to different shear stresses by altering their transcriptional 
networks.6,8,21-23 Through these experiments, numerous key shear sensitive regulatory 
pathways as well as novel mechanosensitive genes and functional gene clusters have been 
illuminated and studied in great detail based on their role in endothelial cell homeostasis 
and disease development.21,25,26  Specific intracellular signaling pathways that become 
prevalent under low/oscillatory, atheroprone shear stress are juxtaposed with pathways 
that dominate under high, atheroprotective, laminar shear areas, cyclic stretch, and 
appropriate hydrostatic pressure (Figure 3.1).11 A host of mechanosensitive, 
atheroprotective genes that are highly expressed in laminar, unidirectional flow 
conditions have been uncovered. This includes eNOS, the gene responsible for nitric 
oxide production and maintenance of vascular tone, and several other genes involved in 
cell survival that have anti-thrombotic, anti-inflammatory, and anti-oxidant properties 
such as the Kruppel-like factor family (namely Klf2 and Klf4), and Superoxide 
Dismutases (Mn-SOD, EC-SOD).75 Additional mechanosensitive genes involved in 
immune response activation (MCP-1,23,76 VCAM-1, ICAM-177, NKFB12)78, reactive 
oxygen species production (NADPH Oxidases), and extracellular matrix reorganization 
causing vascular remodeling (TIMP-3, MMP-1) are found to be pro-atherogenic genes 
whose expression is suppressed under unidirectional laminar flow conditions and 
overexpressed under deleterious disturbed flow conditions. Many mechanosensitive cell 
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cycle regulators involved in endothelial cell homeostasis, including p53, GADD45, p215, 
ERK, play a key role in growth and proliferation suppression or activation.  
One area of special interest lies in the discovery of master regulators that control a 
large network of genes (Figure 3.2). These biomolecules would serve as excellent 
therapeutic targets for disease studies. Potentially important master regulators include 
epigenetic modifiers and transcription factors that participate in pre-transcriptional 
regulation, microRNAs involved in pre-translational regulation of protein expression, and 
post-translational modifiers such as kinases. Epigenetic modifications such as DNA 
methylation, histone modifications, and chromatin remodeling, alter the genomic DNA 
structure and accessibility. Transcription factors are proteins recruited to specific regions 
of a gene promoter to form a transcriptional complex that assists RNA polymerase to 
bind and transcribe the gene to messenger RNA (mRNA). MicroRNAs have a 
complementary sequence to specific mRNAs and can block their translation or cause 
their degradation. Once the mRNA has been successfully translated into protein, post-
translational modifications control their activity and stability. For example, kinases can 
activate or deactivate a protein by phosphorylation, and the post-translational modifier 
ubiquitin may ubiquitinylate a protein to target it for destruction by the proteasome. 
Putative key microRNAs (miR21, miR712, miR10a79) and epigenetic chromosome 
structural organizers (HDACs, DNA-binding proteins) are currently the subject of 
extensive research to determine their role in large-scale gene network regulation.  
Mechanoreceptors Transduce Mechanical Forces into Biochemical Signaling in 
Endothelial Cells 
Mechanoreceptors recognize blood flow patterns and transduce signals within 
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endothelial cells, which respond to unhealthy, disturbed flow by initiating plaque buildup 
in the vessel walls (known as atherosclerosis, a major component of cardiovascular 
disease). Several endothelial cell mechanoreceptors have been identified, including ion 
channels, cytoskeleton, tyrosine kinase receptors, caveolae, G proteins, and cell-matrix 
and cell-cell junction molecules such as integrins, platelet endothelial cell adhesion 
molecule- 1 (PECAM-1) and adherens junctions.80,81 However, the mechanisms by which 
these mechanoreceptors recognize disturbed flow and transduce a signal that results in 
altered global gene expression in endothelial cells is largely unknown. Possible 
mechanisms involved in altered transcriptional activity include changes in transcription 
factor activity and epigenetic changes.  
A subset of the mechanosensitive genes mentioned previously have been found to 
be vital for the endothelial cell’s ability to sense mechanical stimuli. When their 
expression or normal activity is interrupted, cells lose phenotypic or gene expression 
changes associated with a specific mechanical stimulus, for example the transformation 
from a polygonal shape to align with the direction of flow under laminar shear stress 
conditions 82. The intact mechanosensory complex at endothelial cell junctions consisting 
of PECAM-1, VECadherin, and VEGFR2, is crucial for the endothelial cell to be able to 
activate anti-atherosclerotic gene programs in response to laminar flow81. Several other 
important mechanotransduction pathways begin at the cell membrane, including integrins 
(FAK), cell membrane proteins [RTKs (PDGFRa72, EGFR), GPCRs], ion channels 
(Ca2+), and intercellular junctions, and travel biochemically through the cytosol or 




Figure 3.1: Mechanotransduction signaling pathways in endothelial cells in response 
to either (A) laminar or (B) oscillatory shear stress stimuli.  Laminar shear stress 
stabilizes a healthy, anti-inflammatory state in endothelial cells that results in 
cytoskeletal remodeling and endothelial cell alignment in the direction of flow, as 
well as increased nitric oxide production and suppression of inflammatory cell 
adhesion molecules. Conversely, disturbed flow or oscillatory shear stress induces 
an inflammatory and thrombotic state characterized by high expression of cell 
adhesion molecules and production of inflammatory cytokines, high oxidative stress, 
lack of cell alignment with flow, and a leaky endothelial cell barrier that allows 
infiltration of smooth muscle cells and immunomodulatory cell types84,85 . 
 
Figure 3.2: Mechanosensory pathways utilize surface mechanoreceptors to induced 
biochemical cell signaling events.  Mechanoreceptors include ion channels (K+, 
Ca2+, Na+, Cl-), receptor tyrosine kinases, G-protein coupled receptors, etc., cell-
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cell and cell-matrix adhesion complexes (PECAM1/VE-Cadherin/VEGFR2 
complex, Focal Adhesion Kinases, etc.), the glycocalyx, and cytoskeletal elements 
that transduce signals and result in downstream signal amplification via master 
regulators such as kinase cascades and transcription factor networks. These 
signaling events alter the endothelial cell phenotype and behavior in response to 
extracellular biomechanical stimuli 7,84.  
DNA Methyltransferases 
DNA methyltransferases (DNMTs) catalyze the addition of the methyl group to 
cytosine. DNMT1 is thought to preferentially methylate hemimethylated DNA, meaning 
that the complementary strand of a CG dinucleotide often carries the same methylation 
markings. Although DNMT1 is classically referred to as a maintenance methylase, it also 
has de novo methylation capabilities.86,87 Both DNMT1 overexpression and DNMT1 
deficiency are embryonic lethal, and DNMT1 deletion causes genome-wide 
hypomethylation while DNMT1 overexpression causes genome-wide 
hypermethylation.88-91  DNMT3a and DNMT3b are classically referred to as de novo 
methyltransferases that preferentially add methyl groups to fully unmethylated DNA. 
DNMT3a and DNMT3b establish global DNA methylation patterns during 
embryogenesis and gametogenesis.92 
microRNAs 
MicroRNAs (miRs) are potent regulators of gene expression that act post-
transcriptionally to repress a gene by blocking mRNA translation or causing its 
degradation, and there are several miRs that are known to target DNMTs in cancer. 
Additionally, flow is known to regulate several miRs93-101.  
DNMT1 is verified as a direct target gene for miR-148a and miR-152, and the 
miR29 family.102-104 The miR29 family is known to regulate the methylation status of 
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specific genes via regulation of DNMT1, DNMT3a, and DNMT3b, and it is known to be 
dysregulated in several cancers.105,106 The transcription factor Myc, which is 
overexpressed in several cancers, suppresses mir29c.107 Chen et al. showed that oxidized 
low-density lipoprotein upregulates mir29b expression, which downregulates DNMT3b 
and decreases MMP2/9 DNA methylation levels, leading to increased primary human 
aortic smooth muscle cell migration.108 This was implicated as a novel mechanism for 
cardiovascular disease. Additional studies support the epigenetic regulation of MMP2 
and MMP9 in carcinogenesis109,110. Viral infection induces miR29b, which decreases 
DNMT activity111. This very interestingly induces COX2 expression via demethylation of 
its promoter CRE, which also supports our interest in the mechanisms of DNMT-
regulated global gene expression by promoter CRE methylation that is explored in 
Chapter 4.111 Further, shear stress is known to upregulate COX2 expression via increased 
promoter CRE binding by AP1 and C/EBPβ in osteocytes112. Taken together, these 
findings suggest that the mir29 family contains potential DNMT1 regulators that may be 
useful in controlling downstream flow-controlled DNA methylation pathways in 
endothelial cells.  
Methods 
Techniques to Analyze Shear Stress Effects on Endothelial Cells 
Partial Carotid Ligation in ApoE or C57Bl6 mice 
8-week-old C57BL/6 or ApoE-/- mice (Jackson Laboratories) were used for all 
animal studies according to the approved Institutional Animal Care and Use Committee 
protocol by Emory University. Mice were partially ligated under isofluorane anesthesia 
and the resultant disturbed flow conditions in the LCA were determined by ultrasound 
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measurements as described previously 113. Briefly, 3 out of 4 caudal branches of the LCA 
(left external carotid, internal carotid, and occipital artery) were ligated with 6-0 silk 
suture, while the superior thyroid artery was left intact (Figure 3.3). Mice were sacrificed 
by CO2 inhalation and were subsequently perfused with saline containing heparin for 5 
minutes Total carotid intimal RNA or genomic DNA was isolated by flushing the RCA 
and LCA with Qiazol or Buffer AL, respectively, by our method that we have 
demonstrated to be endothelial-enriched without any significant contamination of smooth 
muscle cells and leukocytes 17,101,113. 
 
Figure 3.3: A scheme of the partial carotid ligation mouse surgery model.  A) 
Location of sutures at the external carotid, internal carotid, and occipital arteries 
for partial ligation. B) Low and reversing flow in the LCA one day and one week 
post-ligation by ultrasound. C) Plaque accumulation in the LCA 4 weeks post-
ligation on a high fat diet. D) Carotid flushing for intimal RNA or gDNA114. 
In vitro systems: cell culture and shear stress systems  
Human Umbilical Vein Endothelial Cells (HUVEC, Lonza cc-2519) were 
maintained in M199 (Fisher MT10060CV) base culture medium containing 20% Fetal 
Bovine Serum (SH30071), 10% penicillin/streptomycin/fungizone (Gibco 15240-062), 
10% glutaMax (Mediatech, 25-005-cl), 10% endothelial cell growth serum, and 0.4% 
heparin (McKesson Medical 404867). In vitro shear stress was applied to passage 6 
HUVECs in 10cm culture plates for 24 hours using a cone and plate viscometer that 
exerts 15 dynes/cm2 of unidirectional flow (laminar shear stress, or LS conditions) and ± 
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5 dynes/cm2 of bidirectional flow (oscillatory shear stress, or OS) (Figure 3.4). The cell 
culture plates were secured in place at the bottom by a vacuum pump and the incubator 
was maintained at 5% CO2 and 37°C. Total RNA or genomic DNA was collected by 
scraping cells in Qiazol (Qiagen) or Buffer AL (Qiagen DNeasy Blood & Tissue Kit), 
respectively. 
 
Figure 3.4: In vitro Cone-Plate Shear System    (10 (LS) or ±5 (OS) dynes/ cm2 
exerted on EC monolayer) 
RNA Extraction from Cultured Endothelial cells or Mouse Carotid Artery for Gene 
Expression Analysis 
Microarray 
Using the mouse partial carotid ligation model and the Illumina Bead Chip DNA 
microarray containing 45,281 gene probes, our lab previously identified ~600 
“mechanosensitive” genes whose expression changes in ECs exposed to disturbed flow in 
the left carotid artery (LCA) as compared to unidirectional flow in the right carotid artery 
(RCA) for 12 and 48 hours (C57Bl6 mice; n=3 for each timepoint, each n contains 3 
pooled carotid samples).17 We have additional subsequent array data using the 
Affymetrix Mouse HT-MG-430 array platform for 12, 24, 48 hours and 2 weeks post-
ligation (C57Bl6 mice; n=5 for each timepoint, each n is one individual carotid sample).  
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qPCR 
Total carotid intimal RNA isolated by flushing the RCA and LCA with 150 ul 
Qiazol was purified by the Qiagen miREasy Kit and reverse-transcribed into cDNA using 
SuperScript III and random primers (Invitrogen). Total RNA was collected from HUVEC 
cultures in 700 ul of Qiazol and purified by the same method as above. QPCR for specific 
genes was performed using Brilliant II SYBR Green qPCR Master Mix (Stratagene) with 
custom designed primers (Table 3.1) on the ABI StepOne Plus Real-Time PCR System. 
Results were normalized to the 18S housekeeping gene and the fold change between 
siRNA-treated and negative control samples were determined using the ΔΔCt method 115. 
 
Table 3.1: Primers used for qPCR or bisulfite sequencing (BS-Seq).  
 
Immunohistochemistry and Oil-Red-O Staining on Mouse Carotid Arteries and Aortic 
Arch  
Frozen blocks containing the heart, aortic arch, and carotid arteries were prepared 
in TissueTek and stored at -80℃. Immunohistochemistry was performed on selected 
sections from specific intervals of the frozen blocks using the following antibodies: 5-
methylcytidine (Eurogentec, BY-MECY), DNMT1 (Santa Cruz sc-20701), DNMT3b 
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(Abcam ab2851), DNMT3a (Abcam ab23565), and CD45 (eBioscience 13-0454). 
Selected sections from specific intervals from the blocks were stained with Oil-Red-O by 
fixing the frozen tissues with 10% formalin for two minutes, rinsing twice with distilled 
water for five minutes, orbital shaking in 100% propanediol for ten minutes and 
incubation in 0.2% Oil Red-O solution for five minutes at 85℃. For hematoxylin 
staining, the previous method was followed by two rinses with distilled water, a 
hematoxylin dip for 30 seconds, two rinses with distilled water, one rinse with Scott’s 
water, two rinses with distilled water, and then mounting. Plaque size was quantified 
using ImageJ software.  
5-Aza-2-Deoxycytidine and siRNA treatment of HUVECs in vitro 
Optimal 5-Aza-2’-deoxycytidine (5Aza; Sigma A3656) treatment conditions were 
determined by a dose-curve using 0, 0.5, 1, 5, and 20 µM 5Aza for 5 days, and by 
duration curve of 5uM 5Aza for 0, 0.5, 1, 2, 3, 5, and 7 days. DNMT enzymatic activity 
and DNMT1 protein expression assays indicated the optimal dose of 5 µM. For shear 
studies, 5 µM 5Aza was treated for 5 days prior to in vitro shear, and the LS or OS 





Figure 3.5: 5-Aza-2’-deoxycytidine decreased DNMT1 protein expression, activity, 
and global DNA methylation in HUVECs a dose- and time-dependent manner.   (A) 
Western blot of DNMT1 protein expression in static HUVEC cells treated with 0, 
0.5, 1, 5, and 20 µM 5Aza for 5 days (right) or with 5 µM 5Aza for a duration of 0, 
0.5, 1, 2, 3, 5, or 7 days (left). (B) DNMT enzymatic activity in HUVEC cells treated 
with 0, 0.5, 1, 5, and 20 µM 5Aza for 5 days (right) or with 5 µM 5Aza for a duration 
of 0, 0.5, 1, 2, 3, 5, or 7 days (left). (C and D) DNMT enzymatic activity increases in 
HUVECs in OS conditions. This increase is blunted in a dose- and time-dependent 
manner by treatment with 5Aza.  
SiRNA was transfected using oligofectamine (Invitrogen 12252-011) with 100nM 
final concentration of siDNMT1 (Dharmacon RNAi ON-TARGET plus SMART pool) or 
100nM stealth RNAi negative control (medium GC content, Invitrogen 12935-112) in 
OptiMEM (Invitrogen 31985-088) for 6 hours followed by normal HUVEC media 
replacement. After 48 hours, shear stress (either LS or OS) was applied for an additional 
24 hours. SiRNA dose optimization was done in static HUVECs in doses of 25, 50, 75, 
100, 400nM of siRNA in a total volume of 0.5ml. After 6 hours of incubation with 
siRNA, media was replaced with standard HUVEC media, and RNA and protein were 




Figure 3.6: Dose (mRNA level) and time (protein level) curve optimization of 
DNMT1 siRNA.  (A) DNMT1 mRNA expression was measured by qPCR in static 
HUVEC cells treated with either 100nM or 200nM of either negative control siRNA 
or siRNA targeting DNMT1 for 48 hours. (B) Western blot of DNMT1 protein 
expression in static HUVEC cells treated with 100nM of either negative control 
siRNA or siRNA targeting DNMT1 for either 48 or 72 hours.  
Western Blot on Protein Extracts from HUVECs 
Western Blotting was performed by the standard method using antibodies for the 
following: DNMT1 (Santa Cruz sc-20701), DNMT3a (Abcam ab23565), DNMT3b 
(Abcam ab2851), and β-actin (Sigma A5316), and HoxA5 (Abcam ab82645). 
MspI/HpaII Restriction Enzyme Assay to Determine Global DNA Methylation Status In 
Vitro  
Genomic DNA was collected and purified by the DNeasy Blood and Tissue kit 
(Qiagen) from HUVECs treated with either 5µM 5Aza or vehicle control for 5 days. 
Either MspI or HpaII (ThermoSci ER0541) were reacted with the genomic DNA 
according to the recommended protocol for the restriction enzymes. The reaction 
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products were run on a 2.5% agarose gel stained with ethidium bromide alongside a 100 
bp ladder (NEB N3231L) and imaged under UV light. MspI and HpaII cut at the C/CGG 
recognition site. MspI cleaves regardless of the internal cytosine methylation status, 
while HpaII is blocked from cleavage by internal cytosine methylation. 
 
Figure 3.7: Results of the MspI/HpaII methylation restriction enzyme assay  show 
that global methylation decreases in static HUVECs treated with 5uM 5Aza for 5 
days. Lanes 5, 10, and 15 contain the molecular weight ladder (marked on the right 
of the figure). Lanes 1-4 and 6-9 are duplicates and lanes 11-14 are using either fully 
unmethylated or fully methylated DNA to show the effect of methylation on the 
restriction digest for the two enzymes. Lanes 2 and 6 contain genomic DNA from 
untreated HUVECs, and HpaII cleavage was blocked due to methylated cytosine. 
The band disappears in lane 4 and 9, when HpaII can cut the hypomethylated DNA 
from 5Aza-treated HUVECs.  
DNMT Activity Assay 
The DNMT enzymatic activity assay was performed according to the 
manufacturer’s protocol (Epigentek, P-3010). Briefly, nuclear extracts from HUVEC that 
underwent either LS or OS for 24 hours, with or without 5Aza pre-treatment (5uM for 5 
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days before shear), were incubated with the DNMT substrate (unmethylated cytosine) 
and an antibody binding and fluorometric assay was used to measure the ratio of 
methylated to unmethylated cytosine to determine overall DNMT enzymatic activity.  
Monocyte adhesion assay 
HUVECs were pre-treated with either 5Aza or siRNA and were subjected to 
either LS or OS for 24 hours. Separately, human peripheral blood mononuclear 
leukocytes (THP-1 cells) were cultured in serum-containing RPMI medium (Fisher 
MT10040CM) and were labeled in serum-free RPMI with 5µl/ml 2’7’-bis-(2-
carboxyethyl)-5-(and-6)-carboxyfluorescein (BCECF-AM; Molecular Probes B-1170) at 
37°C for 30 minutes. As a positive control, HUVECs were activated by 1 ng/ml TNFα in 
serum-free RPMI for 3 hours to induce monocyte adhesion. After shear, each 10cm plate 
of HUVECs was exposed to the labeled THP-1 cells at a concentration of 5 x 105 THP-1 
cells/ml (in a total of 6ml) for 30 minutes at 37°C. Non-adherent monocytes were washed 
away with HBSS (Fisher MT21023CV) and the bound monocytes were fixed with 4% 
paraformaldehyde for 5 minutes. Bound monocytes were imaged in 8 fields/plate via 
fluorescent and bright field microscopy and quantification was done using ImageJ. 
In vivo 5Aza Treatment Scheme 
Mice were treated by intraperitoneal injection at doses of 0.1, 0.2, or 0.4 
mg/kg/day of 5-Aza-2’-Deoxycytidine (5Aza; Sigma) daily for four weeks (the acute d-
flow-induced atherosclerosis model), or at 0.2 mg/kg/day for three months (the chronic 
diet-induced atherosclerosis model). Mouse weight was monitored weekly, and food and 
water intake and feces were monitored daily. 
 33 
High Resolution Melting Curve Analysis to Quantify Global DNA Methylation In Vivo 
Global genomic DNA methylation as represented by genomic repeat element 
methylation was quantified by LINE1 and B1 high resolution melting curve assays 
(HRM) for each mouse in the RRBS and array studies to determine the effect of 5Aza 
treatment. HRM was done according to the protocol set by Newman et al. 116. Whole 
blood was collected by the submandibular technique one week after the start of 5Aza 
treatment. Genomic DNA was extracted from blood using the DNeasy Blood and Tissue 
kit (Qiagen) and genomic DNA was bisulfite converted using the Epitect Bisulfite 
Conversion kit (Qiagen). Bisulfite-converted genomic DNA was subjected to HRM using 
the F_unmeth_mLINE1 and R_unmeth_mLINE1, and the F_mod_unbiased_B1_Mm and 
R_mod_unbiased_B1_Mm primers from Newman et al. and normal qPCR methods as 
described above116.  
Statistical Analyses 
Statistical analyses were performed using Graph-Pad Prism 5 (GraphPad 
Software). Error bars are reported as the standard error of the mean. Pairwise 
comparisons were done using two-tailed Student’s t-tests. Multiple comparisons of means 
were performed using one-way analysis of variance followed by Tukey’s multiple 
comparison tests. Differences between groups were considered significant at P-values 
below 0.05 (*) and the P-values are denoted separately for values below 0.01 (**).  
Results  
To identify flow-sensitive genes in arterial endothelium in vivo, endothelial-
enriched RNA was obtained directly from mouse carotid arteries at various timepoints 
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post-partial carotid ligation surgery in C57BL/6 mice (Figure 3.3A) and applied to a 
microarray. Using this method, our lab previously identified ~600 “mechanosensitive” 
genes whose expression changes in ECs exposed to disturbed flow in the left carotid 
artery (LCA) as compared to unidirectional flow in the right carotid artery (RCA) for 12 
and 48 hours. 
Discovery of D-flow-induced DNMT1 Overexpression Using Microarray 
DNMT1 was initially identified as a potential mechanosensitive gene in 
endothelial cells from these previous in vivo mRNA array studies described in detail in 
the methods section17. The mRNA array showed that DNMT1 expression was ~2.4-fold 
higher in the left carotid artery (LCA, which was partially ligated and exposed to d-flow 
for 48h) than in the contralateral right carotid artery (RCA, exposed to s-flow)17. 
DNMT1 is Upregulated at the mRNA and Protein Level by D-flow Exposure to the 
Mouse Endothelium In Vivo 
We validated this endothelial microarray data by qPCR, immunostaining, and 
western blot both in vivo and in vitro. DNMT1 mRNA expression showed a significant 
increase by more than 2-fold in the LCA endothelium as compared to that of the RCA at 
48 hours post-partial carotid ligation (Figure 3.8B). Similarly, robust DNMT1 protein 
expression was observed in the flow-disturbed LCA (48 hours post-ligation) compared to 
the contralateral RCA and sham-controlled LCA and RCA (Figure 3.8C). Importantly, a 
robust DNMT1 protein expression was also observed in endothelial cells in the lesser 
curvature (LC) of the aortic arch, which is naturally and chronically exposed to d-flow 
without the ligation surgery, but not in the greater curvature (GC, an atherosclerosis-
resistant region, which is naturally exposed to s-flow) (Figure 3.8D and E). Interestingly, 
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DNMT1 expression was increased in the intimal and medial layers of the LCA (Figure 
3.8C), suggesting that d-flow affected the protein expression in both endothelial and 
smooth muscle cells.  Of the catalytically actives, DNA methyltransferase DNMT1 is the 
only one with increased expression by D-flow in vivo (Figure 3.9). 
 
Figure 3.8: DNMT1 expression is induced by d-flow in endothelial cells in vivo and 
in vitro. Schematic diagram of the partial carotid ligation model, in which 3 of the 4 
caudal branches of the left common carotid artery (LCA) are ligated, while the 
contralateral right common carotid artery (RCA) remains untouched as an internal 
control. Also depicted are the naturally, chronically flow-disturbed lesser curvature 
(LC) and the unidirectional- flow greater curvature (GC). (B) Validation of 
microarray results by qPCR was performed with endothelial-enriched total RNA 
obtained from the LCA and RCA at 0, 24, and 48 hours after ligation in C57BL/6 
mice. DNMT1 mRNA levels were normalized to 18S. Data are shown as the mean ± 
SEM. *P < 0.05, n = 8 (0 hours), n = 9 (24 hours), n = 12 (48 hours)16. (C) LCA and 
RCA frozen sections 48 hours after ligation (scale bars: 50 µm) and (E) the LC and 
GC (en face preparation; scale bars: 100 µm) from C57BL/6 mice without ligation 
surgery were stained with DNMT1 antibody (red)16. Nuclei are stained with DAPI 
(blue), and elastic laminae autofluoresce green. The lumen (L) is indicated. (D) 
Diagram of the endogenously s-flow (greater curvature) and d-flow(lesser 





Figure 3.9: (A) q-PCR validation of microarray results demonstrating a time-course 
study of the fold-change in DNMT1, DNMT3a, and DNMT3b  expression at 12 and 
48 hours post-ligation in C57/BL6 mice. DNMT3a levels were undetectable by qPCR 
at 12 hours post-ligation. (B) Representative immunohistochemical staining of 
DNMT3a and DNMT3b protein (red) in carotid artery sections at 48 hours post-
ligation in C57/BL6 mice. Nuclei are stained with DAPI in blue and the elastin 
laminae autofluoresce green. L indicates the lumen of the blood vessel. (C) 
Representative immunohistochemical staining of DNMT1, DNMT3a, and DNMT3b 
protein (red) in the naturally flow-disturbed lesser curvature (LC) and 
unidirectional flow greater curvature (GC) and thoracic aorta (TA) in C57/BL6 
mice. Nuclei are stained with DAPI in blue and the elastin laminae autofluoresce 
green. 16  
DNMT1 is Overexpressed at mRNA and Protein Level in Cultured Endothelial Cells 
Exposed to D-Flow Using the Cone and Plate Viscometer 
These in vivo data were further confirmed in cultured human endothelial cells 
(HUVECs) exposed to oscillatory shear stress (OS, mimicking d-flow in vitro) compared 
to unidirectional laminar shear stress (LS, mimicking s-flow in vitro) for 24 hours. 
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DNMT1 mRNA and protein expression were significantly higher in HUVECs exposed to 
OS as compared with LS (Figure 3.10A and B), which directly demonstrates that 
DNMT1 expression is regulated by OS in endothelial cells. DNMT3b was also 
upregulated at the mRNA and protein levels by d-flow, but to a much lesser extent. In 
contrast, expression of DNMT3a was barely detectable and did not show significant 
changes in protein level (Figure 3.10). These results indicate that the expression of 
DNMT1 is strongly regulated in a flow-dependent manner in endothelial cells in vivo and 
in vitro, and that the other catalytically active DNMTs (DNMT3a or DNMT3b) do not 
have a dramatic effect. Therefore, subsequent studies focused on the role of DNMT1. 
 
Figure 3.10: DNMT1, DNMT3a, and DNMT3b mRNA expression in HUVECs  
exposed to either LS or OS for 24h measured by qPCR (A) and protein expression 
measured by Western Blot (B). ***p<0.001. HUVECs exposed to LS (15 dyn/cm2) 
or OS (±5 dyn/cm2, at 1 Hz) for 24 hours were used for qPCR and Western blot 
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analyses for DNMT1 using 18S and β-actin as respective internal controls. (C) 
DNMT enzymatic activity increases in HUVECs in OS conditions. This increase is 
blunted by a 5-day 5µM treatment of 5Aza. 16 
DNMT1 Inhibition in Endothelial Cells by 5-Aza-2’deoxycytidine (5Aza) or siRNA 
Inhibits D-flow-induced Inflammation In Vitro 
To determine the functional importance of DNMT1 in endothelial cells, human umbilical 
vein endothelial cells (HUVECs) were treated with either the DNMT inhibitor 5Aza or 
DNMT1 siRNA (siDNMT1). Optimization studies showed that 5Aza treatment in 
HUVECs decreased DNMT1 in a dose and time dependent manner (Figure 3.5). It was 
determined that a five day treatment of 5uM resulted in significant DNMT1 knockdown 
and a concomitant decreased DNMT activity with minimal cell death (Figure 3.5, Figure 
3.10C, and Figure 3.11).117 5Aza has preferential targeting of DNMT1 in ECs as is 
reported in other cell types, and it was found that 5Aza could prevent OS-induced 
DNMT1 overexpression and hyperactivity (Figure 3.10C), and decrease global 
methylation (Figure 3.7). Dose and time optimization studies for DNMT1 siRNA 
determined that a 48h treatment with 100nM siRNA led to sufficient knockdown of 
DNMT1 protein expression under both laminar and oscillatory shear conditions (Figure 
3.6 and Figure 3.12).  
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Figure 3.11: HUVEC TUNEL staining on a dose-curve treatment for 5 days of 5Aza  
showing endothelial apoptosis (red), using DNaseI treatment as a positive control for 
cell death.  
Exposure to OS increased DNMT1 expression and DNMT activity compared to 
LS and 5Aza inhibited this increase (Figure 3.12A). Treatment with 5Aza significantly 
prevented OS-induced monocyte adhesion to HUVECs (Figure 3.12C). Moreover, 
siDNMT1 also decreased OS-induced DNMT1 expression as well as monocyte adhesion 
to HUVECs (Figure 3.12B and D). Together, these results suggest that DNMT1 plays a 







Figure 3.12: DNMT inhibition blocks OS-induced endothelial inflammation.  
HUVECs were pre- treated with either 5-aza-2′-deoxycytidine (5Aza) at 5 µM for 5 
days or DNMT1 siRNA (siDNMT1) at 100 nM for 48 hours, and subsequently 
exposed to OS or LS for an additional 24 hours. (A and B) Cell lysates were then 
analyzed by Western blotting with the DNMT1 antibody and quantified by ImageJ 
analysis using β-actin as an internal control (n = 4 each, data are shown as the mean 
± SEM. *P < 0.05; **P < 0.01). (C and D) Under the same conditions and following 
shear, endothelial inflammation was determined by quantification of the number of 
THP-1 monocytes adhered to sheared endothelial cells (n = 4 each, data are shown 
as the mean SEM. **P < 0.01). 16 
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DNMT Inhibition by 5-Aza-2’deoxycytidine Blocks Atherosclerosis Development in 
Chronic and Acute Models of Atherosclerosis in Mice 
We used two different ApoE-/- mouse models to study the role of DNMT in 
atherosclerosis: the acute partial carotid ligation model with western diet which rapidly 
develops atherosclerosis within 3 weeks 113, and the conventional western diet-fed model 
that chronically develops atherosclerosis in 3 months 101,118. In the carotid ligation model, 
the LCA rapidly developed atherosclerosis within 3 weeks (Figure 3.13A), and this was 
inhibited by 5Aza treatment in a dose-dependent manner with 0.2 mg/kg/day being the 
lowest effective dose (Figure 3.13A and B). Immunostaining for the leukocyte marker 
CD45 showed a remarkable inhibitory effect of 5Aza on inflammatory cell infiltration at 
the 0.2 mg/kg/day dose (Figure 3.15A), which was consistent with the atherosclerosis 
data. In the conventional western diet model, 5Aza treatment (0.2 mg/kg/day) also 
significantly inhibited atherosclerosis development in the aortic arch and brachiocephalic 
arterial branch (Figure 3.13C and D). In both models, 5Aza treatment did not show a 
significant effect on the serum lipid profile (Figure 3.16A and C) and apparent health, but 
induced a smaller body weight gain than the control groups (acute study: 25 grams in 
control vs. 23 grams in 5Aza mice at 3 weeks; Chronic study: 34 grams in control vs. 31 
grams in 5Aza group at 3 month) (Figure 3.16B and D). As an additional control, we 
examined the effect of d-flow, atherosclerosis, and 5Aza treatment on 5-methylcytosine 
(5mC) content by immunostaining. The dramatically induced 5mC level in the partially 
ligated LCA at the 3-week time-point was significantly reduced by 5Aza treatment in a 
dose-dependent manner (Figure 3.15B). Taken together, these results provide strong 
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support that 5Aza treatment prevented atherosclerosis by reducing DNMT expression and 
activity in the arterial wall.  
 
 
Figure 3.13: Treatment with the DNMT inhibitor 5Aza inhibits atherosclerosis.  (A 
and B) Acute, partial carotid ligation model of atherosclerosis: ApoE–/– mice were 
given daily i.p. injections of 5Aza for 1 week at 0.1, 0.2, or 0.4 mg/kg/d, or saline as a 
vehicle control. Then, partial carotid ligation was done, and mice were fed a 
Western diet while continuing the same 5Aza treatment for 3 more weeks. Frozen 
sections of the carotid arteries were examined by oil red O staining (scale bars: 200 
µm) (A), and plaque area quantification (mm2) was done using ImageJ (B) (n = 13 
each, data are shown as the mean ± SEM. **P < 0.005). (C and D) Chronic, diet-
induced atherosclerosis model: ApoE–/– mice were fed a Western diet (without 
partial ligation surgery) and treated with 5Aza (vehicle or 0.2 mg/kg/d, daily i.p. 
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injections) for 3 months. Aortic arches were longitudinally sectioned and stained 
with oil red O (scale bars: 1 mm) (C), and plaque area (mm2) was quantified (D) (n 
= 10 for vehicle, n = 9 for 5Aza, mean ± SEM. **P < 0.005). 16  
Global methylation is reduced by 5Aza treatment in the acute D-flow and chronic 
diet-induced models of atherosclerosis. The decreased melting temperature of bisulfite-
converted repetitive DNA elements indicates a decrease in global DNA methylation, 
demonstrating the efficacy of 5Aza treatment (Figure 3.14).  
 
Figure 3.14: 5Aza treatment reduces global methylation in mouse blood cells.  (A,B) 
High resolution melting curve analysis shows decreased methylation in the normally 
highly methylated LINE1 long interspersed (A) and B1 short interspersed (B) repeat 
elements of the genome. The analysis was done on blood genomic DNA collected by 
submandibular bleed just before beginning the 5Aza treatment and one week after 
the start of the daily 0.2 mg/kg/day 5Aza injections. (n=20; mean ± s.e.m; * p<0.05)16 
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Figure 3.15:  5Aza treatment inhibits immune cell infiltration and DNA methylation 
in mice.  (A) Representative immunohistochemical staining of CD45 (red) in the 
LCA of the acute, d-flow induced atherosclerosis model, demonstrating a dose-
dependent decrease in immune cell infiltration after 4 weeks of 5Aza treatment from 
0.1-0.4 mg/kg/day doses compared to the vehicle control (scale bar = 100 µm). (B-C) 
Representative images show immunostaining of 5-methylcytosine (B) and DNMT1 
(C) in red in LCA frozen sections from the partially-ligated ApoE-/- mice as 
described in Figure 3, demonstrating a dose-dependent decrease in global DNA 
methylation and DNMT1 expression by 5Aza treatment (scale bars = 50 µm). Nuclei 




Figure 3.16: 5Aza has no major effects on serum lipid profiles and body weight.  
(A,C) Total blood serum cholesterol, triglycerides (TG), high density lipoprotein 
(HDL), and low density lipoprotein (LDL) in the acute, d-flow induced 
atherosclerosis model (A) and the chronic, diet-induced atherosclerosis model. 
Blood was collected from mice immediately before sacrifice. (B,D) Mouse body 
weights were measured weekly over the course of the 5Aza treatment in the acute, 
d-flow induced atherosclerosis model and in the chronic, diet-induced 
atherosclerosis model.16  
Mechanoreceptors and MicroRNAs are Potential Upstream Regulators of the DNMT1 
Shear Response 
The miR29 family are Flow-Sensitive MicroRNAs that are validated to target DNMTs 
These studies provide novel insight into the mechanism by which flow regulates 
gene expression in a DNMT1-dependent manner and uncovers novel genes involved in 
the endothelial flow response. However, much remains to be understood about the 
mechanism by which flow controls DNMT1. Our preliminary microarray data shows that 
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the miRNA29 family (mir29a, b, and c) is suppressed by d-flow and in silico analysis 
suggests that they may regulate DNMT1 directly. Using MirWalk, we performed a gene-
microRNA interaction search and discovered 50 miRs that have been experimentally 
validated to target DNMT1. We compared this list of DNMT1-targeting miRs to our 
microarray dataset of global miR expression at 48 hours post-ligation, and we discovered 
that 18 miRs that can regulate DNMT1 are downregulated significantly (by more than 
33%) by d-flow (Table 3.2). Future studies will be focused on the microRNA29 family 
(mir29a, b, and c) because they are known to regulate key biological functions, including 
epigenetics, cell cycle, and matrix remodeling, but miR29s have not been previously 
described in the context of endothelial biology.  




Endothelial Cell Mechanoreceptors are Intermediate Players Between Flow Sensing and 
Overexpression of DNMT1  
As an additional route of examining the potential upstream regulation of DNMT1, 
we developed a predictive model to understand how the activity of different endothelial 
cell mechanoreceptors affects the expression and activity of DNA Methyltransferase. 
Well-studied mechanosensors known to play a role in endothelial cell 
mechanotransduction (Appendix A Table A1) were subjected to systems biology analysis 
using Ingenuity Pathways Analysis to determine their potential network connectivity to 
DNMT1. No direct binding interactions were found to occur between mechanosensors 
and DNMT1. However, a highly interconnected protein interaction network emerged as a 
potential regulator of the DNMT1 shear response (Figure 3.17). This involved the 
primary mechanosensors Platelet/Endothelial Cell Adhesion Molecule 1 (PECAM1), 
caveolin 1 (CAV1), and Vascular Endothelial Growth Factor Receptor (VEGFR), and 
secondary signaling molecules cyclin D1 (CCND1), Protein Kinase B (PKB, or AKT), 
annexin A5 (ANXA5), and embryonic ectoderm development (EED). We developed a 
directional regulatory map and created a computational model of gene expression and 
protein activity in the system using Matlab (Appendix A, Figure 1 and Table 2). The 
model was further expanded to include the DNMT1 inhibitor 5-Aza-2’deoxycytidine to 
determine whether we could accurately predict behavior of the system upon perturbation 
of DNMT1 expression. 5Aza is also known to upregulate expression of the 
mechanoreceptor CAV1119. Several assumptions were used due to lack of literature 
available and to enable sufficiently simple model development for the scope of this 
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analysis (Appendix A) and it is emphasized that this model should not be interpreted as 
predictive of the actual system, but rather should be used as a basis to guide future 
experimental design to analyze the upstream regulation of DNMT1. 
 
Figure 3.17: A Schematic Representation of the Endothelial Cell Mechanoreceptors 
and the Signal Transduction Pathway to DNMT1.  
Using this model we tested all possible cases based on combinations of initial 
states (S) of the mechanosensors (simplified to either S=0: not expressed, inactive; S=1: 
expressed, inactive; and S=2: expressed, active). We found that a negative feedback 
mechanism turns off DNMT1 when both PECAM1 and CAV1 are expressed +/- active, 
and the state of VEGFR doesn’t affect negative feedback (Appendix A, Figure 5). 
Additionally, when PECAM1 and CAV1 are not both expressed together, DNMT1 stays 
expressed and active indefinitely (Appendix A, Figure 6). Finally, the addition of 5Aza 
alters the dependence of negative autoregulation of DNMT1 on both PECAM1 and 
CAV1, so that only PECAM1 needs to be expressed to achieve negative autoregulation 
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(Appendix A, Figure A7 and A8).  
Discussion 
Prior to 2014, there had been no accounts of flow-regulated DNA 
methyltransferases (DNMTs) and their functional relevance to endothelial cell (EC) 
biology. 5-Aza-2’deoxycytdine (5Aza) and siRNA treatment allowed us to directly 
observe the functional consequence of DNMT1 inhibition on EC function. Results from 
in vitro studies predicated the question of a functional effect of DNMT1 inhibition on 
disease outcome. Our two in vivo models of acute d-flow-induced and chronic diet-
induced atherosclerosis are robust and well-tested systems that we used to analyze 
DNMT inhibition effects. The question of whether DNMT1 inhibition affects EC 
inflammation in vitro and atherosclerotic plaque development in vivo had never been 
addressed before. 
We showed that DNMT1 is a mechanosensitive gene upregulated by d-flow and 
that DNMT inhibition prevents d-flow-induced endothelial inflammation in vitro and 
atherosclerosis development in vivo. Given its dramatic flow-sensitivity, we expect that 
DNMT1 is the dominant DNMT involved in endothelial inflammation and 
atherosclerosis. However, it would also be interesting to examine the role of the other 
catalytically active DNMTs (DNMT3a and DNMT3b) in EC function, especially given 
our findings that DNMT3b is slightly upregulated by d-flow at the protein level (Figure 
3.10) and that DNMT3a was found to be shear-responsive in ECs in other model 
systems57,65. In April 2014, Jiang et al. reported that DNMT3A is overexpressed by d-
flow in human aortic endothelial cells (HAEC) and that this regulates Klf4 
transcription.65 Klf4, a key mediator of endothelial function, maintains an anti-
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inflammatory, quiescent endothelial state in unidirectional flow conditions. The group 
showed that d-flow increases DNMT3A binding to the Klf4 promoter leading to DNA 
hypermethylation and blocking MEF2 (myocyte enhancer factor-2) binding. Using 
methods similar to ours, they showed that DNMT inhibition decreased Klf4 promoter 
methylation, increased its expression, and reversed the d-flow-induced dysregulation of 
downstream Klf4 targets eNOS, thrombomodulin (THBD), and monocyte 
chemoattractant protein-1 (MCP-1). This study demonstrates that in other experimental 
setups analyzing the shear effect on endothelium, other DNMTs also appear to be 
dysregulated. Additionally, DNA methylation via DNMTs plays a direct role in gene 
expression control. Before these studies, DNMTs in ECs had not been previously 
implicated as a mechanism for flow-mediated gene expression control. 
In order to determine whether there is a further functional role for DNMT1 in 
atherosclerosis development, additional markers of EC dysfunction that increase in d-
flow (including inflammation, apoptosis, proliferation, thrombosis and cell migration) 
could be examined in future studies. Additionally, the in vivo effect of EC-specific 
DNMT1 knockdown on plaque development can be tested. Due to the potential off-target 
and non-tissue-specific effects of 5Aza, the acute and chronic in vivo mouse 
atherosclerosis experiments done here can be repeated endothelial cell specific DNMT1 
knockout mice as described in the Future Directions section of Chapter 6.  
While we established that DNMT1 is upregulated in d-flow and plays a key role 
in atherosclerosis development, the mechanism of DNMT1 upregulation is unknown. The 
goal of the initial microRNA and mechanosensor computational analyses described here 
were to aid in the design of future experiments to analyze the upstream regulation of 
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DNMT1. We anticipate the usefulness of future studies to examine the effect of mir29, 
PECAM1, CAV1, or VEGFR silencing or overexpression on DNMT expression and 
activity, as well as EC biology and atherosclerosis development. Such potential studies 
are described in more detail in Chapter 6 Future Directions. 
  Overall, in Chapter 3 we found that DNMT1 is a functionally important 
mechanosensitive gene that plays a key role in endothelial cell (EC) inflammation in vitro 
and plaque development in vivo. D-flow-induced DNMT1 upregulation was verified at 
the transcript and protein level in vitro and in vivo. The role of DNMT1 in atherosclerosis 
development in vivo was tested using the DNMT1-specific inhibitor 5Aza on chronic and 
acute atherosclerosis models to determine the functional outcome of blocking DNMT1 
overexpression in d-flow. Results show that DNMT1 inhibition by 5Aza blocks 
endothelial inflammation in vitro and atherosclerosis progression in vivo, implicating 




CHAPTER 4 DNA METHYLATION-DEPENDENT 
ENDOTHELIAL GENE EXPRESSION RESPONSE TO FLOW 
Summary 
In this study, we sought to determine the mechanism of action of DNMT1 
overexpression and conversely inhibition by 5Aza in disturbed-flow-exposed 
endothelium. Since DNMT1 is known to methylation genomic DNA, and DNA 
methylation may control gene expression, we designed two parallel “omics” studies to 
examine the effects of both disturbed flow and DNMT inhibition on the endothelial cell 
DNA methylome and transcriptome in vivo. We carried out the reduced representation 
bisulfite sequencing (RRBS) study using endothelial-enriched genomic DNA (gDNA) 
obtained from the RCA and LCA of partially ligated mice at two different time points of 
two days and one week post-ligation. To further determine whether the flow-dependent 
DNA methylation changes were regulated in a DNMT-dependent manner, mice treated 
with 5Aza were compared to a saline vehicle control. Moreover, to determine which 
mechanosensitive genes has transcriptional dysregulation, potentially by DNA 
hypermethylation, we carried out a concomitant gene transcript microarray study using 
endothelial-enriched RNA obtained from the LCA and RCA of partially-ligated mice 
treated with either saline (RCA vs. LCA) or 5Aza (Aza-RCA vs. Aza-LCA). From these 
studies we found that DNMT inhibition by 5Aza rescues global gene expression in LCA 
to healthy state. While genome-wide and functional genomic elements did not have 
dramatic methylation changes under these conditions, we followed a specific hypothesis 
and found a subset of genes that had d-flow-induced promoter hypermethylation 
correlating with gene suppression, both were 5Aza-reversible. Based on a systems 
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biology and further bioinformatics analysis, we found that gene promoters containing 
cyclic AMP Response Elements (CRE) are preferentially methylated by d-flow in a 
5Aza-dependent manner. We further discovered that, on the genome scale, CRE 
hypermethylation corresponds to decreased gene expression. These studies used “omics” 
datasets to uncover a key regulatory network regulated by DNA methylation that may 
provide a basis for novel therapeutic approaches for atherosclerosis. A substantial portion 
of Chapter 4 was published as follows: Dunn, J., Qiu, H., Kim, S., Jjingo, D., Hoffman, 
R., Kim, C. W., Jang, I., Son, D. J., Kim, D., Pan, C., Fan, Y., Jordan, I. K. Jo, H. Flow-
dependent epigenetic DNA methylation regulates endothelial gene expression and 
atherosclerosis. J Clin Invest 124, 3187-319916. 
Introduction 
The Relationship Between DNA Methylation and Gene Expression 
CG methylation in the promoter region of a gene, close to the transcription start 
site, is associated with repression of gene expression. Although debated, promoter 
methylation is thought to affect the transcription of genes in two ways.120-122 First, 
methylation of DNA physically impedes the binding of transcriptional proteins to the 
gene. Second, methylated DNA is bound by methyl-CpG-binding domain proteins 
(MBDs). MBDs then recruit additional repressive proteins to the locus, such as histone 
and chromatin modifiers, and this complex causes chromatin compaction. The exact 
mechanism of crosstalk between DNA methylation and histone modifications remains a 
topic of extensive research.123,124 
CG methylation in the gene body is less straightforward125-127. Initial studies on 
intragenic methylation indicated that gene body hypermethylation is correlated with 
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increased gene expression 128. On the contrary, it has been argued that intragenic 
methylation causes chromatin compaction and blocks RNA Polymerase II binding, which 
prevents transcript elongation 129. Gene body methylation may activate or repress genes 
depending on the location (exon/intron/alternative promoter), density (CpG Island), and 
extent of methylation 130. For example, expressed genes may be associated with 
methylated gene bodies, and unmethylated intragenic CpG island EP300-bound 
enhancers, and vice-versa for silenced genes 127.  
Methods to Analyze DNA methylation 
MspI/HpaII 
To examine the overall level of methylation at the genome level, a restriction 
enzyme digest can be done using MspI and HpaII (methylation insensitive and sensitive, 
respectively; both recognize the 5’-CCGG-3’ restriction site). When DNA is 
hypermethylated globally, HpaII is blocked from cutting, but when DNA is 
hypomethylated, HpaII is able to cut. 
Bisulfite Conversion and BS-Seq 
Additional methylation assays rely on bisulfite technology, the gold standard in 
DNA methylation analysis 131. Bisulfite salt deaminates unmethylated cytosines in 
genomic DNA, which converts them to uracil. However, methylated cytosines are 
protected from this chemical conversion and remain cytosine after bisulfite conversion. In 
this way, the only cytosines that remain in the genomic DNA are those that were 
originally methylated. After PCR amplification, the unmethylated cytosines become 
thymine, while methylated cytosines are still cytosine (Figure 4.1). 
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Figure 4.1: Scheme for Bisulfite Conversion.  Adapted from 
http://www.epigenomics.com/en/science-and-technologies/bisulfite-technology/ 
There are several possible subsequent steps one can take with the bisulfite 
converted DNA. Bisulfite sequencing, for example, involves PCR amplification of the 
bisulfite-converted genomic DNA with specially designed PCR primers. Bisulfite 
sequencing primers are limited to regions that have no CG sites (any cytosine in the 
primer design region will always be converted to a U and will be represented as a T in 
primer design) but must encompass several CG sites in the amplified region in order to be 
a useful probe. Amplicon size is generally limited to 500bp or less due to genomic DNA 
fragmentation (to ~3kb fragments) during bisulfite conversion and due to the difficulty of 
specific primer design. Because bisulfite conversion alters the DNA sequence, 
comparison of the sequencing product to the reference sequence for that locus reveals 
cytosines that were methylated and unmethylated in given conditions. Bisulfite converted 
genomic DNA can also be subjected to high resolution melting curve analysis to 
determine the number of C’s vs. T’s in a specific region amplified by qPCR 132. More 
methylated DNA will have more C’s after bisulfite conversion, and will thus have a 
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higher melting temperature due to more hydrogen bonding between C-G bonds as 
compared with A-T bonds 116,133. 
RRBS 
Reduced Representation Bisulfite Sequencing (RRBS) enables researchers to 
determine genome-scale methylation patterns at the nucleotide resolution. 134-136 Genomic 
DNA is cut with the methylation-insensitive restriction enzyme MspI to enrich for 
sequences containing many CG sites, and fragments are then size-selected and cloned 
into a library for sequencing. RRBS enables researchers to probe relevant, CG-rich 
portions of the genome, eliminating the need for full genome sequencing. Conveniently, 
Meissner et al. further modified the RRBS technique to allow for as low as 30ng of input 
DNA, which makes it compatible for application with our in vivo mouse carotid artery 
ligation model 137. RRBS is a cost-effective technique to scan the genome for interesting 
loci based on methylation changes 138. 
OMICS approaches to DNA methylation and gene expression studies 
Genome-Wide Analysis 
With the advent of high throughput genome-wide analysis technology such as the 
microarray it became possible to study the expression of thousands of genes throughout 
the genome simultaneously 139. This greatly impacted the field of vascular 
mechanobiology by enabling researchers to track a large host of genes in a controlled, 
well-defined environment. The resulting studies displayed clear evidence of the 
endothelial cells’ keen ability to sense and convert mechanical stimuli into biochemical 
signaling responses. Microarray studies illuminated numerous key regulatory pathways 
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and their dynamics while also supporting the discovery of novel mechanosensitive genes 
and functional gene clusters. These datasets continue to support the working hypothesis 
that laminar, unidirectional flow upregulates “atheroprotective” genes and downregulates 
“atheropathogenic” genes while disturbed, reversing, or stagnant flows result in the 
opposite phenomenon of enhancing atheropathogenic genes and suppressing 
atheroprotective genes. 
In 2001, the complementary DNA (cDNA) microarray was first utilized in vitro to 
study the effect of shear stress on gene expression profiles of cultured endothelial cells. 
Gimbrone et al. used the cDNA array to define gene expression profiles of 11,397 genes 
in cultured human umbilical vein endothelial cells (HUVEC) exposed to steady laminar 
flow, turbulent flow, or static flow over 24 hours. Functional tests determined that several 
“mechanosensitive” genes activated under laminar flow were, in fact, atheroprotective, 
and that the reciprocal was true regarding atheropathogenic genes.6,20 Chien et al. 
discovered 125 differentially regulated mechanosensitive genes in human aortic 
endothelial cells (HAEC) exposed to laminar flow versus static conditions by a less 
comprehensive cDNA microarray but under more rigorous statistical testing as compared 
to Gimbrone.26  Both groups used RT-PCR validation and array analyses described later 
in further detail. Broadly, it was found that gene expression profiles in endothelial cells 
exposed to laminar, unidirectional flow are distinctly different from those under disturbed 
flow, while static flow profiles have a strong resemblance to turbulent shear expression 
profiles. More specifically, laminar shear stress causes suppression of genes associated 
with inflammatory responses, matrix remodeling, and cell proliferation, and activates 
genes involved in signal transduction, cytoskeletal remodeling, and angiogenesis.  
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There are various approaches to microarray data analysis. Raw data can be 
analyzed in the most straightforward manner by comparison of the relative intensities of 
probe hybridization, expressed as a fold change, which represent the levels of differential 
transcript expression. Rigorous statistical analysis and filtering is necessary to lend 
significance to fold change values. Large datasets can be parsed by hierarchical clustering 
based on various criteria such as gene ontology, location in the genome, or expression 
patterns alluding to co-regulation. However, this method may disregard underlying trends 
and often cannot tease out complex biological interactions formed by specialized gene 
circuitry. The Gimbrone group created the analytical software Argus, which allows the 
integration of multiple experimental conditions to help account for this difficulty. Both 
open source and proprietary systems biological tools like Ingenuity Pathways Analysis 
have become available. In addition to systems-wide analyses, computational tools at the 
gene-specific level such as DAVID, amiGO, NCBI UniGene, and the UCSC Genome 
Browser, make gene ontology and functional studies quite feasible.  
Integrative approaches to analyzing DNA methylation and gene expression 
datasets from high-throughput approaches such as microarray and next generation 
sequencing-based assays are highly useful to determine the interplay between these two 
“omics” datasets. 
Cyclic AMP Response Elements and the Cyclic AMP Response Element Binding Protein 
CREB 
Cyclic AMP response elements (CRE) were discovered in 1986 by separate 
analyses that converged on the importance of a sequence motif existing in the promoters 
of several cAMP-responsive genes, including somatostatin, proenkephalin, and 
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phosphoenolpyruvate carboxykinase (PEPCK) 140-142. The finding that the 8 bp 
palindrome sequence 5'-TGACGTCA-3' conferred gene expression responsiveness in the 
presence of cAMP was later found to also exist in many other genes. 143 In fact, many cell 
cycle genes such as cyclins A and D1 contain CREs, as do an abundance of metabolic 
genes 143-146. In additional to the full CRE (fCRE) motif TGACGTCA, CREs also exist in 
half-sites (hCRE) as CGTCA or TGACG 147,148. As of the year 2001, there were 105 
identified genes containing functional CREs (~50% containing the fCRE and the other 
50% containing a hCRE) and the majority were found between -50 to -150bp upstream of 
the transcription start site 143. Gene ontology analysis of CRE-containing genes revealed 
that 38% of all CRE-containing genes are transcription factors 149.  
The cAMP response element binding protein (CREB) is a transcription factor that 
binds to cAMP response elements (CRE) of genes and regulates transcription. In this 
manner, CREB controls global gene expression and its dysregulation is linked to many 
developmental pathways and diseases. CREB can selectively distinguish its binding motif 
from that of AP1 (which is TGACTCA), and it is thought that two key lysines (304 and 
305) are key for CREB recognition of the CRE site. Interestingly, lys304 mutation 
interrupts CREB binding to fCRE, but not to the hCRE 150. Additionally, while fCRE has 
a higher overall binding affinity for CREB as compared to hCRE, the affinity of hCRE 
increases much more dramatically than that of fCRE upon CREB phosphorylation, and 
this has been implicated as a mechanism of fine-tuning gene expression of hCRE-
containing genes 151,152. Additional bZIP transcription factors, including C/EBPα, also 
bind to CRE 153.   
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It is known that methylation of the cytosine in CpG dinucleotide of both hCRE 
and fCRE blocks CREB binding, but can actually increase C/EBPα binding to hCRE 
149,153,154. Methylation-dependent CREB binding is a key mechanism in Wp gene 
silencing on the Epstein-Barr virus during viral-induced B cell to lymphoblastoid 
transformation, and also in hCRE control of the testis-specific expression/somatic cell 
silencing of Pdha2 155-157. CREB binding affinity may also relate to sequence motifs 
surrounding the CRE, for example Tax-responsive elements (TREs) contain the CGTCA 
motif but are surrounded by highly CG-rich flanking regions and TREs demonstrate a 
significantly lower binding affinity for CREB158,159. 
CREB was one of the first transcription factors found to have activity regulated 
by phosphorylation. It has been shown that protein kinase A (PKA) downregulation in 
ECs ecxposed to d-flow leads to decreased CREB phosphorylation and decreased CREB 
binding to CRE elements 160. Interestingly, while cilostazol, a phosphodiesterase III 
inhibitor that increases cAMP and activates CREB, is used clinically to treat patients with 
PAD, its mechanism is still unclear, and it is contraindicated for heart failure patients. 
Methods 
Partial Carotid Ligation Surgery and 5Aza-2’deoxycytidine Treatment Schemes  
To decrease complications arising from the hypercholesterolemic conditions in 
ApoE-/- mice, C57BL/6 mice were used for these studies. At the earlier timepoint, 
C57BL6 mice were partially ligated by Chanwoo Kim (see methods in Chapter 3 for 
detailed explanation) without any other treatment and gDNA was collected by Jessilyn 
Dunn and Soyeon Kim from the carotid arteries two days later to determine the effect of 
flow alone on DNA methylation. At the later timepoint, mice were pre-treated with saline 
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or 5Aza (0.2 mg/kg/day) for two weeks by intraperitoneal injection, then were partially 
ligated by Chanwoo Kim and the 5Aza treatment was continued for one week after. 
ligation.  
 
Figure 4.2: 5Aza treatment scheme to study the effect of Flow on Genome-Wide 
DNA Methylation  (by reduced representation bisulfite sequencing, or RRBS) and 
Gene Expression (by microarray) Patterns in the Endothelium in vivo. C57BL/6 
mice were treated with 5Aza or saline for 2 weeks at 0.2 mg/kg/day via i.p. 
injections. Then, partial carotid ligation was done and mice continued to receive the 
same 5Aza or saline treatment for 1 more week. Following sacrifice, endothelial-
enriched genomic DNA (gDNA) was collected from the LCA and RCA.  
Endothelial Cell Genomic DNA and RNA Preparation Quality Control 
To measure the purity of endothelial cells in our gDNA and RNA preparations 
from flushing the carotid arteries, we performed a number of control experiments on 
C57Bl6 mice at 7 days post-ligation. The goal of these experiments was to determine the 
cell populations existing in our samples as a ratio of ECs to SMCs and immune cells. 
These control experiments included qPCR on eNOS, aSMA, and CD11B, single-gene 
bisulfite sequencing of eNOS, and immunohistochemistry and cell counting of ECs, 
SMCs, and immune cells using cell profiler (see Appendix B for details and results).   
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Genomic DNA and RNA Extraction from Mouse Carotid Arteries for Transcriptome and 
Methylome Studies 
Microarray 
Total intimal RNA was collected by flushing the RCA, LCA, Aza-RCA, and Aza-
LCA with 150 µl of Qiazol and was purified using the miRNeasy Mini Kit (Qiagen). 
Three carotid RNA samples were pooled and the combined sample was amplified and 
reverse transcribed, and the cDNA was applied to Illumina Mouse WG6 microarray 
chips. The microarray detected 45,281 probes corresponding to 30,854 genes. 
The two repeated timepoints in our lab’s previous microarray studies using the 
Illumina and Affymetrix microarrays make it possible to verify the first microarray 
results. Previously published shear-sensitive genes were found to have similar expression 
patterns in our arrays, and numerous novel mechanosensitive genes were also discovered 
through this in vivo microarray study 
RRBS 
Genomic DNA was collected from mouse carotid arteries (as described 
previously) by flushing with 200 ul of a 1:1 solution of Buffer AL and nuclease-free 
water. Genomic DNA was purified using the DNeasy Blood and Tissue Kit (Qiagen) and 
20 genomic DNA samples were pooled per RRBS sample. gDNA for the RCA, LCA, 
Aza-RCA, and Aza-LCA was examined for quantity and quality using the Nanodrop 
(Table 4.1) and samples were sent to Zymo Research Corp. where RRBS was carried out 
by bisulfite conversion, genome reduction by restriction enzyme digest and size selection, 






Table 4.1: Quantity and quality of gDNA at 7 days (with or without 5Aza treatment) 
or 2 days post-ligation as measured by Nanodrop.  The gDNA was submitted to 










Computational Analysis of Genome-wide Methylome (Reduced Representation Bisulfite 
Sequencing) and Transcriptome (Microarray) Datasets 
Next generation sequencing reads from the RRBS study were mapped to the Mm9 
genome assembly by Zymo Research Corp. The resulting mapped files were analyzed by 
our lab. Methylome coverage was determined by dividing the number of unique CG sites 
covered by each individual RRBS dataset by the number of total CG sites in the Mm9 
genome assembly (21,342,492 CG sites in chromosomes 1-19, X, and Y). Promoter 
coverage was determined by confining the RRBS and Mm9 assemblies to gene 
transcription start sites (TSS, as defined by the NCBI reference sequences database) ± 
1kb (there are 2,130,470 CG sites in these Mm9 Assembly promoters), and then again 
 
Amount of gDNA (ng) 260/280 ratio 
7 d Ctrl LCA 650.7 1.65 
7 d Ctrl RCA 477.0 1.49 
7 d Aza LCA 414.0 1.49 
7 d Aza RCA 255.6 1.66 
2 d LCA 1,550 1.64 
2 d RCA 1,450 1.79 
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calculating coverage in these confined regions. The methylation ratio at each CG site was 
calculated by the number of methylated reads divided by the total number of reads at that 
site, and the percent methylation at each site is the methylation ratio multiplied by 100. 
Heatmap correlation scatterplots were generated using the smoothScatter function 
in R. The log of the methylation ratios of only those unique CG sites covered by all four 
datasets were plotted and the R2 values were determined by fitting linear models with the 
R lm function 10,161,162.  
Analysis of the DNA methylation Levels Around the Transcription Start Site, Gene 
Body, and Transcription Termination Site and its Relationship to Gene Expression Levels  
The average percentage (± standard error) methylation levels was calculated using 
100bp windows spanning the transcription start site (TSS), gene-body, and transcription 
termination site (TTS), using the regions 3kb and 5kb upstream and downstream of the 
TSS respectively and 5kb and 3kb upstream and downstream of TTS, respectively, across 
five gene expression level bins. This analysis was done by Dr. Daudi Jjingo in 
collaboration with Dr. I. King Jordan 126.  
Emergent Methylation Patterns 
For the a priori emergent methylation pattern analysis to rank the average 
methylation ratio of each gene promoter from the four experimental groups at 7 days 
post-ligation, was done using only those CG sites confined to promoter regions (TSS ± 
1kb). We calculated the promoter methylation ratio by the total number of methylated 
reads divided by the total number of all reads in the region, normalized to the number of 
CG sites in that region. This was done for each RRBS dataset, and then the methylation 
ratio for each gene promoter was compared between datasets and ranked from highest to 
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lowest methylation ratio. There are 24 possible combinatorial patterns that can result 
from this ranking analysis by ordering the 4 samples from highest to lowest, and we 
counted the number of genes that fell into each of the 24 possible pattern categories. This 
analysis was done in collaboration with Dr. Daudi Jjingo and Dr. I. King Jordan. 
Promoter Cyclic Amp Response Element CpG Methylation  
After discovering CREB as a common network regulator of the 11 gene subset 
discovered in Chapter 5, the RRBS datasets were subsequently mined to determine the 
methylation ratio for each sample (RCA, LCA, Aza-RCA, and Aza-LCA) specifically at 
the CpG dinucleotide within CRE sequences, and then again but for those CRE sequences 
specifically confined to gene promoter regions (TSS ± 1kb). 
The RRBS datasets were analyzed for genomic and promoter (transcription start 
site ± 1kb) CG content and methylation status, as well as CRE element methylation status 
using the R Bioconductor packages BSGenome (specifically, the Mm9 Genome 
Assembly apprehended from the UCSC database), GenomicRanges, Genomic Features, 
and Biostrings.  
The Relationship Between Promoter Cyclic Amp Response Element CpG Methylation 
and Gene Expression 
First, the sequence of the promoters (+/- 1 kb from the transcription start site, or TSS) of 
all genes (34,000) in the Mm9 genome were downloaded from the UCSC Genome 
Browser. Those genes on the hap, un, and rand chromosome maps were removed from 
the set because they come from either alternate assemblies or unmapped contigs (hap: 
different haplotypes/alternative alleles that may cause duplicated sequences in the 
reference; un: unmapped regions; rand: random contigs whose exact location on the 
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chromosome is uncertain). This resulted in 33,826 promoter sequences included in the 
downstream analysis. We performed a string search for the three CRE motifs on this set 
of promoter sequences, and found that there were 9,556 genes containing CGTCA in 
their promoter, 9,536 containing TGACG, and 863 containing TGACGTCA. The 
genomic ranges of these gene promoter sequences were then mapped back to our RRBS 
CpG methylation data using only those sites covered by all RRBS datasets (3,232,969 
CG sites) at a minimum of 10 reads per CG site. We were then able to map the promoter 
CRE CG methylation status of a gene to its expression using our microarray data to 
determine the relationship, which resulted in 4,286 genes containing CGTCA in their 
promoter, 3,326 containing TGACG, and 503 containing TGACGTCA (Figure 4.9). 
Subsequently we filtered out those genes with the most dramatically changed 
promoter CRE CG site corresponding to the most dramatic gene expression changes by 
thresholding so that only those genes that followed our expected trends 
(hypermethylation and lower probe intensity in the LCA vs. RCA) were kept.  For the 
thresholding values, we parameterized the data to account for both the CRE CG 
methylation change as well as the probe intensity change. Using this parameter (arbitrary 
units), the data was thresholded so that the difference between the flow-altered samples 
(measured by the length the line between the LCA and RCA datapoints for each gene, 
which is also the magnitude of the parameter change) in Figure 4.10 was greater than 100 
and the slope of that line (the rate of change of the parameter) was less than -50. 
CpG Methylation Analysis in Functional Genomic Regions  
Global percent methylation for each of the RRBS datasets was determined using 
only those CG sites covered by all datasets (the intersection of the RRBS datasets: 
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3,232,969 CG sites). The values were calculated by averaging the methylation ratios 
across every CG site in the genome or only within specific regions, including enhancers 
(experimentally validated by the VISTA enhancer browser), promoters (+/- 1 kb from the 
transcription start site, or TSS), gene body (the region between the TSS and TTS), and 
transcription termination site (TTS; defined as within ± 1kb of a gene TTS).  
The VISTA enhancer browser is a resource containing experimentally validated 
human and mouse noncoding fragments with gene enhancer activity. Putative enhancers 
are selected by the VISTA group based on their conservation across vertebrates and/or 
positive ChIP-Seq data of enhancer marks. A subsequent in vivo enhancer screen is done 
using enhancer/LacZ reporter transgenic mice to assess spatial expression during 
embryonic development, which enables identification of distant-acting transcriptional 
enhancers. “Positive” enhancers are defined as those experimentally validated by 
demonstrating reproducible expression in the same structure in at least three independent 
transgenic embryos. We used the genomic ranges for only positive mouse enhancer 
regions defined by VISTA (244 regions) to measure global enhancer methylation in our 
RRBS data (Figure 4.7). 
Results 
Quantification of Relative Cell Types for Endothelial Cell Genomic DNA and RNA 
Quality Control 
One major complication of DNA methylation studies on samples taken directly 
from in vivo is the possibility for the inclusion of multiple cell types. To ensure that 
changes seen in our DNA methylation and gene expression data could be attributed to the 
endothelial response to experimental conditions rather than differential DNA methylation 
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or gene expression occurring across different cell types, we performed a brief study 
(Appendix B) to measure the number of contaminating cell types we could expect in our 
endothelial cell genomic DNA and RNA preparations. Detailed analysis of the results 
from these experiments indicate that we have minimal contamination from SMCs and 
immune cells in our endothelial preparations, and underscore the validity of our 
experimental and analytical methods for the following experiments.  
Validation of 5-Aza-2’deoxycytidine Efficacy by High Resolution Melting Curve 
Analysis 
As a control for 5Aza treatment, blood was collected one week after the start of 
the treatment and global DNA methylation was measured by high resolution melting 
curve analysis (HRM). This showed that global methylation decreased as early as one 
week after 5Aza treatment, demonstrating the efficacy of this treatment strategy (Chapter 
3 Figure 15). 
Reduced Representation Bisulfite Sequencing Data Analysis 
The two RRBS datasets for the LCA and RCA at the early timepoint of two days 
post-ligation did not show a significant difference in methylation. Further analysis was 
performed using only the four RRBS datasets collected at the later timepoint of 1 week 
post-ligation, for which we also collected a concomitant transcriptome dataset for 
comparison and analysis. 
The four RRBS datasets (RCA, LCA, Aza-RCA, and Aza-LCA) were mapped to 
the Mm9 (July 2007/NCBI37) mouse genome assembly, which contains a total of 
21,342,492 CG sites. Our four RRBS datasets showed a methylome coverage of ~23% 
(4,967,716 unique CG sites on average) of all CG sites in the mouse genome, including 
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promoters, gene bodies, and intergenic regions (Table 4.2). Interestingly, ~53% 
(1,125,997 CG sites on average) of all CG sites in the promoter regions (defined as 
transcription start site ± 1kb) were covered by our RRBS datasets (Table 4.2), which 
shows a higher coverage in the promoter regions as compared to the other genomic sites. 
 
Table 4.2: The number of CG sites in the Mm9 Genome Assembly and in each 
RRBS dataset, and the number of CG sites specifically in gene promoter regions  
(transcription start site ± 1kb) in each.  
 
To measure the DNA methylation changes at each CG site in the RRBS datasets, 
only those covered in all four datasets (RCA, LCA, Aza-RCA, and Aza-LCA) were 
selected for further analysis (3,232,969 unique CG sites). The methylation ratio at each 
CG site was compared between the RCA and LCA as well as the Aza-RCA and Aza-
LCA using heatmap correlation scatterplots (Figure 4.3A and B). Of the 3.2 million CG 
sites examined, 4.1% (131,176 CG sites) showed hypermethylation by more than 40% in 
the LCA as compared to the RCA, whereas 93% showed no significant difference in 
methylation, defined as less than a 40% difference between the RCA and LCA (Figure 
4.3A). 5Aza treatment reduced the number of hypermethylated CG sites in the LCA by 
more than 50% as compared to the saline group (from 131,176 to 55,224 CG sites), while 
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97% of the CG sites showed no significant difference between the Aza-RCA and Aza-
LCA (Figure 4.3B). This result showed that the small number (4.1%) of CG sites that 
were hypermethylated in the LCA by d-flow was substantially reduced by the 5Aza 
treatment (to 1.7%), suggesting that d-flow regulates genome-wide DNA methylation 
patterns in a DNMT-dependent manner.  
 
Figure 4.3: D-flow alters genome-wide DNA methylation patterns and gene 
expression in a 5Aza-dependent manner.  (A and B) gDNA from 20 LCAs and RCAs 
each were pooled and the genome-level methylation was analyzed by RRBS 
(reduced representation bisulfite sequencing). Shown are density heat map 
correlation plots portraying the methylation status at each of 3,232,969 CG sites 
covered by the RRBS analyses. The numbers indicated in the upper (131,176), 
middle (3,003,588) and lower triangles (98,205) in (A) indicate hypermethylated, not 
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altered significantly and hypomethylated CG sites, respectively, in the partially 
ligated LCA compared to the RCA in saline-treated mice. Likewise, the numbers 
shown in (B) indicate the same as in (A), but in the LCA and RCA obtained from 
mice treated with 5Aza. (C and D) Following sacrifice, endothelial-enriched RNA 
obtained from 3 LCAs and RCAs were pooled as one sample, and 3 samples per 
condition (LCA and RCA from saline vs. 5Aza treated groups) were analyzed by the 
Illumina Mouse WG6 microarray. Shown are correlation scatterplots of gene 
expression values on the log scale. The 11 genes identified in Chapter 5 Figure 1 are 
represented as red dots in each plot.  
Relationship Between Global CpG Methylation and Gene Expression  
To determine how many of these mechanosensitive DNA methylation patterns at 
the promoters correlate to gene expression patterns, we compared the promoter DNA 
methylation data to the gene transcript array data. First, the gene array data analysis 
showed that expression of 1,319 genes (569 down- and 750 upregulated) changed by 
more than 33% in the LCA compared to the RCA (Figure 4.3B and D). Treatment with 
5Aza decreased the number of differentially expressed genes to 385 (152 down- and 233 
upregulated in the LCA) between the Aza-RCA and Aza-LCA (Figure 4.3C). 
Importantly, 5Aza treatment rescued the downregulation of 540 out of the 569 
mechanosensitive genes in the LCA (Figure 4.3C and D), demonstrating the dominant 
effect of 5Aza treatment on mechanosensitive gene expression, either directly or 
indirectly (Figure 4.3B-D, Figure 4.4C and D).  
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Figure 4.4: Genome-wide methylation and gene expression patterns in partially-
ligated mouse carotids.  (A,B) Heatmap correlation scatterplots of the methylomes 
of the LCA compared to the Aza-LCA and the RCA compared to the Aza-RCA. 
(C,D) Gene expression was compared between the LCA vs. Aza-LCA and RCA vs. 
Aza-RCA obtained from endothelial RNA as described in Figure 4.3.  
Analysis of the DNA methylation levels around the transcription start site, gene 
body, and transcription termination site and its relationship to gene expression levels 
further analysis revealed that our RRBS and gene array datasets showed the expected 
pattern, wherein percent promoter methylation inversely correlated with gene expression 
levels on a global scale (Figure 4.5), whereas the same trends were not observed for the 
gene body (GB) and 3’ gene regions surrounding the transcription termination sites 
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(TTS). This finding is consistent with previous reports showing a close correlation 
between promoter hypermethylation and gene silencing 126, validating that our RRBS and 
transcriptome data sets behave in an expected and reliable manner.  
 
Figure 4.5: Global comparison of the RRBS data and the transcriptome data 
demonstrates that our datasets follow expected trends.  Comparison of DNA  
methylation to gene expression for the LCA and RCA of (A) untreated and (B) 
5Aza-treated mice for different regions of the genome: the transcription start site 
(TSS; the promoter is defined as within ± 1kb of a gene TSS), gene body (GB), and 
transcription termination site (TTS; defined as within ± 1kb of a gene TTS). The 
data for TSS shows the expected inverse correlation between promoter methylation 
and gene expression.  
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Emergent Methylation Patterns 
An a priori methylation pattern analysis was performed to determine the global 
behavior of methylation changes across the samples at each CG site by ranking the 
methylation ratio of each gene promoter among the 4 groups. This revealed a pronounced 
emergent methylation pattern, wherein gene promoters in the LCA (2,086 out of 16,493 
genes) were hypermethylated as compared to the RCA, Aza-LCA, and Aza-RCA (listed 
in decreasing order of methylation ratios, L>R>aL>aR; Figure 4.6). This supports our 
hypothesis that d-flow induces promoter hypermethylation in a subset of genes in the 
LCA in a DNMT-dependent manner. 
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Figure 4.6: Emergent methylation pattern analysis.  Analysis of gDNA methylation 
patterns existing in the RRBS datasets by ranking promoter methylation per gene 
for each RRBS sample (LCA=L, RCA=R, Aza-LCA=aL, and Aza-RCA=aR) 
revealed a pronounced emergent methylation pattern wherein gene promoters in the 
LCA are most methylated as compared to the RCA, Aza-LCA, and Aza RCA (in 
decreasing order).   
Functional Genomic Region Methylation Analysis 
In addition, and as expected based on literature reports, we found that overall 
promoter CGs were far less methylated (~29%) in comparison to genome-wide CGs 
(~78%) (Figure 4.7) 126. These results were expected because it is well-established that 
promoter CGs are in general demethylated as compared to their genome-localized 
counterparts 163. Enhancers had intermediate methylation levels (~43%) with slightly 
higher variability between the methylation levels of each enhancer due to the lower 
number of experimentally validated mouse enhancers (244) as compared to genes 
(~34,000) that existed in the VISTA enhancer database (Figure 4.7). Gene body 
methylation was slightly lower than genome-wide levels (~73%) and methylation near 
the 3’UTR in the transcription termination site (TTS) region was the most variable across 
RRBS samples, showing the strongest flow-dependent change at 2 days post-ligation 
(from 88% methylated in the RCA to 100% methylated in the LCA) (Figure 4.7). 
Contrary to our hypothesis, however, the CG methylation status of each type of 
functional genomic region we analyzed was similar regardless of flow conditions and 
5Aza treatment in the RCA, LCA, Aza-RCA and Aza-LCA (Figure 4.7), although this 
result is consistent with the small difference in the number of hypermethylated CG sites 
on the genome-wide level in LCA and Aza-LCA groups shown in Figure 4.3A and B. 
These results suggest a possibility that the 5Aza effect may be specific and limited to a 
relatively small number of genes. 
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Figure 4.7: Global percent methylation for each of the RRBS datasets was 
determined using only those sites covered by all datasets (the intersection of the 
RRBS datasets). The values were calculated by averaging the methylation ratios 
across every CG site in the genome or only within specific regions, including 
enhancers (experimentally validated by the VISTA enhancer browser), promoters 
(+/- 1 kb from the transcription start site, or TSS), gene body (the region between 
the TSS and TTS), and transcription termination site (TTS; defined as within ± 1kb 
of a gene TTS). 
Global and Promoter-specific Cyclic AMP Response Element CpG Methylation  
We next examined whether the CRE elements across the genome display this 
property of d-flow-induced hypermethylation that can be prevented by 5Aza. We found 
that CRE sequences across the genome were nearly fully methylated (95-100%) in all 
four groups (Figure 4.8A). However, CRE elements within just the promoter regions 
showed significantly less methylation compared to that of genome-wide CREs (Figure 
4.8B). In the LCA, the average percent methylation of promoter CREs was 8.7%, which 
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was decreased by ~2% in the Aza-LCA (Figure 4.8B). In both untreated and 5Aza-treated 
RCA, promoter CRE methylation was nearly zero, indicating the dramatic effect of s-
flow in preventing methylation of promoter CRE elements in the RCA (Figure 4.8B). It is 
interesting to note that 5Aza treatment showed only a small reduction in average 
promoter CG site methylation while it dramatically decreased CG methylation at specific 
gene promoters such as HoxA5, Klf3, Cmklr1, and Acvrl1, indicating a targeted effect of 
5Aza toward some gene promoters containing CREs. 
 
Figure 4.8: Global percent methylation for each of the RRBS datasets was 
calculated by averaging the methylation ratios across each CG site localized to CRE 
motifs in the genome (A) or only within promoter regions (B).  
In Figure 4.8 we determined that on average, promoter CRE CG sites have ~10% 
increase in methylation in the LCA, and we next sought to determine whether there exists 
a subset of genes with a more dramatic change. 
The Relationship Between Promoter CRE CpG Methylation and Gene Expression 
Using the 33,826 promoter sequences obtained from the Mm9 Genome Assembly 
using the UCSC Genome Browser, our string search for the three CRE motifs resulted in 
9,556 genes containing CGTCA in their promoter, 9,536 containing TGACG, and 863 
containing TGACGTCA which could be mapped to CG sites covered by our RRBS 
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datasets for 4,286 (CGTCA), 3,326 (TGACG), and 503 (TGACGTCA) genes. A 
preliminary analysis plotting the gene expression (probe intensity as a surrogate marker) 
vs CRE CG methylation ratio showed that there was a strong correlation between the 
promoter CRE methylation status and gene probe intensity measured by the microarray 
study (Figure 4.9).  
Based on these findings, we sought to discover whether flow affected a subset of 
these genes. We filtered the set of genes containing promoter CREs to determine whether 
there was a subset that had dramatic changes in promoter CRE methylation in d-flow 
conditions that could be linked with gene expression changes, and discovered a subset of 
genes for each CRE (Figure 4.10). Subsequently we focused the analysis to those genes 
with the most dramatically changed promoter CRE CG site corresponding to the most 
dramatic gene expression changes by thresholding so that only those genes that followed 
our expected trends (hypermethylation and lower probe intensity in the LCA vs. RCA) 
were kept (Figure 4.10). In this category, we observed that the most flow sensitive genes, 
occurring in the lower right hand quadrant of Figure 4.10D, contained a subset of genes 
we previously discovered by our initial filtering analysis, including HoxA5, Klf3, and 
Cmklr1 (Figure 5.4). We also discovered several novel flow sensitive genes, including 
Stim2, Lima1, Npr2, Slc29a1, and Pcdhga12 (Figure 4.10D). These genes display 
different sensitivities to 5Aza. For example, While Pcdhga12 and Lima1 expression 
increase due to 5Aza treatment, it does not appear to be due to a change in their CRE CG 
methylation status. This indicates that there may be an upstream signaling event that is 
affected by 5Aza and controls their downstream gene expression by a mechanism other 




Figure 4.9: Global correlation between the methylation ratio of the promoter CRE 
and the corresponding gene’s expression for each (A) the LCA, (B) RCA, (C) 
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Figure 4.10: Trajectory and differentials plots showing the change between LCA 
and RCA for each CRE motif  (CGTCA (A), TGACG (B), and TGACGTCA(C); (A-
C) arrows point from LCA values for CRE methylation and gene expression to RCA 
values for the same). The differences between gene expression and methylation for 
all d-flow-hypermethylated CRE CG sites are plotted for the LCA v RCA (D) and 
the AzaLCA v AzaRCA (E).  
Discussion 
The studies described in Chapter 4 analyzing the concomitant endothelial 
methylome and transcriptome enabled us to examine the effects of shear stress and the 
role of DNMT1 in global EC DNA methylation and gene expression. We addressed the 
difficulty of tackling the widely unknown disease mechanism of atherosclerosis by 
limiting the scope of our project to a specific a priori hypothesis based on well-studied 
epigenetic mechanisms, and we recognize the limitations of such directed studies. We 
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used the knowledge that promoter CpG methylation causes gene supression to guide our 
studies and increase the likelihood of rapid, therapeutically actionable discoveries. The 
huge benefit of the data collected with our dual “omics” approach its availability and 
abundant potential for future analyses as new epigenetic mechanisms such as non-CpG 
methylation and functional genomic region methylation changes become clearer. 
5Aza treatment showed a dramatic effect in rescuing the mechanosensitive gene 
expression patterns, recovering nearly 540 genes out of 569 genes that were suppressed 
by d-flow in the LCA (Chapter 5 Figure 1) while having minimal effect on the RCA gene 
expression (Figure 4.4D). The lack of any significant effect of 5Aza on the RCA gene 
expression was surprising, but it may indicate that the 5Aza effect is limited only to the 
d-flow-sensitive genes in the LCA. This may be due to the hyperproliferative nature of d-
flow-exposed endothelial cells in the LCA while the RCA endothelial cells remain 
quiescent. This is consistent with the known effect of 5Aza, which functions in dividing 
cells such as those in leukemia and in the LCA endothelium. This notion is further 
corroborated by the lack of a widespread effect of 5Aza on the genome-wide DNA 
methylation patterns, although 5Aza did reduce the number of hypermethylated CG sites 
significantly for a limited subset of the methylome (from ~130,000 to ~55,000 sites in the 
LCA) and those CG sites may have a functional importance on gene expression (Figure 
4.3A and B).  
Given the known specificity of 5Aza action on highly proliferative myeloid cells 
as opposed to populations with a lower turnover rate, we were interested in exploring 
further whether the targeted effect of 5Aza in the LCA could be a result of altered rates 
on endothelial cell proliferation in altered shear stress conditions. It has been 
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demonstrated that overall rates of endothelial cell (EC) turnover in the artery are very 
low.164 More specifically, ECs in atherosclerosis-resistant regions of the artery have an 
approximate life span of 12 months.165 However, as demonstrated by multiple 
independent groups, when ECs are exposed to disturbed flow the turnover rate increases 
dramatically; ECs at these lesion-prone sites live for weeks and even shorter when 
animals age165,166.  
One of the most striking findings from our RRBS data was that CRE-localized 
promoter CG sites were not methylated at all (~0%) in the s-flow RCA, whereas CG sites 
across all regions of the promoter were ~30% methylated (Figure 4.7 and Figure 4.8). 
This suggests that there is an active hypomethylation mechanism that prevents these 
promoter CRE CG sites from being methylated.  
Our computational analyses in Chapter 4 overlaying the concomitant endothelial 
methylome and transcriptome datasets that we collected were designed to ask very 
specific questions regarding the importance of DNA methylation in atherosclerosis 
development. We also performed a posteriori analyses to allow the data itself to dictate 
the direction of our further analyses. We found that DNMT inhibition by 5Aza rescues 
global gene expression in the LCA towards the s-flow state. While our first pass analysis 
did not demonstrate dramatic genome-wide or functional genomic element methylation 
changes under these conditions, we followed a specific hypothesis and found a subset of 
genes that had d-flow-induced promoter hypermethylation correlating with gene 
suppression in which both were 5Aza-reversible. Using systems biology to direct our 
second pass genome-scale bioinformatics analysis, we discovered that gene promoters 
containing cyclic AMP Response Elements (CRE) are preferentially methylated by d-
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flow in a 5Aza-dependent manner. We further discovered that, on the genome scale, CRE 
hypermethylation corresponds to decreased gene expression. The studies presented in 
Chapter 4 used an “omics” approach to uncover a key gene regulatory network controlled 





CHAPTER 5 MASTER REGULATORS OF ENDOTHELIAL 
FUNCTION THAT ARE CONTROLLED BY DNA METHYLATION 
Summary 
To determine the mechanisms by which 5Aza inhibited atherosclerosis in vivo 
and endothelial cell inflammation in vitro, we tested the hypothesis that d-flow induces 
hypermethylation of anti-atherogenic endothelial cell genes at the promoter regions 
thereby silencing their expression, and that 5Aza treatment prevents this 
hypermethylation, leading to prevention of atherosclerosis.  
The aim of Chapter 5 was to discover genes that are important in endothelial 
biology and regulated by DNA methylation. Detailed examination of the RRBS and 
microarray led to 11 genes that were hypermethylated and had suppressed expression in 
d-flow, and these were reversed by treatment with 5Aza. These included HoxA5, 
Tmem184b, Adamtsl5, Klf3, Cmkrl1, Pkp4, Acvrl1, Dok4, Spry2, Zfp46, and F2rl1. We 
also found that genes containing promoter cyclic AMP response elements (CRE) are 
enriched in these hypermethylated, d-flow suppressed genes. 
Of note, HoxA5 showed the most robust flow-dependent changes in promoter 
methylation and gene silencing that was significantly reversed by 5Aza treatment, 
indicating the potential importance of DNMT-dependent mechanosensitive gene 
regulation by promoter methylation. In addition to HoxA5, we found that the entire 
family of Hox genes, including the co-localized mir10 family, had strong flow-dependent 
methylation changes in the same manner as described for the 11 genes. A portion of 
Chapter 4 was published as follows: Dunn, J., Qiu, H., Kim, S., Jjingo, D., Hoffman, R., 
Kim, C. W., Jang, I., Son, D. J., Kim, D., Pan, C., Fan, Y., Jordan, I. K. Jo, H. Flow-
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dependent epigenetic DNA methylation regulates endothelial gene expression and 
atherosclerosis. J Clin Invest 124, 3187-319916. 
Introduction 
Shear-Responsive Epigenetics 
Histone Modifications and Chromatin Remodeling  
Shear stress has been found to mediate chromatin remodeling and histone 
modifications and this is thought to play a role in shear-induced gene expression changes 
33,34. Early reports of shear-responsive epigenetics described novel pathways by which 
laminar shear mediates chromatin remodeling in cultured endothelial cells via histone 
H3/H4 acetylation and H3 phosphorylation 63,64.In ECs, LS activates genes with intrinsic 
histone acetyltransferase (HAT) activity, such as RSK-2 (ribosomal S6 kinase-2), MSK-1 
(mitogen- and stress-activated kinase-1), and CREB/CBP (cAMP-responsive element–
binding protein/CREB-binding protein) complexes. LS also deactivates histone 
deacetylases (HDACs), and induces histone H3/H4 acetylation and H3 phosphorylation 
in cultured ECs, and this regulates the key EC transcription factors Kruppel-like Factors 2 
and 4 (Klf2, Klf4), and the EC-specific gene endothelial nitric oxide synthase (eNOS), 
via myocyte enhancer factor-2 (MEF2)63,64,167. Conversely, OS causes HDAC 
overexpression, and HDAC inhibition prevents OS-induced EC proliferation and EC 
inflammation in vivo and in vitro 168-170.  
LS blocks HDACs from deacetylating the promoter of myocyte enhancer factor-2 
(MEF2), and this enables MEF2 to be active and mediate KLF2 and eNOS expression in 
LS167. OS induces HDAC overexpression and accumulation in the nucleus via 
phosphatidylinositol 3-kinase (PI3K)/Akt signaling, which blocks the expression of anti-
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inflammatory transcription factors Nrf2 (NF-E2-related factor 2, by HDAC2/3/5) and 
Mef2 (by HDAC1/2/3). It was further found that HDAC1/2/3 inhibition by siRNA or the 
class I-specific (HDAC1/2/3) inhibitor valproic acid prevented OS-induced EC 
proliferation in vivo and in vitro168.  
Endothelial-specific Gene Expression Mediated by Epigenetics 
Early single gene epigenetic studies were mainly focused on defining markers of 
cellular differentiation down the endothelial lineage. Understanding the function and 
regulation of genes that have EC-specific expression is of keen interest to researchers 
because the loss of normally constitutively active EC genes is a hallmark of EC 
dysfunction. 
Histone acetylation is important for both LS-induced and endothelial-specific 
expression of eNOS. HDAC inhibitor-induced increases in eNOS expression were linked 
to decreased DNA methylation of the eNOS promoter, and a trichostatin A (TSA) and 
5Aza combination treatment synergistically increased eNOS expression in non-ECs 171. 
This demonstrates the complementary interactions of histone modifications and DNA 
methylation. It was later found that the eNOS promoter is heavily methylated in non-ECs 
but demethylated in ECs, and that 5Aza treatment can induce eNOS expression in non-
ECs that normally do not express eNOS 172. This demonstrates that basal eNOS 
expression is regulated by DNA methylation. Methylation of the eNOS promoter blocks 
binding of Sp1, Sp3, and Ets1, and thus eNOS transcription 172.  
In addition to eNOS, Roundabout 4 (Robo4) is an EC-specific gene whose 
expression is controlled by promoter DNA methylation in non-ECs which prevents 
binding of essential transcription factor SP1. Both the methylation and gene expression 
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status of Robo4 in non-ECs can be reversed by treatment with 5Aza. Interestingly, while 
Robo4 is suppressed by LS and eNOS is suppressed by OS, neither Robo4 nor eNOS has 
shear-responsive promoter DNA methylation changes 65,173-175. Both eNOS and Robo4 
lineage-specific epigenetic changes have been carefully dissected to show that Robo4-
specific methylation patterns are established during the transition from ES to Flk-1+ 
mesodermal cells, while EC-specific eNOS DNA methylation and concomitant histone 
modifications appear in early proangiogenic cells 173,176.  
Studies of epigenetically-moderated EC-specific gene expression were expanded 
to a repertoire of EC-specific genes, and highly important EC genes PECAM1 (CD31), 
von Willebrand factor (vWF), VE-cadherin, and intercellular adhesion molecule-2 have 
EC-specific promoter demethylation. As with other genes, 5Aza induced their expression 
in non-ECs and TSA had a synergistic effect 177. These studies, taken together, 
demonstrate that DNA methylation is a key mechanism for EC-specific gene expression. 
DNA Methylation is a Novel Epigenetic Mechanism that Regulates Endothelial Cell 
Responses to Shear Stress 
Until recently, there had been little exploration on the potential for endothelial 
cell epigenetic responses to shear stress. In the spring of 2014, several research groups in 
vascular mechanobiology independently converged on the seminal finding that DNA 
methyltransferases are shear responsive proteins that regulate flow-mediated endothelial 
gene expression programs. 
Klf4 is a key mediator of endothelial function and has been well documented to 
maintain an anti-inflammatory, quiescent endothelial state in unidirectional flow 
conditions178-181. Very recently, DNA methylation was discovered as a novel, flow-
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mediated mechanism of endothelial Klf4 transcriptional regulation both in vitro and in 
vivo65. In this study, both DNMT3A expression and DNMT3A binding to the Klf4 
promoter were found to increase due to d-flow. This led to DNA hypermethylation and 
decreased MEF2 binding. MEF2 is a key transcription factor that controls Klf4 
upregulation in response to resveratrol in ECs182. DNMT inhibition by 5Aza or RG108 
rescued Klf4 expression and reversed the DF-induced loss of downstream Klf4 targets 
eNOS and thrombomodulin (THBD), and the DF-induced overexpression of the 
proinflammatory monocyte chemoattractant protein-1 (MCP-1).  
Shortly following these studies, Zhou et al. also reported that d-flow causes 
DNMT1 overexpression 66. Comparing OS to pulsatile, unidirectional shear in HUVECs, 
they found that OS increases DNMT1 mRNA and protein levels, DNMT1 nuclear 
translocation, and 5-methyl-cytosine (5mC) content. 5Aza treatment inhibited the OS-
induced DNMT1 expression and prevented increases in 5mC. Using a rat partial carotid 
ligation model, they demonstrated that d-flow also induced DNMT1 protein expression 
and increased 5mC content.  
The genome-wide studies of DNA methylation and gene expression we recently 
completed provide a much broader view of flow-mediated global DNA methylation 
changes that regulate networks of genes and have a functional effect on atherosclerosis 
development in vivo.  
The Homeobox and MicroRNA10 Gene Families 
Hox genes are homeobox transcription factors whose homeodomains recognize and 
bind to specific DNA sequences, enabling the coordinate regulation of sets of genes. Hox 
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genes are highly conserved, known to be dysregulated in cancer, and are controlled in 
part by DNA methylation183-188.  
The four Hox gene clusters are well known to play key roles in developmental 
patterning of the anteroposterior axis of bilaterian animals. The Hox families exhibit a 
high level of self-interaction, forming 3-dimensional chromatin conformations known as 
a topological domains 189. This global method of establishing a higher order genomic 
structure that also occurs specifically within Hox domains underscores the key 
importance of DNA domain interaction regulation by epigenetic mechanisms. Hox family 
members have been implicated in vascular remodeling, angiogenesis, and disease by 
orchestrating changes in gene expression, extracellular matrix, and integrins 190.  
HoxA5 is known to regulate various vascular functions such as migration, 
angiogenesis, and inflammation by controlling specific endothelial genes 191-195. HoxD3 
and HoxB3 are pro-invasive, angiogenic genes that upregulate β3 and α5 integrins and 
Efna1 in ECs, respectively 196-199. HoxA3 induces EC migration by upregulating 
metalloproteinase-14 (MMP14) and plasminogen activator urokinase receptor (uPAR) 
200. Conversely, HoxD10 and HoxA5 have the opposite effect of suppressing EC 
migration and angiogenesis, and stabilizing adherens junctions by upregulating TIMP1, 
downregulating uPAR and MMP14, and by upregulating Tsp2 and downregulating 
VEGFR2, Efna1, Hif1α and COX-2, respectively 192,193. HoxA5 also upregulates the 
tumor suppressor p53 and Akt1 by downregulation of PTEN 194. Suppression of HoxA5 
has been shown to attenuate hemangioma growth 195. HoxA5 has far-reaching effects on 
gene expression, causing ~300 genes to become upregulated upon its induction in breast 
cancer cell lines 201. HoxA5 protein transduction domain overexpression prevents 
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inflammation shown by inhibition of TNFα-inducible monocyte binding to HUVECs 
191,202. Our study shows, for the first time, that HoxA5 is downregulated by d-flow in a 
DNA methylation-dependent manner and that HoxA5 suppresses endothelial 
inflammation. 
Mir10a and Mir10b are located within the HoxB and HoxD clusters, respectively. 
Both the Hox and Mir10 families are highly evolutionarily conserved, known to be 
dysregulated in several cancers, and are controlled, at least in part, by DNA 
methylation.183-188 Interestingly, Mir10a and Mir10b were both found to be suppressed, 
and HoxA1 overexpressed, in endothelial cells in pro-inflammatory, athero-susceptible 
disturbed flow regions both in vitro and in vivo.79 Mir10a is a regulator of ~1,100 genes 
and was shown to directly target the inflammatory NFKB signaling network in 
endothelial cells.79,203 The known shear-sensitive, anti-atherogenic, tumor suppressor 
gene Klf4 is experimentally validated as a direct target of Mir10b.204 Mir10a and Mir10b 
differ by only one nucleotide and are experimentally validated to target a host of Hox 
genes. HoxA1, HoxA3, HoxD4, and HoxD10, are all targets of Mir10a, and Mir10b is 
thought to regulate HoxB4.186,205,206 De novo methylation at the HoxD4 promoter has 
been observed as a result of Mir10a targeting.206 While DNA methylation is known to be 
an important regulator of these genes under certain developmental and disease conditions, 
whether epigenetic DNA methylation in flow-exposed ECs is an important regulatory 
mechanism of atherosclerosis had not been previously explored. Additionally, Hox was 
not known to be a mechanosensitive gene family until now. The Hox/Mir10 clusters 
merit further study to understand their importance in EC biology and atherosclerosis. 
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Klf3 
Klf3 is a transcription factor, but unlike Klf2 and Klf4, which are well-known 
mechanosensitive transcriptional activators, Klf3 is known to repress transcription207-209. 
Interestingly, both HoxA5 and Klf3 are suppressed in acute myeloid leukemia (AML), 
and the DNMT inhibitor 5Aza is used to treat this disease. While HoxA5 is known to be 
hypermethylated in AML, it has not yet been shown whether 5Aza directly targets these 
genes for demethylation 210,211. AML is also treated with all-trans retinoic acid, a drug 
known to influence DNA methylation of a small number of specific genes and, also 
interestingly, this drug was shown to rescue Klf3 expression by an unknown mechanism 
99,212. It would be interesting to determine whether the therapeutic effects of 5Aza and all-
trans retinoic acid on AML are mediated, at least in part, by rescuing Klf3 promoter 
hypermethylation. 
Mechanosensitive MicroRNAs 
Multiple reports in recent years have indicated the crucial role that miRNAs play in 
the endothelial response to shear stress, as the levels of these miRNAs are directly altered 
in response to shear stress. These miRNAs are known as mechanomiRs and many have 
now been directly implicated in the pathogenesis of atherosclerosis. While some miRNAs 
become upregulated in LS conditions, and thus would be considered atheroprotective, 
many become upregulated in OS conditions, and thus are thought to be atherogenic. 
Some atheroprotective miRNAs that have been discovered in vitro are miR-10a, miR-19a, 
miR-21, miR-23b, miR-101, and miR-143/145 79,93,213-216. 
Conversely, miR-21, miR-92a, and miR-663 are mechanosensitive atheromiRs that 
become highly expressed in OS conditions 217-219. Also, miR-155 is a mechanosensitive 
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miRNA, but its role in atherosclerosis is unclear 220. Given the fact that miRNAs have 
hundreds of gene targets, unsurprisingly, many miRNAs (such as miR-21, 181, and 155) 
have played both anti-atherogenic and pro-atherogenic roles depending on cell type and 
stimulus 221. 
Although many miRNAs have been studied under in vitro conditions of shear stress, 
some miRNAs have directly been studied in mouse models of atherosclerosis. In 2013, 
our group discovered that a miR-712 becomes highly upregulated in endothelial regions 
exposed to d-flow in our murine model of disturbed flow-induced atherosclerosis. 
Furthermore, repression of miR-712 binding (by locked nucleic acid anti-miRNA) to its 
main target, tissue inhibitor of metalloproteinases (TIMP3), drastically inhibited 
endothelial dysfunction and atherosclerosis 222. Additionally, we found that the human 
ortholog of miR-712, miR-205, is also mechanosensitive and mediates the same effects 
both in atherosclerosis and in abdominal aortic aneurysm 223. Other miRNAs that have 
been demonstrated to directly play a role in atherosclerosis are miR-92a and miR-181b. 
Loyer and colleagues demonstrated that miR-92a inhibition by antagomiR treatment 
inhibited endothelial dysfunction and subsequent atherosclerosis in high-fat diet-fed LDL 
receptor-/- mice, whereas Sun et al. demonstrated that systemic injection of miR-181b in 
ApoE-/- mice led to its overexpression in endothelial cells and peripheral blood 
mononuclear cells (PBMCs) and subsequently inhibited NFκB activation and 
atherosclerosis development 224,225.  
 95 
Methods 
A Priori Filtering to Discover Mechanosensitive Genes Regulated by DNA Methylation 
Through DNA Methyltransferase 
The differentially methylated and differentially expressed genes were parsed according to 
our hypothesis that d-flow–induced hypermethylation at the promoter suppresses gene 
expression, and that this could be reversed by 5Aza. We performed thresholding to filter 
out genes that are hypermethylated in the promoter and suppressed by d-flow in a 5Aza-
preventable manner. Specifically, we looked for differentially methylated regions 
(DMRs) in gene promoters, defined by TSS ± 1 kb containing a minimum of 10 CG sites 
with a minimum difference in percent methylation (Δ % methylation = % methylation in 
the LCA – % methylation in the RCA) of 10. There were 421 such genes. We further 
parsed this list to genes whose promoter hypermethylation in LCA was prevented by 
5Aza (Δ% methylation = % methylation in the Aza-LCA – % methylation in the Aza-
RCA < 5), and this resulted in 335 genes. For the mRNA expression criteria, we looked 
for genes downregulated in LCA versus RCA (LCA/RCA < 0.67), which resulted in 569 
genes, and then we further looked for genes whose expression in LCA was rescued by 
5Aza (resulting in 540 genes). By combining these methylation and gene expression 
criteria, we extracted 11 genes that have d-flow–inducible hypermethylation and gene 
suppression that can be prevented by 5Aza. Of the resulting 11 genes, systems biology 
analysis via MetaCore revealed common regulation by the CREB transcription factor in 5 
of the 11 genes (only 4 of which had RRBS coverage specifically at the CRE sequence). 
 96 
Systems Biology Analysis Led to CREB as a Key Network Regulator 
The GeneGO MetaCore program by Thomson Reuters is a data mining and 
pathways analysis tool that enables systems biology analysis of mammalian cells 
incorporating data from ligand-receptor binding interactions, cell signaling and regulation 
pathways, and metabolic pathways. We used this tool as recommended by the company 
to examine whether there were any common network regulators in our parsed gene set. 
The discovery of a common transcription factor as a central node in the systems 
biology analysis of the gene set led to a JASPAR analysis to determine the consensus 
binding motif, and the specificity of binding, for CREB1. 
The promoter sequences of the 11 genes (+/-1kb from the TSS) were obtained 
from the UCSC Genome Browser using the NCBI37/mm9 genome assembly. A string 
search was done for the consensus CREB binding motifs (TGACGTCA, TGACG, and 
CGTCA) on the positive strand of the promoter sequence, although strand configuration 
is unimportant due to the palindromic nature of the CRE sequence.  
QPCR and Single Locus Bisulfite Sequencing  
qPCR was done as described in Chapter 3 methods, and qPCR primers are listed 
in Bisulfite sequencing primers for HoxA5 (Chapter 3 Table 1) were designed using the 
MethPrimer program 226. Genomic DNA collected from 4 mouse carotid arteries as 
described previously was pooled, purified using the DNeasy Blood and Tissue Kit 
(Qiagen) and was bisulfite converted using the Epitect bisulfite conversion kit (Qiagen). 
10ng of bisulfite-converted DNA was subjected to PCR amplification using custom-
design BS-PCR primers (Chapter 3 Table 1) at a Tm of 59.5°C. 
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siRNA and monocyte adhesion 
siRNA and monocyte adhesion studies were performed as described in the 
methods section of Chapter 3. Dharmacon SmartPool siRNAs for HoxA5 and Klf3 were 
used. 
Results 
A Priori Filtering to Discover Mechanosensitive Genes Regulated by DNA Methylation 
Through DNA Methyltransferase 
In order to determine the most robustly flow-sensitive genes that are controlled by 
DNA methylation, we compared the list of mechanosensitive genes that were 
hypermethylated at their promoter and downregulated in the LCA in a 5Aza-dependent 
manner to determine the genes that exhibit the expected correlation between methylation 
and gene expression. This comparative analysis revealed 11 flow-sensitive genes that 
were hypermethylated at their promoter and silenced by d-flow that could be rescued by 
5Aza (Figure 5.1). These included HoxA5, Tmem184b, Adamtsl5, Klf3, Cmkrl1, Pkp4, 
Acvrl1, Dok4, Spry2, Zfp46, and F2rl1. Of note, HoxA5 showed the most robust flow-
dependent changes in promoter methylation and gene silencing that was significantly 
reversed by 5Aza treatment, indicating the potential importance of DNMT-dependent 
mechanosensitive gene regulation by promoter methylation. 
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Figure 5.1: D-flow induces promoter hypermethylation corresponding to suppressed 
expression in a subset of flow-sensitive genes.  (A and B) To identify 
mechanosensitive genes that are hypermethylated in their promoter and their gene 
expression downregulated in a 5Aza-dependent manner, the genes with 
hypermethylated promoters in the LCA that were rescued by 5Aza treatment were 
selected. Using the microarray data, the mechanosensitive genes that were 
downregulated by more than 33% in the LCA and rescued by 5Aza treatment were 
selected. These 2 selected gene lists were compared with each other, result- ing in 11 
genes that were hyper- methylated in the promoters and downregulated in a 5Aza-
dependent manner (data are shown as the mean ± SEM. *P < 0.05; **P < 0.05). 
Gene names containing hypermethylated promoter CRE sites in B are indicated 
with a single asterisk (*).  
Systems Biology Analysis Uncovered Cyclic-AMP Response Element Binding Protein 
(CREB) as a Common Network Regulator 
To explore whether there are any functional regulatory elements that are common 
within the promoter regions among the 11 genes, we first searched for common 
regulatory mechanisms of these genes. The systems biological analysis using GeneGo 
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MetaCore (Thomson Reuters) with these 11 genes as the input predicted CREB1 (CRE 
binding protein) as the transcription factor with the highest potential connectivity. Using 
JASPAR, we determined the CREB1 binding motif to be TGACGTCA (Figure 5.3). A 
thorough literature review revealed that CREB binds to both the full palindromic and also 
half sequence motifs (TGACGTCA, TGACG, and CGTCA). 
 
Figure 5.2: Systems biology analysis using MetaCore GeneGO shows CREB as a 
common network regulator in the parsed gene list. This zoomed in view of the 
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interaction network shows those 5Aza-rescuable, hypermethylated genes (HoxA5 
and Klf3) predicted by MetaCore to have a direct binding interaction with CREB. 
Further sequence analysis revealed that 5 out of the 11 genes contain CREB binding 






Figure 5.3: JASPAR TFBS search revealed the consensus CREB binding motif 
sequence  of TGACGTCA. The size of the nucleotide corresponds to its importance 
in the binding interaction, with the third A being key to the interaction, and the 
other nucleotides having allowable variability of different levels and with different 
possible substitutions. 
The Subset of D-Flow Hypermethylated and Suppressed Genes That Are 5Aza-Rescuable 
Are Enriched For Genes with CRE Motifs in Their Promoter 
This led us to a computational sequence analysis designed to look for the full 
palindromic or half CRE sequences (TGACGTCA, TGACG, and CGTCA) within the 
differentially methylated regions (DMR) of the 11 gene promoters (+/- 1kb from the 
transcription start site). This search revealed that 5 of the 11 gene promoter DMRs 
 101 
contained CRE sites, including HoxA5, Klf3, Cmklr1, Acvrl1 and Spry2. We then 
examined the DNA methylation status of these gene promoter DMRs at the specifically 
the CRE CG site and found that HoxA5, Klf3, Cmklr1, and Acvrl1 indeed showed 
significant hypermethylation at this CG in the LCA, which was prevented by 5Aza 
treatment (Figure 5.4A-D). For example, percent methylation of the HoxA5 promoter 
CRE CG site was dramatically higher in the LCA (55.6%) as compared to the RCA 
(11.5%), the Aza-LCA (17.2%), and the Aza-RCA (20.0%). The promoter CRE CG site 
in Spry2, however, was not fully covered by our RRBS data; therefore we could not 
determine its flow- and 5Aza-dependency.  
 
Figure 5.4: Gene promoters containing CRE are preferentially methylated by d-flow 
in a 5Aza-dependent manner.  Of the 11 genes in Figure 5.1, HoxA5, Klf3, Cmklr1, 
and Acvrl1 contain CREs in their promoter differentially methylated regions 
(DMRs). The methylation ratios (the number of methylated sequencing reads 
divided by the total number of sequencing reads) for the CG site within the CRE are 
displayed for each genomic DNA strand for the RCA, LCA, Aza-RCA, and Aza-
LCA, and average values are shown below in bar graphs.  
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Detailed analysis of the RRBS DNA methylation data in the HoxA gene cluster is 
shown in Figure 5.5 using a UCSC genome browser track to display our RRBS data at 
the nucleotide resolution. The HoxA5 promoter region was clearly hypermethylated in the 
d-flow LCA as compared to the s-flow RCA, the Aza-LCA, and the Aza-RCA (Figure 
5.5A). This RRBS result was further confirmed by manual bisulfite sequencing of 
additional endothelial gDNA obtained from the RCA, LCA, Aza-RCA, and Aza-LCA, 
validating the RRBS data (Figure 5.5A). Further, we validated the HoxA5 expression data 
obtained from the microarray study (Figure 5.5B) by qPCR (Figure 5.15C). The qPCR 
result showed that HoxA5 expression was downregulated in the LCA by more than 50% 




Figure 5.5: RRBS analysis reveals d-flow–induced HoxA5 promoter 
hypermethylation.  (A) DNA methylation data obtained from the RRBS study are 
shown using a University of California, Santa Cruz, browser track that displays our 
RRBS data sets. High methylation is denoted in yellow and low meth- ylation in red. 
(B) A zoomed-in view of the HoxA5 methylation patterns displaying ratios with the 
number of methylated sequencing reads divided by the total number of sequencing 
reads at each individual CG site.  
HoxA5 and Klf3 are Flow-sensitive Genes With Previously Unstudied Roles in 
Endothelial Biology 
Given the potential role of the transcription factors HoxA5 and Klf3 as master 
regulators of gene expression networks, we further examined their relevance to the 
endothelial flow response. We found that HoxA5 is strongly suppressed in response to 
disturbed flow (DF) in vivo by microarray and qPCR (Figure 5.5C and D, respectively), 
and oscillatory shear (OS) in HUVECs in vitro at both the mRNA and protein level 
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(Figure 5.6A and B). We found that the CRE in the promoter of HoxA5 is homologous 
between mouse and human, further implicating its potential importance in human 




Figure 5.6: D-flow induces DNA hypermethylation of the HoxA5 gene promoter and 
downregulates its expression in a 5Aza-dependent manner.  (A) DNA methylation at 
the HoxA5 promoter region in endothelial-enriched genomic DNA from the LCA 
and RCA at 1 week after partial ligation from mice treated with saline or 5Aza was 
fur- ther examined in independent samples by bisulfite sequencing. Black and white 
circles represent methylated and unmethylated cytosines, respectively. Eight CG 
sites (denoted by the columns) were probed in this assay, and 8 to 10 colonies 
(denoted by the rows) were chosen for analysis. Percentages below the figures 
denote the aver- age percent methylation for this region of the HoxA5 promoter. (B 
and C) HoxA5 gene expression was examined in endothelial-enriched RNA from the 
LCA and RCA obtained at 1 week after partial ligation from saline- or 5Aza-treated 
mice by microarray analysis. Data for B are shown as the mean ± SEM. **P < 0.01, 
n = 3 each and were validated by qPCR. Data for C are shown.  (D) HoxA5 gene 
expression was examined in endothelial-enriched RNA from the LCA and RCA 




Figure 5.7: The sequence of the promoter CRE and surrounding region in HoxA5 is 










Figure 5.8: HoxA5 and Klf3 are suppressed by OS in vitro, and HoxA5 increases 
LS-suppressed endothelial inflammation.  (A) HoxA5 expression and Klf3 
expression are suppressed by OS compared with LS.HUVECs exposed to LS (15 
dyn/cm2) or OS (±5 dyn/cm2, at 1 Hz) for 24 hours were used for qPCR using 18S 
as an internal control (n = 6 each, data are shown as the mean ± SEM. **P < 0.01). 
(B) Western blot analysis for HoxA5 was performed on the same samples from A 
using β-actin as the loading control. The bar graph shows the ImageJ Western blot 
quantification normalized to β-actin (n = 3 each, data are shown as the mean ± 
SEM; *P < 0.05). (C and D) HUVECs were pre- treated with siRNA to HoxA5 or 
Klf3 (100 nM for 24 hours), and subsequently exposed to OS or LS for an additional 
24 hours. Following shear, endothelial inflammation was determined by 
quantification of the number of THP-1 monocytes adhered to sheared endothelial 
cells (n = 3 each, data are shown as the mean SEM. *P < 0.05)  
Similarly, Klf3 mRNA expression is suppressed by d-flow both in vivo (Figure 
5.1) and in vitro (Figure 5.6A). We were not able to determine Klf3 protein due to a lack 
of adequate antibody for western blot. To analyze the role of these transcription factors in 
endothelial inflammation, we performed monocyte adhesion assays using siRNAs to each 
HoxA5 and Klf3 in HUVECs under shear. We found that in the LS condition, 
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knockdown of HoxA5 significantly increased monocyte adhesion to HUVECs, 
simulating the OS condition of increased inflammation (Figure 5.6C). However, 
knockdown of Klf3 did not have a significant effect on endothelial inflammation, 
suggesting its potential importance in other flow-responsive pathways (Figure 5.6D).  
We attempted to recapitulate the methylation changes seen in the HoxA5 
promoter in vivo using cultured ECs but these changes do not appear to occur in cultured 
cells. We believe this can be attributed to the methylation changes that occur as a result 
of culturing cells under static, no flow conditions which has been well documented 227,228. 
 
Figure 5.9: In vitro HoxA5 bisulfite sequencing using various endothelial cell types 
at multiple shear timepoints (immortalized mouse aortic endothelial cells (iMAEC) 
for 24 hour shear using the cone and plate system, human umbilical vein endothelial 
cells (HUVEC) and human aortic endothelial cells (HUVEC) both using the Ibidi 
system for long-term shear) in vitro shows that HoxA5 is essentially demethylated in 
all cases of cultured ECs regardless of flow conditions. The equivalent and 
homologous CRE CG site to our RRBS data is boxed in red.  
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We examined the expression of the 5 potentially CREB-regulated genes in vitro to 
determine whether their flow- and 5Aza-sensitivity demonstrated in vivo could be 
recapitulated in vitro. After 5 days of 5Aza treatment, HUVECs were subjected to 24h of 
shear and qPCR was done to determine gene expression levels. We found that OS 
downregulates expression of HoxA5, Klf3, and Cmklr1 (Figure 5.10). Additionally, 5Aza 
rescues expression of Klf3, Cmklr1, and Spry2 in LS, and also slightly rescues their 
expression in OS (Figure 5.10). These results also demonstrate the limitations of in vitro 
studies using cultured ECs, which often do not recapitulate biological events that occur in 
vivo. 
 
Figure 5.10: Shear- and 5Aza-sensitivity of the potential CREB-regulated genes in 
vitro (LS, AzaLS, AzaOS N=6; OS N=7) 
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Hox is a novel mechanosensitive gene family regulated by DNA methylation  
The most prominent changes in DNA methylation in our RRBS dataset occur in the Hox 
gene family. Overall, there was very high coverage of CG sites localized to the Hox 
family gene clusters by our RRBS assay, and these sites exhibit the strongest and more 
densely packed changes in methylation in the d-flow LCA as compared to the non-d-flow 
RCA. These methylation changes occur mainly at key functional regions, including 
promoters where methylation is associated with gene suppression, intron/exon boundaries 
where methylation may be associated with alternative transcript expression, and 
surrounding microRNAs (Figure 5.11A and B). Many of these changes are also 5Aza-

































































Figure 5.11: Flow regulates DNA methylation of the Hox family. (A) HoxA, HoxB, 
and HoxD gene family DNA methylation changes in endothelial cells due to 
disturbed flow are seen by reduced representation bisulfite sequencing (RRBS) 
using the mouse partial carotid ligation model. (B) RRBS data in UCSC Genome 
Browser showing 5Aza-reversible, d-flow-induced Hox promoter hypermethylation 
regions that also correspond to microRNAs: the Mir10a/HoxB4 shared promoter 
(upper panel) and the Mir10b/HoxD3 shared promoter (lower panel) are boxed in 
green. High methylation (yellow) and low methylation (red).  
The Hox families exhibit a high level of self-interaction, forming 3-dimensional 
chromatin conformations known as a topological domains 189. This global method of 
establishing a higher order genomic structure that also occurs specifically within Hox 
domains underscores the key importance of DNA domain interaction regulation by 
epigenetic mechanisms. Although the different Hox family subsets are located across 
different chromosomes, they appear to be co-regulated by methylation. In mouse, the 
HoxA, B, and D families are located on chromosomes 6, 11, and 2, respectively. 
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DNA methylation of Hox genes is a very well studied mechanism of their 
regulation in both development and cancer 229-231. While it is known that Hox genes’ 
DNA methylation status is a useful marker to distinguish between cell types for 
differentiation, we demonstrate below in Figure 5.12 that this is explicitly the case in the 
transition of cell type-specific differentiation. Comparison of the HoxA5 promoter 
methylation profile across cell types from the least differentiated (human embryonic stem 
cells) to the most endothelial-like (human umbilical vein endothelial cells, or HUVECs) 
using ENCODE datasets, as demonstrated by Shirodkar et al. for eNOS and VE-
Cadherin, shows that the HoxA5 promoter is normally heavily methylated in non-
differentiated cells and becomes demethylated as cells differentiate down the endothelial 
lineage (Figure 5.12B) 177,232. We had difficulty recapitulating the in vivo HoxA5 shear 
responsive methylation changes using two different in vitro bioreactor systems to induce 
shear stress over cultured endothelial cells (Figure 5.9A). We determined that this was 
not due to experimental artifact caused by the bisulfite sequencing conditions (Figure 
5.9B). This may be due to significant epigenetic changes occurring during EC culture 
under static conditions and raises an important consideration for the limitations of in vitro 
studies. 
Further, the functional importance of the HoxA5 promoter region in 
transcriptional regulation is demonstrated in Figure 5.12A. Using Encyclopedia of DNA 
Elements (ENCODE) project data to determine locations of transcription factor/complex 
binding to DNA, we discovered enriched Pol2 and CTCF binding at the CpG-dense 
HoxA5 promoter in HUVECs, demonstrating transcriptional activity (Figure 5.12A). The 
HoxA locus is known to contain an insulator characterized by several CTCF binding sites 
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that separate the co-regulation of expression of HoxA1-7 and HoxA9-13 233. CTCF is a 
DNA insulator binding protein that marks the transition from tightly packed 
heterochromatin to relaxed euchromatin. Pol2 contains the active subunit for synthesizing 
RNA from the DNA template, and in combination with other RNA polymerase subunits, 
forms the DNA groove binding domain. 
Our RRBS data indicates the key importance of genome-wide CREB binding sites 
(CRE) as a potential global regulator of gene expression. We expect that the HoxA5 
promoter CRE methylation status regulates CREB binding and downstream expression of 
HoxA5, but unfortunately neither CREB nor its binding partners p300/CBP were covered 
by the ENCODE consortium endothelial Chromatin-IP datasets. However, our lab is 
























Figure 5.12: Flow- and differentiation-dependent methylation changes in the HoxA5 
promoter. (A) UCSC Genome Browser view of the RRBS data showing flow-
dependent methylation changes in the HoxA5 promoter. (B) The ENCODE 
consortium ChIP-Seq datasets for HUVEC show that the transcription factor CTCF 
and RNA Polymerase II are enriched at the HoxA5 promoter. (C) Zoomed-in view 
of the blue boxed area from panel A. UCSC Genome Browser screenshot of the 
ENCODE Methyl450k array datasets, in the region boxed in red in (B), shows a 
comparison of the HoxA5 promoter methylation profile across cell types from the 
least differentiated (human embryonic stem cells) to the most endothelial-like 
(human umbilical vein endothelial cells, or HUVECs). (D) Highly methylated 
regions are shown in orange, partially methylated regions in purple, and 
unmethylated regions in blue. (E) The HoxA5 promoter CRE is not covered by the 
ENCODE dataset. (F) ENCODE Methyl450k array data shows that, as opposed to 
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the case for HoxA5, Klf3 does not demonstrate significant change in its promoter 
methylation status across differentiated and non-differentiated cells. 
The Mir10 family (Mir10a and Mir10b) lies within the Hox clusters and follows 
the criteria for 1) DF-induced suppression; 2) DF-induced promoter hypermethylation; 
and 3) 5Aza Inhibition of DF-induced promoter methylation. MiR10a and HoxB4 share a 
promoter and our RRBS data shows a differentially methylated region (DMR) following 
the proposed silencing pattern in this shared promoter. Additionally, MiR10b and HoxD3 
share a promoter that also contains a DMR following the proposed silencing pattern 
(Figure 5.13). Other Hox genes also repeatedly demonstrate this pattern (Figure 5.11). 
 
Figure 5.13: DNA methylation status of the MiR10a/HoxB4 and the MiR10b/HoxD3 
shared promoters which each contain 16 CG and 23 CG sites, respectively 
(corresponding to the area boxed in green in Figure 5.11B).  
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The Hox genes with strong promoter differential methylation (RRBS) that are 
suppressed in d-flow (microarray) include A1, A2, A3, A4, A5, A9, B4, D3, D4 (Figure 
5.11 and Figure 5.14). In vitro, HoxA1, A4, B4, D3, and D4 had trends toward 













Figure 5.14: Gene array data for Hox Family Gene expression showing differentially 
expressed genes from (A) the HoxA cluster and (B) the other Hox genes. 
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Figure 5.15: Shear-sensitivity of select Hox genes in vitro. HUVEC were subject to 
either LS or OS for 7 days using the Ibidi shear system (n=4 each). 
Discussion 
Using the DNA methylome and transcriptome datasets, our goal was to identify 
those genes that are hypermethylated in the promoter regions and silenced by d-flow, but 
that could be rescued by 5Aza treatment. Functional studies of DNA methylation patterns 
are complicated by the various, and often conflicting, reports of the role of specific 
methylation changes in gene expression control. The described study considered the 
functional consequences of specific methylation patterns by comparing the 
complementary transcriptome, and by performing rigorous single gene studies both in 
vitro and in vivo by a variety of methods including qPCR and bisulfite sequencing to 
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draw a definitive link between specific methylation patterns and the functional outcome 
of gene expression control. Ultimately these in vitro studies will be translated to disease 
development or prevention studies in vivo.  
We would like to emphasize the importance of the user-defined threshold values 
in our method of gene discovery that, by using more strict criteria, enabled us to filter out 
a manageable number of genes for further study. This unbiased genome-wide 
comparative analysis revealed 11 genes that fit these criteria. This result was surprising at 
first, since most of the downregulated genes by d-flow in the LCA were rescued by 5Aza 
treatment (540 out of 569 genes), and because the promoter DNA methylation patterns 
were rescued by 5Aza in the majority of genes (335 out of 421 genes) (Figure 5.1). This 
discrepancy between the 5Aza effect on gene expression and methylation and the number 
of genes that fit our hypothesis could be due to the following possibilities that: 1) 5Aza 
may target a few master regulators such as transcription factors that could in turn regulate 
the rest of the mechanosensitive genes; 2) there are only a few key CG sites on promoters 
that could determine the binding of master transcription factors, which determines the 
expression of most of the mechanosensitive genes; and 3) the majority of other CG sites 
in the promoters do not necessarily lead to functional consequences. To test these 
possibilities, we first searched for potential master transcription factors that could 
regulate the 11 mechanosensitive and 5Aza-sensitive genes using the MetaCore analysis. 
This suggested CREB as a potential master transcription factor that could bind to 5 out of 
the 11 genes. The subsequent computational sequence-based analysis showed that 4 of 
these genes (HoxA5, Klf3, Cmklr1, and Acvrl1) contained a CG site in the promoter CRE 
that was hypermethylated by d-flow in a 5Aza-dependent manner (Figure 5.4). Our 
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results also suggest that d-flow induces hypermethylation in these promoter CRE CG 
sites by a DNMT-dependent mechanism (Figure 5.4 and Figure 5.5), which in turn has a 
major impact on gene expression. 
We chose to study HoxA5 and Klf3 since they are transcriptional activators and 
repressors, respectively, potentially serving as a mechanosensitive master switch.201,207 
Our study implicates HoxA5 and Klf3 as novel mechanosensitive transcription factors 
regulated by DNA methylation that may serve as master regulators of global gene 
expression in response to flow. Interestingly, Klf3 is suppressed in acute myeloid 
leukemia (AML) and 5Aza is used to treat this disease, although it has not yet been 
shown whether 5Aza directly targets Klf3. AML is also treated with all-trans retinoic acid 
and, also interestingly, this drug was shown to rescue Klf3 expression by an unknown 
mechanism 99 Since all-trans retinoic acid is known to influence DNA methylation of a 
small number of specific genes 212, it would be interesting to test whether Klf3 is 
regulated by this mechanism in AML. Although our current study focused on examining 
the role of DNA methylation in vascular biology and disease, these results indicate that 
our work could have far-reaching implications across multiple diseases.  
Our in silico analysis suggests CREB as another key transcription factor whose 
DNA binding is known to be regulated by methylation of the CRE sites of its target 
genes, such as HoxA5 and Klf3149,154. It was shown previously that protein kinase A 
(PKA) downregulation in d-flow leads to decreased CREB phosphorylation and 
decreased CREB binding to CRE elements 160. Here, we identified a novel mechanism by 
which CREB binding to its gene targets may be decreased by d-flow via DNA 
methylation at their promoter CREs. We have been actively working to dissect the 
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detailed mechanism by which CREB may bind to the HoxA5 and Klf3 promoter CREs 
using chromatin immunoprecipitation assays combined with qPCR directed for the CRE. 
The results of this experiment combined with promoter CRE site-specific mutation or in 
vitro methylation of the CRE CG using luciferase assays with the Klf3 or HoxA5 
promoters will enable us to better understand the mechanism by which the expression of 
these master transcription factors is controlled. 
Functional studies of DNA methylation patterns are complicated by the various, 
and often conflicting, reports of the role of specific methylation changes in gene 
expression control. Here, we considered the functional consequences of specific 
methylation patterns by comparing the complementary transcriptome, and by performing 
single gene studies in vitro using qPCR, bisulfite sequencing, and EC inflammation 
assays. Follow-up studies initiated recently by new members in our lab will provide more 
in-depth analysis of a number of EC gene candidates that were illuminated by this study. 
This additional future work will help draw new definitive links between specific 
methylation patterns and the functional outcome of gene expression control and 
ultimately disease development or prevention. The results of this work compounded with 
future studies will continue to elucidate the epigenetic regulation of well known genes 
involved in atherogenesis and will also uncover novel shear sensitive genes and 
regulatory pathways that have yet to be discovered.  
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CHAPTER 6 DISCUSSION 
Here, we demonstrate for the first time, to our knowledge, that blood flow 
epigenetically controls endothelial gene expression by regulating genome-wide DNA 
methylation patterns in a DNMT-dependent manner. Our novel findings have broad 
implications for understanding the biochemical mechanisms of atherogenesis and provide 
a basis for identifying potential therapeutic targets for atherosclerosis.  
We found that d-flow induced expression of DNMT1 in mouse arterial 
endothelium in vivo and in cultured endothelial cells by oscillatory shear (OS) in vitro. 
The DNMT inhibitor 5-Aza-2’deoxycytidine (5Aza) or DNMT1 siRNA significantly 
reduced OS-induced endothelial inflammation. Moreover, 5Aza reduced lesion formation 
in two ApoE-/- mouse atherosclerosis models.  
We applied a dual “omics” approach by overlaying concomitant endothelial 
methylome and transcriptome datasets to determine the mechanism by which 5Aza 
inhibited atherosclerosis in our murine models. We performed reduced representation 
bisulfite sequencing (RRBS) and microarray using endothelial-enriched gDNA and RNA, 
respectively, from the partially-ligated left carotid artery (LCA exposed to d-flow) and 
the right contralateral control (RCA) of mice treated with 5Aza or vehicle. Systems 
biological analyses using RRBS and transcriptome data revealed 11 mechanosensitive 
genes whose promoters were hypermethylated by d-flow, but rescued by 5Aza treatment. 
Of those, the two transcription factors HoxA5 and Klf3 contain cAMP-response-elements, 
and their methylation status could serve as a mechanosensitive master switch in gene 
expression. The results of our combined genome-wide studies demonstrate that d-flow 
controls epigenomic DNA methylation patterns in a DNMT-dependent manner, which in 
turn alters endothelial gene expression and induces atherosclerosis.  
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These robust experimental strategies involved various models of shear stress 
using different endothelial cell types, both in vivo and in vitro. The recurrent findings by 
our group and also by others reveal that epigenetic mechanisms, and particularly DNA 
methylation, are key in regulating vascular biology, endothelial gene expression, and the 
pathophysiology associated with atherosclerosis.  
This project was the first of its kind to combine biomedical engineering 
approaches to understand the effect of mechanical forces on endothelial cell biology and 
cardiovascular disease development. We addressed the difficulty of tackling this widely 
unknown disease mechanism by limiting the scope of our project to a specific a priori 
hypothesis based on well-studied epigenetic mechanisms. However, our dual “omics” 
approach also allowed us to perform a posteriori analyses that enabled the discovery of 
previously unpredictable biological phenomena.  
The genome-wide approaches used here to resolve the endothelial DNA 
methylome and transcriptome were confined by the available and practical technologies 
existing at the time of this study. The transcriptome was determined using Illumina 
Mouse WG6 microarray chips, which limited the breadth of the gene expression study to 
the set of probes covered by the array. This precluded the ability to detect most 
alternative transcripts and noncoding RNAs, which recent evidence suggests may be 
important consequences of differential methylation at alternative intragenic promoters 
and in functional genomic regions that are as of yet undefined. Additionally, variability 
can exist due to differences in the arrays themselves, the dye labeling, efficiency in RNA 
amplification and reverse transcription, and hybridization 234. To address this to the best 
of our ability, we used biological replicates (n=3) consisting of pooled samples (3 carotid 
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arteries in each sample), and performed stringent quality control steps before and after the 
microarray process, including using the Bioanalyzer to analyze our purified RNA 
samples and qPCR validation of a subset of differentially expressed genes as determined 
by the microarray.  
Reduced representation bisulfite sequencing (RRBS) is widely accepted for 
genome-scale methylation studies at the nucleotide resolution, although incomplete CG 
coverage is an inherent limitation of RRBS due to the MspI restriction enzyme digest, 
PCR, and sequencing steps 235. These limitations produce partial genomic coverage, as 
evidenced by the 23% genomic and 53% promoter coverage of our RRBS assays. 
Additionally, we were only able to draw conclusions about differentially methylated 
regions with a functional effect on transcription by limiting our analysis to CG sites that 
were covered in all samples by both the microarray and RRBS. Therefore, genomic 
regions with partial coverage between samples or assays were not considered in this 
particular study, which could have resulted in overlooking potentially important 
methylation sites.  
We would also like to emphasize the importance of the user-defined threshold 
values in our method of gene discovery using both the methylome and transcriptome 
datasets. Using very strict criteria enabled us to filter out a manageable number of genes 
for further study in the scope of this project; however, releasing the threshold stringencies 
would result in more target genes for additional studies. 
Preexisting knowledge at the inception of this study surrounding DNA 
methylation, with a functional relevance to gene expression and disease, was mainly 
focused on CpG methylation in the promoter region of genes, especially in dense CpG-
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rich regions known as CpG islands. We used this knowledge base to guide our studies 
and increase the likelihood of rapid discovery. However, we are aware that DNA 
methylation in other locales, including coding or noncoding gene regulatory regions, and 
at other motifs such as CpH (where H is A/T/C), are known to be important for 
controlling gene expression, alternative transcripts, chromatin conformation and genome 
stabilization 125,126,129,236. While outside the scope of the current study, it would be quite 
interesting to examine whether there is d-flow-induced differential DNA methylation of 
non-CpG cytosines in endothelial cells, and whether any changes are localized to 
potentially functional genomic regions such as enhancers, promoters, intron/exon 
boundaries, transposable elements, 3’UTRs, transcription factor binding sites, and across 
the genome either sporadically or in the context of specific sequence motifs. 
While DNA methylation at the 5’ carbon of a cytosine base pair is the most well 
studied epigenetic covalent DNA modification, several others are known to exist and 
were recently implicated to be important in gene expression regulation, although their 
mechanisms are very unclear. These modifications include 5-hydroxymethylcytosine 
(5hC), 5-formylcytosine (5fC) and 5-carboxycytosine (5cC). Emerging methods of 
detection open up the possibility for future study of these cytosine modifications in 
endothelial biology and pathogenesis 237.  
5-Aza-2’-deoxycytidine (5Aza, also known as Decitabine) is a nucleoside analog 
that traps DNMT1 in a covalent complex with DNA, and also preferentially targets 
DNMT1 via ubiquitin-dependent proteasomal degradation, resulting in DNMT1 
inhibition 57. 5Aza is an FDA approved drug and is currently used to treat 
myelodysplastic syndromes including leukemia 57-62, but its specific mechanism of action 
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and gene targets need to be further determined 58. It should be noted that the dosing 
schedule for 5Aza affects treatment results depending on the dose, method of 
administration, and target tissue, especially due to its short half-life 62. In this study, a 
high frequency, low-dosing strategy was applied to target the endothelium, maintain 
efficacy over time, and reduce toxicity. To address the potential off-target effects of 
5Aza, we also used DNMT1 siRNA in our in vitro studies. However, the practical 
challenges associated with in vivo treatments using siRNAs precluded us from 
performing a DNMT1-specific inhibition study in vivo. During this project we began the 
development of endothelial-targeted DNMT1 knockout mice and in vitro characterization 
of novel DNMT1 chemical inhibitors described in Chapter 3. Both strategies can be 
exploited in future, more targeted in vivo studies of DNMT1. 
We also recognize the potentially important effect of 5Aza treatment in cell types 
other than endothelial cells that are involved in atherogenesis, including smooth muscle 
cells and immune cells. While the aim of our study was to determine whether there is a 
novel epigenetic mechanism of flow-regulated endothelial gene expression and whether it 
plays a vital role in atherosclerosis development, it was recently shown by Cao et al. that 
the anti-atherosclerotic effect of 5Aza also has a mechanistic basis in the immune milieu 
238. Because atherosclerosis is a systemic disease caused by multi-cell type dysfunctions, 
a systems wide approach will be necessary to understand the role of global methylation 
changes and crosstalk between cell types in order to fully realize the therapeutic potential 
of epigenetic interventions. 
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Conclusions  
The study presented here is the first to demonstrate that d-flow-induced global 
gene expression changes in endothelial cells are regulated at the genome level in a 
DNMT-and DNA methylation-dependent manner. We propose that d-flow induces 
DNMT1 expression in endothelial cells, which in turn stimulates DNA methylation in 
specific promoter CRE sites of mechanosensitive, master transcription factors including 
HoxA5 and Klf3. These master genes may then regulate expression of the majority of 
other mechanosensitive genes, resulting in endothelial dysfunction and atherosclerosis. 
We further propose that the DNMT inhibitor 5Aza targets these mechanosensitive master 
regulators to restore anti-atherogenic gene expression profiles. In conclusion, our study 
provides a novel insight into the mechanism by which flow regulates gene expression in a 
DNMT-dependent manner and uncovers novel genes involved in the endothelial cell flow 
response. 
Future Directions  
The goal of this project was to determine how the endothelial DNA methylome 
changes in response to flow, and how this in turn alters gene expression and regulates 
atherosclerosis development. We show that blood flow epigenetically controls endothelial 
gene expression by regulating genome-wide DNA methylation in CRE sequence motifs 
and at specific gene promoters in a DNMT-dependent manner. Several genes were 
identified that merit further study as potential therapeutic and diagnostic candidates, and 
lab members who recently joined our team are actively initiating these detailed studies.  
In Chapter 3 we establish that DNMT1 is upregulated in d-flow and that it plays a 
key role in atherosclerosis development. However, the upstream mechanism controlling 
 130 
DNMT1 overexpression in this system is largely unknown. To address this, we 
performed preliminary studies on the mir29 family and we also developed a 
computational model of known mechanosensors that may control DNMT1 through 
biochemical signaling pathways. These preliminary studies will aid in future 
experimental design and validation of upstream regulators of DNMT1. Future studies 
involving pharmacological inhibitors and anti-miRs can be tested in vitro and in vivo to 
uncover the role of Mir29 in the flow regulation of DNMT1. In addition to the Mir29 
family, we may explore additional d-flow-suppressed miRs that are validated to target 
DNMT1, including the Let-7 family, as well as the other miRs listed in Chapter 3 Table 
2. PECAM1, CAV1, and VEGFR are three of the most important mechanosensors 
involved in atherosclerosis development, but conflicting findings on their expression and 
activity in disturbed flow and atherosclerosis have been reported.239,240 Our model 
predicts that a loss of PECAM1 and CAV1 leads to increased DNMT1 expression and 
future experiments using knockdown or overexpression of each of these 
mechanoreceptors individually will enable elucidation of the mechanism of the regulation 
of the DNMT1 shear response.  
While DNMT1 is the most dramatically altered DNMT at both the mRNA and 
protein level by d-flow in vitro, given our findings that DNMT3b is slightly upregulated 
by d-flow at the protein level (Chapter 3 Figure 11) and that DNMT3a has been found to 
be shear-responsive in ECs in other model systems 57,65, we believe that the DNMT 
family as a whole warrants further investigation. We foresee the benefit of future studies 
to analyze the role of the other catalytically active DNMTs (DNMT3a and DNMT3b) in 
EC functions. Additionally, these studies leave room for further analysis of the role of 
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DNMT1 in other EC biological functions in addition to inflammation. In Chapter 3 we 
show that DNMT1 inhibition reduces inflammation in ECs in vitro and plaque 
development in vivo. In order to determine whether there is a further functional role for 
DNMT1 in atherosclerosis development, additional markers of EC dysfunction that 
increase in d-flow (including inflammation, apoptosis, proliferation, thrombosis and cell 
migration) could be examined using either knockdown or overexpression of DNMT1 in 
future studies. We expect that certain specific markers will be more strongly affected by 
DNMT1 knockdown, which will implicate key gene regulatory pathways that can be 
examined further by systems biology and gene ontology studies. 
Drawing upon epigenetics-based cancer diagnostics currently in use, it is 
foreseeable that epigenetic targets such as DNMTs, specific gene promoter DNA 
methylation, histone modifications, and miRNAs could serve as biomarkers for 
cardiovascular disease diagnosis as well as targets for therapeutic intervention. In Chapter 
3 we show that DNMT1 inhibition by 5Aza blocks d-flow-induced atherosclerosis 
development in vivo in ApoE-/- mice. To address potential off-target effects and non-
tissue-specific effects of 5Aza, we began developing endothelial-targeted DNMT1 
knockout mice to test EC-specific DNMT1 knockdown on plaque development in vivo 
using the acute and chronic mouse atherosclerosis models. Full-body DNMT1 knockout 
is embryonic lethal90. Fortunately, floxed DNMT1 mice are commercially available (UC 
Davis- DNMT1tm2Jae fl/fl mice) and we have begun cross breeding these mice with 
endothelial-targeted Cre mice on an ApoE-/- background (VE-Cadherin-Cre+/-/ApoE-/- 
mice) that we already have in our lab. This will likely enable us to generate endothelial-
 132 
specific DNMT1 knockout mice (DNMT1tm2Jae fl/fl/VE-Cadherin-Cre+/-/ApoE-/-) for 
subsequent chronic and acute atherosclerosis studies. 
We also began in vitro characterization of novel DNMT1 chemical inhibitors such 
as SGI-1027. SGI-1027 is a novel DNMT inhibitor that may become used routinely in 
place of 5Aza due to the cytotoxic effects of 5Aza treatment (both Decitabine and 
Vidaza) caused by their incorporation into DNA. SGI-1027 is a cell-permeable quinoline-
based non-nucleoside compound that inhibits DNMT1, DNMT3a, and DNMT3b and 
results in selective degradation of DNMT1. The mode of action of DNMT inhibition is 
thought to be by competing with AdoMet (S-adenosyl-L-methionine, SAM) for the 
enzyme's cofactor binding site. SGI-1027 has been shown to be more effective than 
Decitabine in reactivating methylation-silenced tumor suppressor genes without inducing 
genome-wide hypomethylation or caspase-3 activation. We performed dose optimization 
studies for novel DNMT1 chemical inhibitors that may be useful in future studies to 




Figure 6.1: Novel chemical inhibitors specific to DNMT1. Dose curve for SGI-1027 
(top) and single dose at 5uM of inhibitors MC2839 and MC2840 (bottom). 
Inhibitors were generously provided by Dr. Xiaodong Cheng. 
The fact that ten-eleven-translocation (TET) enzymes convert 5mC into 5hmC, 
which acts as an intermediate step to demethylated cytosine, introduces the important 
concept of site-specific DNA demethylation, which could play an important role in both 
regulating DNA methylation patterns as well as in establishing aberrant demethylation in 
disease242. Directing DNMT or TET to specific DNA sequences could one day be used as 
epigenetic editing techniques243,244. 
Our computational analyses in Chapter 4 overlaying the concomitant endothelial 
methylome and transcriptome datasets that we collected were designed to ask very 
specific questions regarding the importance of DNA methylation in atherosclerosis 
development. We addressed the difficulty of tackling the widely unknown disease 
mechanism of atherosclerosis by limiting the scope of our project to a specific a priori 
hypothesis based on well-studied epigenetic mechanisms, and we recognize the 
limitations of such directed studies. The huge benefit of the data collected with our dual 
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“omics” approach is the abundant potential for future analyses. For example, these RRBS 
datasets could be the subject of computational analyses to examine changes in non-CpG 
cytosine methylation, as well as CpG methylation changes in other functional regions 
such as introns, exons, intron/exon boundaries, transposable elements, and additional 
transcription factor binding sites or sequence motifs, among others. As a specific 
example, it would be interesting to examine whether other known transcription factor 
binding sites that have binding motifs very similar to the CRE sequence also have 
differential methylation for particular genes or on the genome scale. For example, JunD, 
CST6, and TGA1 all have similar sequence motifs to the CREB binding motif (Figure 
6.2).  
 
Figure 6.2: JASPAR TFBS search shows other transcription factors that bind to a 
similar sequence to CRE.The size of the nucleotide corresponds to its importance in 
the binding interaction, and stacked nucleotides at a single position have potential 
substitutions that affect the TF binding by different levels (corresponding to the 
height of the letter). 
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Very recent major technological developments in next generation sequencing now 
make it possible to repeat our transcriptome study using RNA sequencing to avoid 
sources of error due to microarray experimental setups. This would enable the discovery 
of flow-regulated differential expression of alternative transcripts and noncoding RNAs, 
as well as novel transcribed regions of the genome. 
Functional studies of DNA methylation patterns are complicated by the various, 
and often conflicting, reports of the role of specific methylation changes in gene 
expression control. In Chapter 5, we considered the functional consequences of specific 
promoter CpG methylation patterns by comparing the complementary methylome and 
transcriptome, and by performing single gene studies in vitro using qPCR, bisulfite 
sequencing, and EC inflammation assays. Follow-up studies initiated recently by new 
members in our lab will provide more in-depth analysis of a number of EC gene 
candidates that were illuminated by this study, including Tmem184b, Adamtsl5, Cmkrl1, 
Pkp4, Acvrl1, Dok4, Spry2, Zfp46, and F2rl1, as well as additional functional studies on 
HoxA5 and Klf3. This future work will help draw more definitive links between specific 
methylation patterns and the functional outcome of gene expression control and 
ultimately disease development or prevention.  
Although our current study focused on examining the role of DNA methylation in 
vascular biology and disease, the results in Chapter 5 indicate that our work could have 
far-reaching implications across multiple diseases. While 5Aza is currently used in the 
clinic to treat acute myeloid leukemia (AML), this drug has many potential side effects, 
limiting its therapeutic utility not only for atherosclerosis, but also for AML. Therefore, it 
is crucial to develop more targeted, clinically relevant therapeutic approaches for 
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cardiovascular disease by understanding the mechanism of key epigenetically-controlled 
genes. Defining the mechanisms by which HoxA5 and Klf3 are regulated and control cell 
function in endothelial cells may also help shed light on other disease mechanisms such 
as AML.  
With the understanding that global inhibition of the DNA methylation machinery 
would be an unwise therapeutic strategy given the key role that DNA methylation plays 
in both the global gene expression program as well as in genome stability, we foresee the 
major impact of this study as the identification of specific target genes that directly play a 
role in EC biological functions that regulate atherosclerosis. The results of this body of 
work compounded with future findings will continue to elucidate the epigenetic 
regulation of well known genes involved in atherogenesis and will also uncover novel 









In order to create a manageable model with the most relevant and accurate datasets available, a 
literature search was done to include the most prominent and well-studied mechanoreceptors that 
play a role in endothelial cell mechanotransduction (Table A1).  
 
Table A1: Mechanoreceptors Involved in Endothelial Cell Mechanotransduction of Flow 
Environment1 
Ion Channels Cell- Cell and Cell-Matrix Junctions 
• TRP (transient Receptor Potential) Channels 





• P2RX4 purinoreceptors 
• Inward Rectifying K+ Channels 




• Adherens Junctions 
a. VE Cadherin 






This list was reduced using the Ingenuity Pathways Analysis (IPA) toolkit, a proprietary 
algorithm that performs a systematic literature search on molecules of interest. IPA outputs the 
molecules’ connectivity based on publications detailing the mode of interaction of two or more 
species. This toolkit can also perform predictive analyses based on gene or protein sequence 
similarity; however, this function was not applied for the prescribed project. Only published data 
describing molecular interactions was used to create the model in order to maintain the highest 
level of accuracy possible. 
To produce the initial model, mechanoreceptors in Table A1 were used alongside 
DNMT1 as inputs into IPA and the ‘build-connect’ function was used to uncover true 
connections reported in the literature. No interactions existed directly between DNMT1 and a 
mechanoreceptor. This falls in line with literature reports that DNMT1 in general terminates 
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signaling cascades to directly transduce the biochemical signal into transcriptional changes. Due 
to lack of primary connectivity between species in the model, the ‘build-grow’ function was used 
to expand the network to putative secondary and tertiary interactions and the ‘build-connect’ 
function was iterated, restricting the resulting map to 100 molecules.   
This map was overly expansive given the desired scope of this particular model and thus 
the map was trimmed. We isolated only secondary and tertiary interactions in which intermediate 
signaling molecules had either a direct connection to a mechanoreceptor and also to DNMT1, or 
had just one intermediate signaling molecule. A highly interconnected map emerged from this 
analysis involving three mechanoreceptors, Platelet/Endothelial Cell Adhesion Molecule 1 
(PECAM1), caveolin 1 (CAV1), and Vascular Endothelial Growth Factor Receptor (VEGFR), 
and four intermediate signaling molecules, cyclin D1 (CCND1), Protein Kinase B (PKB, or 
AKT), annexin A5 (ANXA5), and embryonic ectoderm development (EED) (Figure A1). 
The nature and directionality of each connection in this conceptual model was expanded 
upon using literature reports. The findings could be summarized into a basic description of how 
the upstream molecule regulated either the expression or activity of the downstream molecule in 















Figure A1: A Schematic Representation of the Endothelial Cell Mechanoreceptors and the 






























Table A2: Interactions between molecules. P- signifies that a molecule is phosphorylated. 
 
 
In order to convert this information into a computational model, it was necessary to first 
define two crucial states for each molecule, expression (E), and activity (A). When E=0, the 
molecule is not expressed (this ignores the basal expression level, which is very low and 
negligible, and is assumed to be present even when E=0), and when E=1, the molecule is 
maximally expressed. When A=0, the molecule is inactive, and when A=1, the molecule is 
maximally active. A third state called (S) takes both the expression and activity into 
consideration, and three new states can be defined: S=0: not expressed, inactive; S=1: expressed, 
inactive; S=2: expressed, active. Assumptions were justified by literature evidence as detailed 
below: 
 
Assumptions and Logic Rules 
1. Activity and expression of the upstream “regulator” molecule are the two dominant factors 




2. The effect of the upstream regulator on the expression or activity of the regulated molecule 
can be estimated by “Tri Boolean” logic†: 
a. If the regulator (r) decreases expression of the downstream molecule (d)† 
 Ed(t+1) Ad(t+1) 
Sr(t)=0 or 1 No change No change 
Sr(t)=2 0 No change 
b. If the regulator (r) increases expression of the downstream molecule (d) 
 Ed(t+1) Ad(t+1) 
Sr(t)=0 or 1 No change No change 
Sr(t)=2 1 No change 












†Assumes that the regulator must be both expressed and active (S=2) to alter the activity or 
expression of the downstream molecule, except in the case of a binding interaction, in which the 
regulator only needs to be expressed, but not necessarily active, to cause its downstream effect.  
 
3. If both binding partners are expressed (Er=1 and Ed=1) then they will bind and perform their 
function. Binding is dominated by chemical interactions and isn’t a function that requires 
activity, so only presence of the molecule is necessary.  
4. Homodimerization and heterodimerization interactions increase the activity of the proteins 
involved, and binding of two proteins does not affect the expression of either constituent. 
 Ed(t+1) Ad(t+1) 
Sr(t)=0 or 1 (non binding) No change No change 
Sr(t)=1 (binding) No change 1 
Sr(t)=2 (binding or non) No change 1 
 Ed(t+1) Ad(t+1) 
Sr(t)=0 or 1 (non binding) No change No change 
Sr(t)=1 (binding) No change 0 
Sr(t)=2 (binding or non) No change 0 
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This assumption is justified for this model in particular because as activation by complexing 
is a hallmark of the constituents in this system. This would not necessarily hold true in other 
molecular networks. 
5. If two interactions of equal an opposite affect are combined, then there is no resulting 
change. Thus, molecules are not weighted based on their ability to affect a downstream 
molecule (all affects are assumed to be equal). 
 
To test the model’s ability to recapitulate experimental findings, we perturbed system 
with the inclusion of 5’ Azacytidine, a DNMT1 inhibitor that has been used to treat various 
cancers because it blocks the methylation of anti-tumorigenic genes. Preliminary data from our 
lab shows that 5’ Azacytidine also inhibits the formation of atherogenic plaques, however, the 
mechanism behind this remains unclear. 5’ Azacytidine was shown to have an effect on both 
DNMT1 and the mechanoreceptor CAV1.  
A sensitivity analysis was done to discover whether there is correlation between the 
initial conditions of the mechanoreceptors and the time for the system to reach steady state. For 
this model, steady state was defined by the time (t) when the state S of each molecule in the 
system was equivalent to the state S at the next time step (t+1). In this event, the system cannot 
be perturbed out of steady state because no conditions in the current state may change (this 
model excludes noise and random perturbations that would truly exist in a stochastic system).  
  
Results 
In the first trial run, all possible initial states of the mechanoreceptors were used to find 
trends in the system. For all trials, the intermediate molecules (IM) were assumed to be 
expressed, because when IM are not expressed, DNMT1 will never become activated (Figure 













Figure A2: The case where S=0 for all IM. DNMT1 never becomes active. This state is 
ignored for trials varying mechanoreceptor states. 
 
Case 1. All 3 mechanoreceptors are expressed +/- active, or both M1 and M2 are expressed +/- 
active (but not necessarily M3) 







   
 
 
Figure A3: The Dynamics of DNMT1 activity given different initial conditions. The 
numbers underneath the plots represent the state S of each molecule in the system for the 
above plot (the first 3 values are for M1, M2, and M3, the next four values are the 
intermediate molecules of the signaling pathway, and the last value is DNMT1). In the 
third graph, activity precedes expression due to the initial state setup, as described in the 
discussion section. 
 
The conclusion based on the above results is that negative feedback turns off DNMT1 





M1 M2 M3 




Case 2. M1 or M2 or M3; M1&M3; M2&M3; No receptors expressed/active 
 
Table A4: Initial Conditions for Case 2 
 
     


















Figure A4: The Dynamics of DNMT1 activity given the different initial conditions in Table 
A4. 
The conclusion based on the above results is that when M1 and M2 are not both 
expressed together, DNMT1 stays expressed and active indefinitely 
 
Case 3. The addition of the DNMT1 inhibitor 5’ Azacytidine under the previous initial 
conditions 
 
        Case 1 Initial Conditions       Case 2 Initial Conditions 
   
M1 M2 M3 
1 or 2 0 0 
1 or 2 0 1 or 2 
0 1 or 2 1 or 2 
0 1 or 2 0 
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Figure A4: The Dynamics of DNMT1 expression and activity under administration of 5’ 
Azacytidine (a DNMT1 inhibitor). (Right) M1 & M2, M1 & M3, M1 only  (Left) None, M2 
& M3, M2 only, M3 only 
 
The addition of 5’ Azacytidine causes the joint dependence of negative autoregulation on 
both M1 and M2 to be lost. Here, only M1 needs to be expressed to achieve negative 
autoregulation. The effects of expressed, or both expressed and active (denoted expressed +/- 


















Figure A5: The effects of varying the initial states of IM from S=1 to S=2 for Case 3 
(DNMT1 inhibitor) so the effects on expression can be viewed in solation. (A) Delay in 
expression of DNMT1when IM are expressed but not active. (B) Delay, so shorter length of 
time of expression of DNMT1 when IM are expressed but not active. When M are 




The sensitivity analysis was done to test how the various initial conditions affect the time 
for the system to reach steady state. In this case, all possible initial states were tested 
(combinations of each molecule, where S=0, 1, or 2). Steady state is defined as the time when the 
state of each molecule does not deviate at the next timepoint.  It was found that under certain 
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conditions, shown below in Tables A5 and A6, the system reached steady state, however under 
the conditions in Table A7, the system never reached steady state. 
 
Table A5: Initial Conditions where  Table A6: Initial Conditions where  
steady state is reached at timestep   steady state is never reached. 
3 (top) or timestep 4 (bottom).  












It was found that under the conditions where steady state is not reached, one or more of 
the following 3 conditions are found to oscillate: M1 and/or M2 oscillate between active and 
inactive (S=1 or S=2) and IM4 between expressed and not expressed (S=0 or S-1). 
 
Discussion           Table A7: S Matrix 
 It would have been possible to set the initial conditions with an S matrix 
for all possible initial states of each molecule (Tab. 8). The current model, 
however, initiates separate E and A matrices to allow a state where E=0 and A=1 
that accounts for basal expression at E=0. The S matrix would equate the state 
where E, A=0 to E=0, A=1, but this neglects the activation of the basally expressed molecules. 
The current model maintained this state because it wasn’t clear if this detail would be important. 
However, this complicated matters because the initial states expanded from 6,561 possibilities 
(38) to 65,536 (28*28) possibilities. The method of programming also had redundancy in 
combining the E and A matrices. In the future expanded model this redundancy must be 
corrected or the method stated above for the S matrix will be implemented (and the basally 
expressed molecules will not be able to be activated in the model). 
In the first trial, to make the number of plots manageable, the initial conditions were only 
changed for the mechanoreceptor molecules since these molecules are a major control element of 
M1 M2 M3 IM 
1  1 1  1 or 2 
1 0 0 or 1 1 or 2 
0 1 0 or 1 1 or 2 
1 1 0 1 or 2 
M1 M2 M3 IM 
0 0 1 or 2 2 
M1 M2 M3 IM 
0 0 1  1 
0  0 0 0 
E A S 
0 0 0 
0 1 0 
1 0 1 
1 1 2 
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the system. Then, the values of the intermediate molecules were varied synchronously. Graphs 
for each set of initial conditions were only plotted in the case where the dynamics of DNMT1 
changed from the previous initial conditions. In the future model, a more systematic approach to 
plotting only the relevant graphs with important dynamical changes will be necessary to avoid a 
large number of redundant plots. 
The model proved useful for depicting the overall dynamics of DNMT1 expression and 
activity for different initial conditions. It was found that this model predicts a negative feedback 
mechanism for DNMT1 expression under certain initial conditions. Two mechanoreceptors  
(M1/PECAM1 and M2/ CAV1) are implicated to be vital to the negative feedback system, while 
the third mechanoreceptor (M3, or VEGFR) is not found to be involved in this negative 
feedback. When VEGFR is expressed +/- active in the absence of PECAM1 and CAV1 
expression, DNMT1 remains expressed indefinitely. 
 In disturbed flow conditions, three major mechanoreceptors, PECAM1, CAV1, and 
VEGFR, are involved in the development of atherosclerotic lesions, and DNMT1 expression is 
upregulated by an unknown mechanism. It has been shown that PECAM1-/- mice have reduced 
atherosclerotic lesions size,15 and that CAV1 expression is upregulated in atherosclerosis (but 
CAV1 is deactivated under disturbed flow)16. This model predicts that a loss of PECAM1 and 
CAV1 leads to increased DNMT1 expression, but the literature supports the idea that decreased 
expression of these mechanoreceptors leads to slowed atherosclerosis progression (which would 
imply lower DNMT1 levels). These conflicting results are not clear because there remain gaps in 
the literature, and also several assumptions were made for this working model, so the results may 
not be predictive of actual system. A brief discussion of the validity of important model 
assumptions follows.  
 
1. The assumption that the effect of the upstream regulator on the expression or activity of 
the regulated  molecule can be estimated by “Tri Boolean” logic leads to inaccuracy in 
the model and should be modified with data that quantitatively describes the extent to 
which the upstream regulator affects the expression or activity of the regulated molecule 
(e.g. downstream protein expression for regulator knockdown or overexpression by 




2. The assumption that the effects of a molecule are not weighted by the specific molecule 
in question adds some uncertainty to the model, and the combinatorial effects of 
molecules will have to be determined by further mining of the literature to find available 
data.   
 
3. The assumption that if both binding partners are expressed then they will bind and 
perform their function should be modified in future studies. The rate of binding isn’t “all 
or nothing,” but rather depends on the relative amount of each molecule as well as their 
affinity to bind. The goal of this model was to support the educated design process of 
future experiments to study the  role of mechanoreceptors in the expression of DNMT1 
during the progression of atherosclerosis. It is likely that future experiments will involve 
knocking down or upregulating expression or activity of each of these mechanoreceptors 
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Quantification of Endothelial Purity in genomic DNA and RNA preparations 
from mouse carotid arteries 
 
Our lab recently showed that partial ligation of the mouse carotid artery induces disturbed 
flow with characteristic low and oscillatory wall shear stress, which in turn rapidly induces 
atherosclerosis, directly demonstrating the causal relationship between disturbed flow and 
atherosclerosis.1 The goal of the studies detailed in Appendix B were to non-EC infiltration in 
our mouse partial carotid ligation model of atherosclerosis, which we have used to capture gene 
expression and epigenetic changes in endothelial cells caused by disturbed blood flow (d-flow).  
One major complication of DNA methylation studies on samples taken directly from in 
vivo is the possibility for the inclusion of multiple cell types. To ensure that changes seen in our 
DNA methylation and gene expression data could be attributed to the endothelial response to 
experimental conditions rather than differential DNA methylation or gene expression occurring 
across different cell types, we performed a brief study to measure the number of contaminating 
cell types we could expect in our endothelial cell genomic DNA and RNA preparations.  
Given our methods involving flushing of the complete vasculature, including the carotids, 
with saline prior to flushing with cell lysis buffer, we do not expect to see contamination of 
blood or other circulating cells. However, it is well established that immune cells invade the 
vessel wall to sites of injury. Because our disturbed flow conditions increase inflammatory 
signaling in the surrounding region, we expect that there should be some level of immune cell 
infiltration into the vessel wall, however, whether these cells would lie directly on the endothelial 
surface, causing them to be lysed along with our endothelial cells, was unknown.  
It is well established that ligation increases the number of monocytes in the media and 
developing intima in mouse partial-ligation models.2 Previously, our lab determined there are 
almost no monocyte, macrophage, or NK cell infiltrates (CD11B+ cells) in the intima.1 However, 
we did not characterize the total number of white blood cells present on the intima of the LCA or 
RCA. Here, we performed CD45+ cell staining and FACs to examine all leukocyte cell 
infiltrates, including T-cells and B-cells.  
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I.  Methods 
 
1) qPCR 
To assess EC purity for our mRNA preparations, we examined gene expression for the 
EC-specific platelet endothelial cell adhesion molecule 1 (PECAM1), smooth muscle cell-
specific alpha smooth muscle actin (αSMA), and immune-specific cluster of differentiation 
molecule 11B (CD11B) markers. C57Bl6 mice were partially ligated and carotid arteries were 
flushed with Qiazol lysis buffer at 7 days post-ligation. RNA was collected and purified as 
described in the methods section of Chapter 4.  
 
2) eNOS Bisulfite Sequencing 
Endothelial Nitric Oxide Synthase (eNOS) is a well-known EC-specific gene that is 
demethylated only in ECs, enabling its cell-specific expression3. We performed bisulfite 
sequencing on eNOS in our LCA/RCA model because others have shown that eNOS DNA 
methylation increases in endothelial cells exposed to d-flow. gDNA was collected from the 
carotid arteries using the same scheme as for qPCR, but flushing with Buffer and gDNA 
isolation as described in the Chapter 4 methods. Additionally, the leftover carotid tissue after 
flushing was saved and digested with Buffer AL, and genomic DNA was extracted by the same 
method. Bisulfite sequencing was done according to the protocol by Chan et al., using their 
primers listed in Table B1 and qPCR cycling methods detailed in their publication3. 







3) Immunohistochemistry and cell counting algorithm 
C57Bl6 mice were partially ligated and en face staining was done on the carotids either 
before or after flushing with Buffer AL at 7 days post-ligation. Frozen blocks containing the 
heart, aortic arch, and carotid arteries were prepared in TissueTek and stored at –80°C. 
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Immunohistochemistry was performed on sections from the frozen blocks using the following 
antibodies at a 1:50 dilution: VE-Cadherin (sc-6458; Santa Cruz Biotechnology), CD45 (13-
0454; eBioscience), and DAPI (1:10,000).  
The stained carotids were imaged using confocal microscopy. The field of view of each 
image was 0.25 mm2. The total number of cells present in the region was quantified using DAPI 
nuclear stain, the number of endothelial cells was quantified by the number of cells staining 
positive for VE-Cadherin, and the number of immune Cells was quantified by the number of 
cells staining positive for CD45. The CD45+ stain includes all leukocyte groups: Granulocytes, 
Monocytes, T lymphocytes, T helper cells, Cytotoxic T cells, B lymphocytes, Thrombocytes, 
Dendritic cells. 
To determine the ratio of endothelial and immune cells in the carotid intima, we 
developed and validated an automated method to count total cells, endothelial cells only, and 
CD45+ cells only using CellProfiler. The steps in our CellProfiler macro included first 
separating the confocal image by color filters into an RGB image.  
We then used the Blue image (DAPI-only) to define and remove SMCs from the total cell 
count. SMCs are easily identified according to their nuclear shape (Figure B1). We used 
eccentricity of the nucleus (blue stained area) as a measure of elongation to separate between 
ECs and non-ECs because EC’s are known to align with flow. We used published images by 
Ferrara et al. to define the nuclear eccentricity for a non-SMC as < 0.88, and for a SMC as > 
0.88.4 For reference, the eccentricity of a perfectly straight line is 1, and the eccentricity of a 
perfect circle is 0. We next counted the number of non-SMC nuclei (nucleus eccentricity < 0.88) 
and used this as the total cell count (ECs + intimal cell infiltrates). Automated cell counts for 
ECs, SMCs, and immune cells using Cell Profiler were validated by undergraduate researcher 




Figure B1: Differences in nuclear morphology found by Ferrara et al. are evident by 
nuclear staining of ECs and SMCs.4 
 
Figure B2: Cell Profiler macro was developed to count the number of endothelial cells 
based on their nuclear morphology. The ellipticity of objects identified by DAPI stain 
(nuceli; Blue channel image to left) was used as a threshold to distinguish between ECs and 
SMCs  
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To further determine the breakdown of ECs vs immune cells, we used the red image to 
count the number of CD45+ stained cells. We then determined the number of ECs by subtracting 
the number of CD45+ cells from the number of non-SMC cells. We validated this approach for 
determining the number of ECs using VE-Cadherin staining for ECs on separate samples.  
 
A workflow for the Cell Profiler macro is as follows: 
1. Separate the image into the Red, Green, and Blue (RGB) components  
2. Using the blue image (the DAPI stain), separate by eccentricity 
– Define non-EC cell nucleus eccentricity <0.88 
– Count # EC nuclei 
3. Using the CD45+ red image: 
– Count the number positive stained cells 
– Calculate the total # ECs = [nonSMC cells - CD45+ cells] 
4. Validate the EC count using the VECadherin+ green image: 
– # ECs ≈ # VECadherin-positive cells 
 
4) Fluorescence Activated Cell Sorting (FACs)  
FACs studies were performed with the help of Noah Alberts-Grill and Amir Rezvan. 
Secondary staining of CD45-biotin was performed using streptavidin-conjugated Qdot 655. 
Immunofluorescence was detected using a LSR II flow cytometer, using AccuCount Ultra 
Rainbow Fluorescent Particles to determine absolute cell numbers. All flow analyses were 














As expected, we found that a low level of smooth muscle cell (SMC) and immune cell marker 
gene expression in our preparations. The levels of aSMA were consistent among all preps and 
CD11B was increased only in the LCA, with a reduction in its expression upon 5Aza treatment. 
This indicated that gene expression changes we observe could potentially be due to 




Figure B3: Endothelial, Smooth Muscle, and Immune cell marker expression in 
endothelial-enriched carotid artery RNA preparations 
 
2) eNOS Bisulfite Sequencing 
Bisulfite sequencing of the eNOS promoter of gDNA from both endothelial-enriched and 
leftover tissue samples demonstrate that in the RCA endothelial-enriched gDNA, eNOS is 
demethylated at the promoter. In the LCA, eNOS is hypermethylated (~50% of clones are fully 
methylated), but upon treatment with 5Aza this hypermethylation is diminished. In the leftover 
samples consisting mainly of smooth muscle cells and fibroblasts, the eNOS promoter is heavily 























































from the carotid arteries, and that the ratio of infiltrating cells to ECs is not sufficient to 
contribute to BS-Seq results significantly.  
 
Figure B4: DNA methylation of EC and non-EC cells in the carotid arteries. 
As a specific example of this analysis, CG site #4 in Figure B4 has a methylation ratio of 8/11 
methylated CG sites, and so the eNOS promoter at site #4 in the LCA is ~73% methylated. If this 
result were due solely to infiltration of non-EC populations into our gDNA preparation, 
infiltrating cells would have to make up > 73% of the total cell population (8/11) in the LCA. 
This is because under normal circumstances endothelial cells are never methylated at this site 
(see site #4 of the RCA (Figure B4), and refer to Chan et al)3, and thus any methylation present 
would either have to come from infiltrating cells or increased methylation in ECs. Further results 
from cell counting below indicate that infiltrating cell types comprise a minimal subset of the the 
gDNA preparation, and thus we can attribute these methylation changes to endothelial cell DNA 
methylation changes rather than an increase in the number of non-ECs in the gDNA preparation.  
 
3) Immunohistochemistry and cell counting 
The cell profiler algorithms were able to distinguish well between ECs, SMCs, and immune 
cells. As can be seen in Figure B5 (lower panel), the EC nuclei line up with VECad+ cells, 
whereas the SMC nuclei do not. As a validation of our methods, we found that the number of 
EC’s we observed in the carotids and aortic arch were consistent with literature reports of EC 
densities in the LC, GC, and descending thoracic aorta (DT), where an EC density of ≈2500 ECs 
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per millimeter squared was reported in the murine aorta (Table B2).5 Final calculations of EC 
numbers is listed in Table B3.  
 
 
Figure B5: Representative images output from the Cell Profiler cell counting algorithm, 
showing processing steps from original RGB image (left) to capture of all non-SMC nuclei 
(center) to capture of CD45+ cells only (right). (upper) and VE-Cadherin/DAPI co-stain 
(lower) (20X magnification, 0.25 mm2 field of view) 
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Figure B6: Number of EC’s and Immune cells in either the vessel wall or the GC and LC 
per field view (n=3; each carotid imaged twice) 
 
Table B2: Number of EC’s observed in the carotids and aortic arch (left) are consistent 






Although we have EC-enriched gDNA, there may be some heterogeneity due to 
contaminating cell types that have contributed their methylation signatures. We found our 
preparations to be at least 80% endothelial cells (Table B3). 
 
Table B3: The percent of EC vs. Immune cell populations existing on the inner surface of 
the vessel wall as determined by IHC staining and cell counting using Cell Profiler. 
 
% ECs % CD45+ cells 
LCA 80.2 19.8 
RCA 94.4 5.6 
GC 98.7 1.3 
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LC 90.7 9.3 
 
 
4) FACs validation of cell counts  
Our FACs analysis demonstrated a higher immune cell infiltration into the vascular wall than 
shown by the previous studies. However, these experiments were done on the whole vessel wall 
rather than just the intima, and thus we expect that a major portion of these infiltrating 
leukocytes are coming from regions of the blood vessel wall other than the intimal layer. This is 
supported by our previous experiments examining just the intimal layer. Additionally, we only 
performed two replicates (n=2, each contains 5 mouse carotids pooled), and although each 
replicate shows significant immune cell infiltration into the LCA of C57Bl6 mice 7 days post-
ligation, we cannot conclude whether these results are statistically significant from this data 
alone. 
 








Figure B8: Number of CD45+ cells per artery. Each sample is 5 mouse carotid arteries 
pooled. Two samples are shown above. 
 
Discussion 
While our carotid intima DNA preparations using the flushing method are endothelial-
enriched, they are not 100% endothelial pure. We do expect some contributions of genetic 
material from non-endothelial cells, particularly infiltrating leukocytes, that settle on the intima 
of the vascular walls. It is of vital importance to understand the level of endothelial cell purity of 
our genomic DNA or RNA preparations obtained by flushing the intimal layer of the carotid 
artery. We thus undertook this study to quantify the number of CD45+ cells (which includes all 
leukocyte groups: Granulocytes, Monocytes, T lymphocytes, T helper cells, Cytotoxic T cells, B 
lymphocytes, Thrombocytes, Dendritic cells- cite).  
Detailed analysis of the results from these experiments indicate that we have minimal 
contamination from SMCs and immune cells in our endothelial preparations, and underscore the 
validity of our experimental and analytical methods for the following experiments.  
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